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1.1. Definition 
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as “a common 
preventable and treatable disease, characterized by persistent airflow limitation that is usually 
progressive and associated with an enhanced chronic inflammatory response in the airways and the 
lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity 
in individual patients 
1
.” 
Spirometry, the most reproducible test for pulmonary function, is the gold standard for the clinical 
diagnosis of COPD and should be considered in any patient presenting with dyspnea, chronic cough 
or sputum production and with a history of exposure to risk factors. A ratio of the Forced Expiratory 
Volume in one second (FEV1) to the Forced Vital Capacity (FVC) below 0.70 determines the presence 
of airflow limitation. FEV1 is the maximum volume of air that can be forcedly exhaled in one second 
after complete inspiration, while FVC represents the maximum volume of air that can be forcedly 
exhaled. A classification of GOLD severity is made based on post-bronchodilator FEV1 values and is 
subdivided into 4 stages by the GOLD initiative (Table 1) 1. 
Table 1. Classification of severity of airflow limitation in COPD.                                                                  
Table adapted with permission of Vestbo et al. Am J Respir Crit Care Med 2013;187(4):347-365  
1
. 
 
GOLD stage COPD FEV1/FVC  FEV1 
 Absent ≥ 0.70   
GOLD 1 Mild < 0.70  and ≥ 80% predicted 
GOLD 2 Moderate < 0.70  and 50% ≤ FEV1 < 80% predicted 
GOLD 3 Severe < 0.70  and 30% ≤ FEV1 < 50% predicted 
GOLD 4 Very severe < 0.70  and < 30% predicted 
 
COPD results from a complex interplay between genetic susceptibility and environmental exposure, 
most importantly tobacco smoke. The best known genetic risk factor linked to COPD is a deficiency of 
the serine protease α1 antitrypsin, causing early-onset emphysema, but is only present in a small 
percentage of patients  2.  The genetics underlying COPD are currently unknown, although recent 
studies have identified interesting genetic loci associated with lung function 3;4. While tobacco smoke 
is the most important environmental risk factor in western countries, exposure to biomass smoke is 
the most prevalent risk factor in developing countries. Also occupational exposure to dusts and 
gases, respiratory infections and asthma are associated with COPD 5.   
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To date, COPD is treatable, but not curable, since none of the existing medications for COPD has 
been shown to slow down the disease progression. Its management consists of controlling symptoms 
and reducing exacerbations 1. Smoking cessation is the single intervention that can slow down the 
accelerated decline in lung function 6. Pharmacologic treatment, including long-acting 
bronchodilators and inhaled corticosteroids is used to reduce symptoms and exacerbations 1. 
Although COPD is a chronic inflammatory disease, effective anti-inflammatory drugs are lacking, due 
to a poor understanding of the underlying mechanisms and heterogeneity of the disease 7.   
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1.2. Epidemiology 
 
COPD is a highly prevalent disorder and represents a substantial economic burden throughout the 
world (Figure 1). COPD prevalence, morbidity and mortality are highly variable across countries, 
probably because of differences in defining and diagnosing COPD. Moreover, the prevalence and 
incidence of COPD are underestimated, since COPD is frequently underdiagnosed and undertreated 
1.  
 
 
Figure 1. The burden of COPD, around 2010, in 
the 28 countries of the European Union.  
#
: Global Initiative for Chronic Obstructive Lung 
Disease stages II–IV. An additional 17 million 
adults aged ≥40 years had stage I chronic 
obstructive pulmonary disease (COPD). 
Figure reproduced with permission of the 
European Respiratory Society © The European 
Lung White Book Respiratory Health and Disease 
in Europe. Published 2013, Print ISBN 978-1-
84984-042-2; online ISBN 978-1-84984-043-9 
8
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An increasing number of epidemiological studies on COPD prevalence has been published. The Latin 
American Project for the Investigation of Obstructive Lung Diseases (PLATINO) study estimated 
prevalence rates of COPD ranging from 7.8% in Mexico City (Mexico) to 19.7% in Montevideo 
(Uruguay)9. The Burden of Obstructive Lung Diseases (BOLD) study, a population-based study in 12 
different countries, found a prevalence of stage 2 or higher COPD of 10.1% overall, 11.8% for men, 
and 8.5%  for women 10. In a cohort study in the Netherlands (Rotterdam Study), the overall 
incidence of COPD was estimated around 9.2/1,000 person-years in an elderly population (> 55 
years), with a remarkably high incidence in the youngest women 11. 
Morbidity measurements include physician visits, emergency department visits and hospitalizations. 
COPD is also associated with significant comorbid diseases, such as cardiovascular disease, cancer 
and musculoskeletal impairment 1.  COPD has a substantial morbidity that is underestimated by both 
the healthcare providers and by the patients 12. 
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Approximately 2.7 million deaths from COPD occurred worldwide in 2000 13.  The WHO World Health 
Report listed COPD as the fifth leading cause of death worldwide in 2002. It is estimated that COPD 
will be ranked as the third leading cause of death by 2020, due to continued exposure to risk factors 
and the aging of the world’s population 14.  
Keeping these data in mind, it is not surprising that COPD is associated with significant economic 
burden (Figure 2). According to the ERS European Lung White Book, the overall annual cost for 
healthcare and lost productivity due to COPD are estimated as €48.4 billion in the 28 countries of the 
European Union. Remarkably, approximately half of the economic burden of respiratory disease is 
attributable to smoking 15. 
 
 
Figure 2. The economic burden of COPD. Distribution of direct and indirect costs by category.  
Figure reproduced with permission of the European Respiratory Society © The European Lung White Book 
Respiratory Health and Disease in Europe. Published 2013, Print ISBN 978-1-84984-042-2; online ISBN 978-1-
84984-043-9 
15
. 
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1.3. Clinical manifestations 
 
COPD is a heterogeneous disease and patients typically present with symptoms such as chronic and 
progressive dyspnea, cough and sputum production. These symptoms vary over time and not all 
patients display all the symptoms 1.  
Cough and sputum production are an important respiratory defense mechanism against possibly 
dangerous inhaled particulates. It is usually the first symptom of COPD to develop and may precede 
the development of airflow limitation by many years 16. Regular production of sputum for 3 months 
or more in 2 consecutive years is the epidemiological definition of chronic bronchitis, but this 
definition does not really reflect the symptoms as seen in patients with COPD 12;17. Breathlessness is 
usually the reason why patients seek medical help. It is characteristically persistent and progressive 
in the course of COPD 12. Additionally, fatigue, weight loss and anorexia are common problems in 
severe disease 18. To assess these symptoms, the COPD Assessment Test (CAT) is a reliable and 
responsive questionnaire to measure the impact on the patient’s daily life and well-being  16.  
Another important contributor to the morbidity and progression of COPD are exacerbations. An 
exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory 
symptoms that is beyond normal day-to-day variations and leads to a change in medication 19. 
Several different definitions of exacerbations exist and exacerbations can be classified according to 
severity or etiology. Several factors can evoke an exacerbation, such as respiratory tract infections 
(viral and/or bacterial), noninfective causes (air pollution and cold temperatures); however, in some 
patients, no etiological factor can be identified. Acute exacerbations are the main cause of 
hospitalization among COPD patients and are associated with long-lasting consequences 20. 
Patients with COPD also suffer from comorbidities, such as osteoporosis, cardiovascular diseases, 
psychiatric illness (depression) and lung cancer 21. Comorbidities can occur at any stage during the 
course of COPD, irrespective of the degree of airflow limitation 22. Cardiovascular diseases are the 
most frequent diseases coexisting with COPD and include ischemic heart disease, heart failure, atrial 
fibrillation and hypertension 1;23. Importantly, the majority of patients with (especially mild to 
moderate) COPD die of other conditions than of COPD itself, therefore comorbidities deserve specific 
attention 24. 
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COPD is generally a progressive disease with an irreversible decline in lung function, however not all 
individuals follow the same clinical course over time. The concept that smoking causes irreversible 
obstructive changes in susceptible people, was developed by Fletcher and Peto 25. Furthermore, 
impaired lung development can predispose to COPD (Figure 3). Stopping exposure to noxious agents 
may slow the progression of airflow obstruction. However, COPD cannot be cured. The degree of 
airflow limitation in COPD is only loosely related to symptom severity 12. End-stage patients have a 
progressively worsening dyspnoea and often present with multiple comorbidities, resulting in poor 
quality of life 26.  
 
 
Figure 3. “New” Fletcher and Peto Curve. Natural progress of COPD in smokers. Host characteristics (such as 
genetic susceptiblity) and environmental exposures (such as smoking) influence lung growth in childhood and 
adolescence and determine the rate of decline in lung function in adulthood. FEV1:forced expiratory volume in 
one second. 
Figure adapted with permission of Brusselle N Engl J Med 2009;361(27):2664-2665 
27
. Copyright  © 2009 
Massachusetts Medical Society. 
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1.4. Pathology of COPD 
 
Inhaled particles cause an abnormal inflammatory response in persons who will develop COPD. This 
response will lead to pathological changes in the airways, lung parenchyma and pulmonary 
vasculature, which are responsible for the airflow limitation and symptoms that define COPD. 
Importantly, these inflammatory and structural changes - illustrated in Figure 4 - persist upon 
smoking cessation 1. 
The main site of mucus hypersecretion is the central airways (larger than 2 mm in diameter). 
Enlarged bronchial mucous glands and an increased number of goblet cells have been found in 
patients with COPD 28, although an increase in the number of goblet cells has not been consistently 
reported 29. Chronic bronchitis is also characterized by inflammation in the subepithelial region of 
the bronchial wall, consisting of neutrophils, macrophages and CD8+ T lymphocytes 30;31. 
Figure 4. Pathophysiological processes involved in COPD. A) Normal airway. B) Airway of a patient with COPD, 
characterized by 1) inflammatory cellular infiltration, 2) mucus hypersecretion, 3) airway lumen narrowing, 4) 
subepithelial fibrosis, 5) smooth muscle cell hypertrophy, 6) development of lymphoid follicles and 7) 
destruction of the alveolar walls or emphysema.  
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The smaller conducting airways (less than 2 mm in diameter) are considered to be the major sites of 
increased airway resistance in patients with COPD 32. A process called “obstructive bronchiolitis” 
which encompasses inflammatory cellular infiltration, goblet cell metaplasia, mucus plugging in the 
airway lumen, subepithelial fibrosis and smooth muscle cell hypertrophy, is present 29;33-35. The 
inflammatory cell infiltrates in the airway wall consist of neutrophils, macrophages, B lymphocytes, 
CD4+ and CD8+ T lymphocytes 33. The increase in lymphocytes, which organize into lymphoid follicles 
in advanced stages of COPD, is associated with a decline in FEV1 (see Chapter 2) 
33;36. All together, 
these changes lead to an increase in airway wall thickness, the subsequent narrowing of the airway 
lumen and decreased FEV1.  
In the alveolar compartment, a pathological process called emphysema occurs. Emphysema is 
defined as an abnormal enlargement of airspaces, distal to the terminal bronchioles, accompanied by 
alveolar destruction 1. Centrilobular emphysema affects the respiratory bronchioles in the central 
area of the acinus. This type of emphysema is more prominent in the upper lung zones and is 
characteristically associated with tobacco smoking. Panlobular emphysema involves dilatation of the 
entire acinus. This form of emphysema is associated with deficiency of a1-antitrypsin and early onset 
37;38. Emphysema reduces the elastic recoil, which predisposes the airways to collapse prematurely 
during exhalation 39.  Both the narrowing of peripheral airways and parenchymal destruction will 
progressively lead to gas trapping during expiration, resulting in hyperinflation 1. 
Anatomic abnormalities in the pulmonary vasculature consist of remodelling of pulmonary arteries 
and arterioles. In studies using necropsy material and surgical specimens, a thickening of the intima 
of pulmonary arteries in patients with mild to moderate COPD and a thickening of both the intima 
and media in patients with severe COPD have been described 40. Also muscularisation of pulmonary 
arterioles, which have no muscular layer in normal subjects, is shown in patients with emphysema 41. 
In contrast to patients with pulmonary arterial hypertension, no plexiform lesions have been found in 
patients with COPD. Consequently, endothelial dysfunction in pulmonary arteries of COPD is present 
42;43. Similar to the inflammation in the airway wall,  mainly CD8+ T lymphocytes infiltrate the 
adventitia of pulmonary muscular arteries and this inflammatory reaction is associated with an 
impaired vascular relaxation and thickening of the intimal layer 44. 
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1.5. Pathogenesis of COPD 
 
Effective therapy for patients with COPD is still lacking. Despite multiple efforts worldwide, the 
pathogenetic mechanisms underlying COPD are still not fully elucidated. The above- mentioned 
pathology appears to be an amplification of the normal inflammatory response to inhaled irritants. 
The inflammation persists after smoking cessation in patients with  COPD, indicating that the 
inflammation is maintained through autonomous mechanisms. Oxidative stress and protease-
antiprotease and apoptosis-proliferation imbalances further modify lung inflammation. Importantly, 
genetic susceptibility, involving a broad set of known (such as TGF-β1, MMP-9 and hedgehog 
interacting protein…) and unknown genes and epigenetic changes also contribute to the 
development of COPD. These mechanisms do not operate separately and several interactions occur, 
making the pathogenesis even more complex (Figure 5). 
 
Figure 5. Schematic overview of the pathogenetic mechanisms underlying COPD. Four important mechanisms 
take part in the development of COPD: 1) inflammation: influx of innate and adaptive immune cells, leading to 
the development of lymphoid follicles in severe disease, 2) oxidative stress: imbalance between oxidants 
(including hydrogen peroxide [H2O2], nitrosothiol [RSNO], lipid peroxidation products) and anti-oxidants will 
result in oxidative stress,  3) imbalance between proteases (e.g. neutrophil elastase and MMP-9, MMP-12) and 
antiproteases: the net result is an increased proteolytic activity and breakdown of connective tissue and 
emphysema, 4) imbalance between apoptosis and proliferation:  increased apoptosis of endothelial and 
epithelial cells not counteracted by proliferation can trigger matrix destruction. These disease mechanisms all 
interact with each other leading to the pathophysiology and symptoms seen in COPD. MMP: matrix 
metalloproteinase, NRF2: nuclear factor erythoid 2-related factor. 
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1.5.1. Chronic inflammation 
As a first line of defence, the lungs have innate immune mechanisms encompassing the epithelial 
barrier and innate immune cells, specifically macrophages/monocytes, neutrophils, eosinophils, mast 
cells, natural killer (NK) cells and dendritic cells. These cells recognize microbes (Pathogen Associated 
Molecular Patterns or PAMPS) and danger signals (Damage Associated Molecular Patterns or DAMPs) 
by Pattern Recognition Receptors (PRR) 45. Importantly, the innate immune system is sufficient to 
develop pulmonary inflammation and emphysema, as shown by studies using Severe Combined 
Immune Deficient (SCID) and Recombination Activating Gene (RAG)1 deficient mice, which lack 
adaptive immunity 46;47. 
Exposure to cigarette smoke (CS) leads to activation of several PRRs on epithelial cells and 
production of a broad range of chemokines and inflammatory mediators (IL-8, IL-1β, TGF-β1, MCP-1, 
LTB4) 
48-51. In addition, cigarette smoke can directly cause injury to epithelial cells, which will release 
DAMPs. Elevated levels of DAMPS, such as extracellular adenosine triphosphate (ATP) and high-
mobility group box 1 (HMGB1) have been found in the bronchoalveolar lavage (BAL) fluid of patients 
with COPD compared to never smokers and smokers without COPD 52;53. All together, these 
mechanisms will activate the innate immune system (Figure 6). 
 
Figure 6. Innate and adaptive immune cells in the pathogenesis of COPD. Figure adapted with permission of 
Brusselle et al Lancet 2011;378 (9795):1015-1026 
54
. Copyright © 2011 Elsevier Ltd. 
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Macrophages contribute to most hallmarks of COPD. Increased numbers of macrophages are present 
in patients with COPD and there is a correlation between the numbers of macrophages and 
increasing severity of COPD 33;55;56. This increase may be due to increased recruitment of CXCR2+ 
monocytes, increased proliferation and reduced cell death of macrophages 57;58. Activated 
macrophages release inflammatory mediators and chemokines, adding to the inflammation and 
recruitment of other immune cells  59;60. Macrophages also contribute to tissue damage through the 
production of reactive oxygen species and the release of proteolytic enzymes such as matrix 
metalloproteinases (MMP-1, -9 and -12) 61-63. MMP-12 (or macrophage elastase) knockout (KO) mice 
are protected against CS-induced airspace enlargement, indicating the importance of MMP-12 in the 
development of emphysema 64. Furthermore, alveolar macrophages from patients with COPD have 
reduced phagocytic capacity, which may result in increased bacterial load 65. 
The presence of neutrophilic inflammation in the airways is a characteristic feature of COPD. 
Neutrophils are increased in sputum and airway smooth muscle cells of patients with COPD and to a 
lesser extent in the lung parenchyma 66;67. Neutrophil numbers in sputum and bronchial mucosa are 
associated with peripheral airflow obstruction and a lower FEV1 value 
55;68. The functional role of 
neutrophils in COPD is not yet clear. Neutrophils can contribute to alveolar destruction by the 
production of neutrophil elastase, proteinase-3, cathepsin G and MMP-8 and -9. In this context, 
animal studies using neutrophil elastase KO mice revealed a requirement for neutrophil elastase in 
CS-induced emphysema 69. However, no association was found between airway neutrophilia and 
severity of emphysema in patients with COPD 68. Additionally, neutrophils can release neutrophil 
extracellular traps (NETs), which are fibrillary networks of nuclear components (DNA and histones), 
decorated by granule proteins with antimicrobial capacity.  Although NETs are important for the host 
immunity against infections, they can simultaneously be harmful and are linked to COPD 70;71. It has 
been suggested that neutrophils are involved in mucus hypersecretion, since neutrophil elastase and 
cathepsin G, serine proteases produced by neutrophils, can stimulate mucus secretion from airway 
gland serous cells 72. Similar to macrophages, the phagocytic capacity of neutrophils is impaired upon 
cigarette smoke extract (CSE) treatment 73.  
Eosinophil numbers are elevated in blood, BAL fluid, sputum and biopsy specimens of a subgroup of 
patients with COPD compared to healthy controls 74;75. During exacerbations of chronic bronchitis, 
increased numbers of eosinophils are present in bronchial biopsies and sputum 76. The role of 
eosinophils in the pathogenesis of COPD is not clear (in contrast to their well-known role in asthma), 
but they may represent a distinct COPD phenotype. In patients with pulmonary emphysema, 
eosinophilic inflammation in the airways has been related to the reversible part of the airflow 
obstruction in response to glucocorticoids 75. 
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While mast cells have a key role in asthma through the release of several bronchoconstrictors, their 
role in COPD is unknown. Increased, reduced or unchanged numbers of mast cells have been 
reported in COPD airways and lungs. The morphology and molecular expression of mast cells are 
changed in lungs of patients with COPD, but the functional consequences of these alterations are yet 
to be determined 55;77;78. 
Natural killer (NK) cells were originally classified as lymphocytes based on their morphology, but are 
now generally accepted as components of the innate immune system, because they lack antigen-
specific cell surface receptors 79. Patients with COPD have increased numbers of NK cells in the 
subepithelium and induced sputum compared with healthy smokers, while in a mouse model of 
chronic cigarette smoke exposure no changes in the numbers of NK cells were demonstrated 55;80;81. 
The increased proportion of NK cells is inversely correlated with the degree of airflow limitation in 
smokers 55.  Cytotoxic activity of NK cells is reduced in the peripheral blood of patients with COPD, 
while in the airways the cytotoxic activity is elevated 81;82.  
Dendritic cells (DCs) are specialized antigen-presenting cells that form the link between innate and 
adaptive immunity, by taking up antigen (Ag), migrating to the lymph nodes and presenting the Ag to 
the T lymphocytes via expression of major-histocompatibility-complex (MHC) proteins. By 
immunohistochemistry, our group showed selective accumulation of langerin positive myeloid DCs in 
the epithelium of small airways of patients with COPD, associated with increased expression of the 
chemokine CCL20 83;84. Langerin positive DCs are very efficient in inducing CD8+ T cell responses by 
cross-presentation 85. On the other hand, an electron microscopy study found decreased bronchial 
mucosal DC numbers in current smokers with COPD compared to ex-smokers with COPD  86.  COPD 
progression is associated with increases in costimulatory molecule expression by lung DCs 87. The 
exact role of DCs in COPD is unclear as the antigenic stimulants have not yet been identified.  
The adaptive immune system functions through antigen-specific receptors and comprises T and B 
lymphocytes. CD8+ cytotoxic T lymphocytes predominate over CD4+ T lymphocytes in the airways, 
lung parenchyma and pulmonary arteries of patients with COPD and their numbers are significantly 
correlated with the degree of airflow limitation in smokers 88;89.  The CXCL10/CXCR3 chemokine axis, 
increased in peripheral airways of smokers with COPD, might be implicated in CD8+ T cell recruitment 
90. These cytotoxic T cells are highly activated in COPD and release proteolytic enzymes, such as 
perforin and granzyme b and show increased cytotoxic potential  91;92. There is an association 
between apoptosis and CD8+ T cells in the alveolar wall, suggesting that cytotoxic T cells could 
contribute to the process of emphysema 93.  
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Adoptive transfer of pathogenic CD4+ T cells into naïve mice results in the development of 
emphysema, indicating that also CD4+ T cells are involved in the pathogenesis of COPD 94. The CD4+ T 
lymphocytes that accumulate in the airways and lungs of patients with COPD are mainly Th1 cells. 
Th1 cells expressing CCR5 and CXCR3 secrete more interferon-γ (IFN-γ) in COPD patients than in 
control smokers 95.  However, the response of Th1 cells to endotoxin is impaired in smokers with and 
without airflow limitation, which may account for the increased susceptibility to bacterial infections 
in COPD 96.  
Th17 cells are a distinct lineage of CD4+ T cells that mediate immunity against extracellular pathogens 
and are involved in autoimmunity by production of IL17A and IL17F 97. Patients with COPD have 
higher numbers of IL17A+ cells in the bronchial submucosa than smokers and never smokers 98;99. By 
flow cytometry, the Th17 subset was reported to be increased in the peripheral blood of patients 
with COPD, which is inversely correlated with the FEV1 value 
100. IL17R KO mice failed to develop 
emphysema after 6 months of CS exposure 101. Th17 cells are known for stimulating neutrophilic 
inflammation upon LPS treatment 102. 
Another subtype of CD4+ T lymphocytes that may be involved in COPD are regulatory T cells (Tregs). 
Tregs have immunoregulatory functions and inhibit autoimmunity by producing anti-inflammatory 
cytokines such as IL-10 and TGF-β1 103. In BAL fluid, CD4+-CD25bright cells were increased in smokers 
with normal lung function compared with healthy never-smokers and patients with moderate COPD 
in one study 104, whereas another study demonstrated that smoking induces CD4+ - CD25 bright cells 
independent of lung function 105. Tregs are decreased in the lungs of patients with emphysema and 
this is associated with reduced levels of FoxP3 (transcription factor characteristic for Tregs) and IL-10 
106. In lymphoid follicles on the other hand, the number of CD4+ FoxP3+ cells is raised in patients with 
COPD, indicating that Tregs might be involved in dampening excessive inflammation (and 
autoimmunity) in COPD 107. Apparently, the number of Tregs is dependent of the anatomical location 
that is studied. An upregulation of FOXP3-positive cells in large airways of patients with COPD was 
present, but a downregulation was found in small airways that correlated with airflow limitation 108.  
Next to T lymphocytes, B lymphocytes are also implicated in the pathogenesis of COPD. B cells are 
increased in bronchial biopsies of large airways of patients with COPD and are higher in more severe 
COPD 109.  Progression of COPD is associated with the development of organized lymphoid follicles, 
consisting of B and T lymphocytes (Figure 6) 33. The mechanisms behind this process - called 
lymphoid neogenesis - will be discussed extensively in Chapter 2.  
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1.5.2. Oxidative stress 
Oxidative stress may be an important amplifying mechanism in COPD. The lungs are continuously 
exposed to oxidants, either generated endogenously or exogenously. Lung cells are protected against 
this oxidative challenge by antioxidant systems. Oxidative stress arises when there is a disequilibrium 
between oxidants and antioxidants in favor of the former 110. 
Numerous studies have shown that oxidative stress is present in patients with COPD. Several markers 
of oxidative stress, such as hydrogen peroxide, nitrosothiol, lipid peroxidation products (such as 8-
isoprostane,…) are increased in exhaled breath condensate of patients with COPD 111-113. Moreover, 
oxidant production increases further during exacerbations 112. There is evidence for systemic 
oxidative stress, since products of lipid peroxidation are elevated in plasma in smokers with COPD 114. 
There may also be a reduction in antioxidants in COPD. Glutathione and nuclear factor erythoid 2-
related factor (NRF2) protein levels are reduced in lungs of patients with COPD 115. NRF2 is a redox-
sensitive transcription factor that is involved in the regulation of many antioxidant genes 110. 
Epidemiological studies have shown a significant association between reduced dietary intake of 
antioxidants (vitamin E and C) and lung function and demonstrated that antioxidant supplementation 
reduced the risk of  developing chronic lung disease in women 116;117. 
The environmental sources of airborne oxidative stress include oxidant gasses, ultrafine particulate 
matter and most importantly CS. CS contains around 1017 oxidant molecules per puff 110. However, 
cessation of smoking does not stop the continued oxidant burden, indicating that oxidative stress 
most likely arises from endogenous sources 118. Inflammatory cells (neutrophils, eosinophils and 
macrophages) and structural cells (e.g. epithelial cells) that are activated in the airways of patients 
with COPD produce reactive oxygen species 119. 
Oxidative stress occurs in the presence of inflammation, but can also enhance the inflammation. 
Through the upregulation of redox-sensitive transcription factors, such as nuclear factor κB (NF-κB) 
and activating protein 1 (AP-1), oxidative stress may induce neutrophilic inflammation via increased 
expression of IL-8 120-122. Oxidative stress is also implicated in mucus hypersecretion, inactivation of 
antiproteases and apoptosis of structural cells and subsequently emphysema 123-125. Ablation of Nrf2 
in mice resulted in increased susceptibility to CS-induced inflammation and emphysema compared to 
wild-type mice 126. Furthermore, there is a link between oxidative stress and the relative resistance to 
corticosteroids in patients with COPD. Histone deacetylase activity, required for the anti-
inflammatory action of corticosteroids, is reduced upon CS exposure and this is correlated with a 
reduction in glucocorticoid responsiveness in vitro 127. 
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1.5.3. Protease-antiprotease imbalance 
It has been long proposed that there is an imbalance between proteases and antiproteases, resulting 
in an increased proteolytic activity, breakdown of connective tissue and emphysema. This imbalance 
may occur either by an excessive release of proteases or by an increased breakdown of 
antiproteases. This hypothesis was proposed after the observation that smokers with a deficiency of 
α1-antitrypsin developed early onset pulmonary emphysema  128.  
Neutrophil elastase (NE) is a serine protease, produced by neutrophils, which is inhibited by α1-
antitrypsine. Intratracheal instillation of human NE in mice resulted in the development of 
emphysema, whereas NE deficient mice are protected against CS-induced emphysema 69;129. 
Exogenous α1-antitrypsin was able to inhibit matrix degradation, as assessed by lower desmosine 
(elastin breakdown) and hydroxyproline ( collagen breakdown) levels 130. NE is also involved in mucus 
production, stimulates neutrophil influx and increases oxidative stress 131;132. Given these 
observations, it was thought that neutrophils and neutrophil elastase were the main effector cell and 
protease respectively, however no significant correlation between neutrophil numbers and the 
degree of tissue destruction was found in humans, suggesting other proteases may be involved 133.  
The idea that macrophages and macrophage-derived matrix metalloproteinases (MMPs) are 
important, emerged when several studies found that  MMP-1, -2 and -9 levels are higher in lungs or 
lavaged macrophages of patients with emphysema 134;135. Interestingly, MMP-12 deficient mice do 
not develop airspace enlargement upon exposure to CS 64. MMP-12 levels and activity are elevated in 
induced sputum of patients with COPD compared to healthy smokers and never smokers 61. However 
the function of MMPs as matrix-degrading proteases is still unproven. Most likely, emphysema is the 
result of different proteases working together and interacting with other types of mediators. It was 
shown that both MMP12 and neutrophils are required for matrix breakdown in mice exposed to CS 
136. 
Normally proteases are counteracted by endogenous antiproteases. α1-antitrypsin and secretory 
leukocyte protease inhibitor (SLPI) are the major inhibitors of serine proteases. As mentioned above, 
oxidative stress can inactivate these inhibitors 124. Cleaved SLPI is found in BAL fluid of patients with 
emphysema in contrast to healthy controls, indicating that cleavage is another mechanism whereby 
antiproteases can be inhibited 137. Tissue inhibitor of MMPs (TIMP)1-4 inhibit MMPs.  The 
inflammation driven TIMP-1 secretion from alveolar macrophages is blunted in cells derived from 
patients with COPD 138. TIMP-3 KO mice demonstrate a spontaneous, age-related emphysema 139. 
Finally, genetic mutations that result in loss of function or reduced protein levels of antiproteases 
have been described, of which genetic deficiency of α1-antitrypsin is the best known example 128;140. 
CHAPTER 1: CHRONIC OBSTRUCTIVE PULMONARY DISEASE 25 
 
 
 
1.5.4. Apoptosis-proliferation imbalance 
It is generally accepted that CS induces an exaggerated influx of inflammatory cells into the lungs and 
that these inflammatory cells produce proteases and reactive oxygen species that cause tissue 
destruction and eventually emphysema. A new concept in the pathogenesis of emphysema has been 
proposed that loss of epithelial and endothelial cells via apoptosis can trigger matrix destruction and 
alveolar space enlargement. Apoptosis is a tightly regulated mechanism leading to programmed cell 
death and is critical for the maintenance of normal tissue homeostasis. 
This hypothesis was confirmed by several studies in animal models. In the study of Kasahara and 
colleagues, intravascular administration of a vascular endothelial growth factor (VEGF)-receptor 
antagonist generated non-inflammatory emphysema 141. Adding to this, a single intratracheal 
injection of active caspase 3 (pro-apoptotic enzyme) induced airspace enlargement in rats, even 
without inflammation 142. In a CS-induced mouse model of COPD, apoptosis of type II alveolar 
epithelial cells was higher compared to the air-exposed littermates 143. Similar data are found in 
human studies. Apoptotic cells (alveolar epithelial cells, interstitial cells and inflammatory cells) are 
elevated in lungs of patients with COPD and emphysema and this increase persisted despite smoking 
cessation 144-146. Also, expression of Bax and Bad (pro-apoptotic proteins) was detected in 
emphysema 145. On the other hand, other studies did not demonstrate a difference in apoptosis 
between COPD patients and healthy controls, but described an association between apoptosis and 
pack years 93. 
In physiologic circumstances, apoptosis and proliferation are in balance to maintain tissue 
homeostasis. In COPD, this balance is disturbed. While apoptosis is increased in patients with 
emphysema, proliferation rate is not different 147. On the other hand, increased proliferation 
together with apoptosis has been reported in emphysema compared to smokers and never smokers 
148. VEGF is a growth factor required for endothelial cell survival. Expression of VEGF and its receptor 
are reduced in emphysema, suggesting that a decrease of endothelial cell maintenance factors may 
be part of the pathogenesis of emphysema 149. 
Although it has been shown in animal studies that apoptosis of structural walls is sufficient to cause 
emphysema, it is probable that interaction between apoptosis and inflammation (and other 
pathogenetic mechanisms) will take place in patients with COPD. In this context, alveolar 
macrophages from patients with COPD have decreased phagocytic ability, contributing to inefficient 
clearance of apoptotic cells 150. 
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2.1. Lymphoid neogenesis in COPD 
 
The primary purpose of the immune system is to defend the human body against potential 
hazardous antigens and pathogens. In tissues that harbor a persistent source of antigen, the immune 
system has evolved in a way that lymphocyte infiltrates will organize themselves in lymphoid follicles. 
This process is called  ‘lymphoid neogenesis’ and refers to the development of ectopic lymphoid 
tissue which resemble secondary lymphoid organs (e.g. lymph nodes, mucosal-associated lymphoid 
tissue and spleen) in non-lymphoid tissues that are targeted by chronic inflammatory processes or 
auto-immunity 151.  
A distinction should be made between lymphoid aggregates and follicles. Aggregates lack functional 
architecture and their primary function is local priming and activation. Following criteria have to be 
fulfilled before the term lymphoid follicles can be used 152;153: 
a) Specific arrangement of anatomically distinct yet adjacent B and T cell compartments 
b) The presence of follicular dendritic cells (FDCs) that present antigen-antibody immune 
complexes to B lymphocytes 
c) The development of high endothelial venules (HEV) that allow continuous transmigration of 
lymphocytes 
d) Evidence of B cell class switching, as demonstrated by the presence of activation-induced 
cytidine deaminase (AID) enzyme 
e) Germinal center reactions in the B cell area, which are the principal site of B cell maturation 
An alternative name for lymphoid follicles are tertiary lymphoid organs (TLOs) as opposed to primary 
lymphoid organs (thymus and bone marrow), where lymphocytes are generated, and secondary 
lymphoid organs.  While secondary lymphoid organs are pre-programmed during ontogeny, tertiary 
lymphoid organs arise under environmental influences in adults. TLOs are architecturally similar to 
secondary lymphoid organs, share the same molecular and cellular requirements for their formation  
and contain all the necessary cell types  to elicit adaptive immune responses. In contrast to lymph 
nodes, TLOs are not encapsulated and are not supplied by afferent lymph vessels 151;154. 
In the lung, it was originally stated that lymphoid structures in close association with the bronchial 
epithelium were constitutively present as part of bronchus-associated lymphoid tissue (BALT), similar 
to the gut-associated lymphoid tissue (GALT). However, in normal human lung no lymphoid tissue 
was observed, except in lungs of children and adolescents 155;156. 
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BALT can be induced (iBALT) upon antigenic stimuli, such as CS or bacteria and viruses, but also in 
pathological situations, such as rheumatoid arthritis or lung transplantation. More than 20 years ago, 
the presence of BALT has been reported in smokers, being significantly more  prominent in smokers 
compared to never smokers. Moreover, these authors reported that BALT is not per se associated 
with a specialized epithelium, therefore the term ‘lymphoid follicles’ will be used instead of BALT 
36;157.  
Higher numbers of small airways containing lymphoid follicles were found in patients with severe 
COPD compared to healthy subjects and patients with mild-to-moderate COPD (Figure 7). 
Importantly, the number of lymphoid follicles is associated with the progression of COPD 33. B-cell 
follicles were not only demonstrated in association with small airways but also in the lung 
parenchyma of patients with COPD 158.  Furthermore, individual B cells were found to be increased in 
the lungs of patients with COPD 109. Similarly, mice exposed to long-term CS develop lymphoid 
follicles around airways and blood vessels as well as in the lung parenchyma 158;159 (Figure 7). The 
number and size of the follicles correlates with airspace enlargement in CS-exposed mice 158. 
 
 
Figure 7. Lymphoid follicles in severe COPD and cigarette smoke (CS)-exposed mice. A) Representative image 
of immunofluorescence staining with anti-CD20 antibody (green) in lung tissue of patients with severe chronic 
obstructive pulmonary disease (COPD) GOLD III. Counterstaining with 4’,6-diamidino-2-phenylindole (DAPI) is 
shown in blue. B) Representative image of immunohistochemical staining with anti-CD3 antibody (brown) for T 
lymphocytes and anti-B220 antibody (blue) for B lymphocytes in lung tissue of CS-exposed mice.  
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Several studies have been published where the cellular organization of these structures has been 
investigated. The follicles consist of a B cell core, which comprises the majority of cells, surrounded 
by T cells. The B cells are predominantly CD27+ memory B cells, but also CD138+ plasma cells are 
detected in the direct vicinity of the follicles. The B cells within the follicle are mainly IgM positive. 
Immunoglobulin gene analysis of B cells isolated from lymphoid follicles demonstrated ongoing 
mutations in individual B cell contigs, suggestive for oligoclonal B cell proliferation, stimulated by an 
unidentified antigen. These data, together with the expression of the proliferation marker Ki-67 
within lymphoid follicles, are suggestive for the presence of an active germinal center 158. In this 
context, numbers of memory B cells in the lungs of patients with COPD are significantly higher 
compared to non-COPD controls, also suggestive for antigen-specific stimulation  160. 
The T cell periphery of lymphoid follicles consists mainly of CD4+ T cells (80-90 %), and to a lesser 
extent CD8+ T cells 158.  Also increased numbers of CD4+ FoxP3+ immunomodulatory Treg cells were 
observed in follicles of patients with COPD 107. The density of CD57+ cells, important effectors of 
cytotoxicity, within lymphoid follicles of patients with COPD is increased compared to that of never 
smokers and smokers without COPD 161. Antigen presentation in the lymphoid follicles is mediated by 
FDCs and DCs. FDCs are specialized reticular fibroblasts and are located within the B cell center as 
shown by staining for CD21 and CD35, 2 markers for FDCS 152. Myeloid and plasmacytoid DCs are also 
found within the T cell zone 152;162 (Figure 8). Moreover, the number of pDCs is higher in lymphoid 
follicles of patients with mild-to-moderate COPD compared to smokers without airflow limitation 162. 
Figure 8. Structure 
of pulmonary 
lymphoid follicles in 
COPD.  Treg cell: 
regulatory T cell,  
FDC: follicular 
dendritic cell, HEV: 
high endothelial 
venule, mDC: 
myeloid dendritic 
cell, pDC: 
plasmacytoid 
dendritic cell, CD: 
cluster of 
differentiation, Ig: 
Immunoglobulin. 
Figure adapted with 
permission of 
Brusselle et al 
Lancet 2011;378 
(9795):1015-1026 
54
. Copyright © 
2011 Elsevier Ltd. 
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The pathogenic role of lymphoid follicles in COPD is not yet clear. The unique organization and 
cellular composition (presence of lymphocytes and Ag presenting DCs) create the optimal conditions 
for an effective immune response at the site of antigen deposition. In addition, lymphoid follicles are 
not encapsulated, making them directly accessible for encountering antigens. In that regard, ectopic 
lymphoid follicles may develop as protective structures against infectious agents and prevent 
infections from spreading to other parts of the body. This makes sense, knowing that the presence of 
pathogens in the airways/lungs of patients with COPD is a common occurrence and also increases 
with worsening airflow obstruction, in parallel with lymphoid follicles 163. Animal studies with 
influenza infection confirm that tertiary lymphoid organs are protective in an infectious setting. 
Genetic targeted mice without peripheral lymphoid organs but with iBALT can clear influenza 
infection and even survive higher doses of virus 164. Another approach, where iBALT was depleted by 
elimination of DCs, but where the secondary lymphoid organs were intact, emphasizes the role of 
DCs and iBALT in humoral immunity upon influenza infection in mice 165.  
Consistent with these data, IgM and IgA, which are essential for mucosal immune responses are 
produced within lymphoid follicles in patients with COPD 157;158. Accordingly, there was a strong 
negative association between oral and/or inhaled corticosteroid therapy and the percentage of 
airways containing lymphoid follicles in COPD 166. It can be hypothesized that the steroid-induced 
suppression of lymphoid follicles may account for the increased risk of pneumonia in patients who 
use corticosteroids, pointing towards a protective role of lymphoid follicles 167. 
On the other hand, lymphoid follicles may contribute to the tissue destruction and poorly reversible 
progression of COPD, since their numbers increase with disease severity 33. Lymphoid follicles are a 
concentrated source for inflammatory cells and concomitant pro-inflammatory mediators and 
proteases. The persistent inflammation and destruction may give rise to injury-related neo- or self-
antigens in the lung tissue, triggering the development of lymphoid follicles.  Numerous studies 
demonstrated the presence of autoantibodies in COPD, such as auto-antibodies against HEp-2+ 
epithelial cells, endothelial cells and elastin 106;168;169. Higher numbers of anti-decorin IgG antibody 
producing cells were present in peripheral blood mononuclear cells (PBMCs) derived from patients 
with COPD compared to healthy controls 160.  Injection of xenogeneic endothelial cells in rats resulted 
in the development of emphysema 170. In contrast, others could not confirm auto-antibody responses 
in COPD 171. Although Tregs are increased in lymphoid follicles of patients with moderate COPD, it is 
possible that they fail to suppress autoimmunity in severe COPD 107 
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2.2. CXCL13 
 
 The organization of tertiary lymphoid organs is the result of a coordinated interplay between 
haematopoietic and stromal cells, adhesion molecules, cytokines and chemokines 151. CXC-chemokine 
ligand (CXCL)13 is one of those lymphoid chemokines. Lymphoid or homeostatic chemokines are 
constitutively expressed in lymphoid tissues and mediate the formation and maintenance of 
lymphoid tissues, through the trafficking of leukocytes to the lymphoid organs 172. 
Formation of lymphoid follicles follows many of the pathways used for the organogenesis of 
secondary lymphoid organs. Therefore, it is important to first summarize the mechanisms involved in 
secondary lymphoid tissue development. Crucial is the mutual interaction between haematopoietic 
inducer cells and stromal organizer cells. Binding of the cytokine lymphotoxin (LT)α1β2, expressed by 
inducer cells, to lymphotoxin β receptor (LTβR) on the surface of organizer cells induces the 
expression of lymphoid chemokines [CXCL12/13, CC-chemokine ligand (CCL)19/21] and adhesion 
molecules [vascular cell adhesion molecule (VCAM)1, intercellular adhesion molecule (ICAM)1, 
mucosal addressin cell adhesion molecule (MADCAM)1] in organizer cells. This will attract additional 
haematopoietic cells and will initiate clustering of the cells. This is followed by HEV differentiation, 
further recruiting naïve lymphocytes from the blood stream. As a result, a well-organized structure 
with a distinct B and T cell zone is formed 153;172. 
The necessity of LTβR signaling for the development of secondary lymphoid tissue is further 
substantiated by the absence of lymph nodes and Peyer’s patches and impaired spleen organization 
in LT-deficient mice 173. The chemokines and adhesion molecules are involved in attracting and 
retaining the cells required for formation. CCL19 and CCL21 are produced by stromal cells and attract 
naïve T cells and mature DCs via CCR7 to T cell areas. The secondary lymphoid organs of CCR7 
deficient mice have a disturbed architecture due to the impaired entry of T lymphocytes and DCs 
174.CXCL12 and CXCL13 attract CXCR4+ and CXCR5+ B cells into the B cell zone. CXCR5 deficient mice 
lack inguinal lymph nodes and have only a few Peyer’s patches, which are phenotypically abnormal 
175. CXCL13 deficient mice have a more severe deficiency and lack most lymph nodes 176. CXCL13 has 
a role in B cell compartmentalization by mediating B cell attraction. Additionally, CXCL13 induces 
LTα1β2 expression on B cells, subsequent LTβR stimulation and up regulation of its own expression 
through this positive feedback loop 175;176. 
Tertiary lymphoid structures develop in a broad variety of human chronic inflammatory disorders, 
including autoimmune diseases (rheumatoid arthritis, multiple sclerosis…), infectious disease, cancer 
and COPD 151;153. The cellular and molecular mechanisms behind the formation of lymphoid follicles 
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remain to be fully elucidated, but it is clear that many features are shared with the formation of 
peripheral lymphoid organs. Instead of the specific inducer cells, B and T cells and DCs could express 
LTα1β2 and provide the initial trigger 176-178. An organizer cell type of mesenchymal origin that 
promotes the development of lymphoid follicles has not yet been identified, but stromal cells are 
detected in lymphoid follicles of influenza-infected mice 179.  Increased expression of homeostatic 
chemokines, such as CXCL12, CXCL13 and CCL19, is found in tissues harboring lymphoid follicles 
ranging from patients with Sjörgen’s syndrome to the CS-induced murine model of COPD 180-183. 
Overexpression of LT-α, CXCL13 or CCL21 is sufficient to induce the development of ectopic lymphoid 
tissue, while CXCL12 and CCL19 promote leukocyte accumulation 184-186. 
In COPD, the underlying mechanisms of lymphoid follicle formation remain to be elucidated. It has 
been hypothesized that lymphoid follicles are formed by the recruitment of CXCR3-expressing T and 
B lymphocytes, which increase with disease severity. The CXCR3 ligands CXCL9 and CXCL10 are 
expressed by cells in and around lymphoid follicles 187. In our CS-induced model of airway disease, we 
have proposed the following mechanism of lymphoid neogenesis 180;181 (Figure 9):   
a) Initiation of inflammation 
-     CS induces pulmonary inflammation with lymphocytes that express LTα1β2 
- LTβR signaling on nearby stromal cells induces the expression of lymphoid chemokines: 
CXCL13 will attract B cells via CXCR5 and CCL19 will attract T cells and DCs via CCR7 
- Positive feedback loop via CXCL13-induced LTα1β2 expression on B cells 
 
b) Clustering of lymphocytes and DCs into unorganized lymphoid aggregates at inflamed site  
 
c) Organization of lymphoid follicles in the presence of chronic inflammation 
- Separation into T and B cell zones upon persisting expression of CXCL13 and CCL19 
- Differentiation of activated endothelial cells into HEVs, allowing additional supply of 
naïve lymphocytes 
- Differentiation of stromal cells into FDCs in the B cell core which function as a scaffold for 
B cell organization and germinal center formation 
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Figure 9. Proposed mechanism of lymphoid neogenesis in COPD. A) Cigarette smoke (CS) induces LTβR 
signaling which in turn stimulates the production of chemokines CXCL12, CXCL13, CCL19 en CCL21. B) 
Clustering of lymphocytes and DCs into aggregates. C) Organization into organized lymphoid follicles with the 
presence of follicular dendritic cells (FDCs) and high endothelial venules (HEVs). 
 
 
Our research group has already studied the involvement of CCR7 and LT-α in CS-induced 
inflammation and lymphoid follicle formation. CCR7 signalling was not required for the development 
of lymphoid follicles. CCR7 deficiency modulated the accumulation of innate inflammatory cells in 
lungs and airways; in contrast, the influx of airway derived DCs and T cells into the lymph nodes was 
CCR7-dependent 181. The development of CS-induced lymphoid follicles is not impaired by LT-α 
deficiency, but the production of secretory IgA is attenuated in LT-α deficient mice, suggesting a 
possible role of LT-α in the functionality of CS-induced follicles. Moreover, CXCL13 expression is 
present in lymphoid follicles and the induction of CXCL13 upon CS exposure is dependent on intact 
lymphotoxin signaling, pointing towards a role of CXCL13 in the organization of CS-induced lymphoid 
neogenesis 180.  
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Indeed, another approach to target lymphoid follicles is to neutralize CXCL13, blocking the 
recruitment of B lymphocytes. This has been tested in experimental models of several chronic 
inflammatory and autoimmune diseases. Genetic deficiency of CXCL13 in an experimental mouse 
model of multiple sclerosis resulted in a mild, self-limited form of disease with an attenuation of 
white matter inflammation and gliosis, which may be partly due to poor lymphocyte priming 188. In a 
model of type 1 diabetes using non-obese diabetic (NOD) mice, neutralization of CXCL13 unraveled B 
lymphocyte organization in islet lymphoid follicles, without impairing their functionality or having an 
impact on disease progression 189.   
Deficiency in CXCR5, the receptor for CXCL13, leads to a complete lack of gastric lymphoid follicles 
upon Helicobacter pylori infection and an overall reduction of chronic gastric inflammation 190. The 
same CXCR5 knockout mice were protected from antigen-induced arthritis and also demonstrated 
impaired development and organization of tertiary lymphoid tissue 191.  Also in collagen-induced 
arthritis, mice treated prophylactically with a neutralizing antibody to CXCL13 developed less severe 
arthritis in combination with reduced follicular response 192. In the therapeutic setting, these mice 
were still protected against disease, although formation of germinal centers was not altered 193. 
 The effect of CXCL13 neutralization on the development of pulmonary lymphoid follicles was also 
studied in the context of influenza infection and asthma. CXCL13 is not necessary for the formation 
or function of lymphoid follicles upon influenza infection. The only apparent defect is a loosely 
organized B cell zone that lacks FDCs 179. In the murine model of OVA-induced allergic asthma, 
CXCL13 neutralization abrogated the allergic reaction as measured by IgE production and pulmonary 
inflammation 194. Clearly, these preclinical studies suggest that interfering with the CXCL13/CXCR5 
axis might provide a therapeutic target in several diseases.  
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Based on ‘TGF-β superfamily in obstructive lung diseases: more suspects than TGF-β alone’ Verhamme FM, 
Bracke KR, Joos GF, Brusselle GG. American Journal of Respiratory Cell and Molecular Biology. 2014 November 
14. Epub ahead of print 
195
.  
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3.1. The TGF-β superfamily 
 
The transforming growth factor (TGF)-β pathway is one of the most evolutionarily conserved signal 
transduction pathways within the animal kingdom 196. There are more than 30 TGF-β superfamily 
ligands in mammals, including the TGF-βs, activins, bone morphogenetic proteins (BMPs) and growth 
differentiation factors (GDFs).  
All ligands of the TGF-β superfamily are synthesized as prepropeptide precursors and then processed 
and secreted as homodimers or heterodimers. The mature ligands are dominated by the cystine-knot 
architecture that results from 6-9 conserved cysteine residues forming intra- and intermolecular 
disulfide bonds. Next to structural features, this protein family also shares a similar signal 
transduction cascade. For signalling, each ligand requires a set of type I and type II serin/threonine 
kinase receptors. In humans, 5 type II and 7 type I receptors  have been identified. The activated 
receptor complex propagates the signal into the canonical pathway through phosphorylation of the 
receptor-regulated Smads (R-Smads). TGF-βs and activins signal through Smad2/3, whereas 
Smad1/5/8 act downstream of BMP and GDF signalling. Subsequently, the R-Smads form complexes 
with Co-Smad4 and translocate to the nucleus to regulate gene expression (Figure 10). Other 
pathways can also be activated by the TGF-β family, such as mitogen-activated protein kinase 
(MAPK) and phosphoinositide 3-kinase (PI3K), and are referred to as ‘non-canonical’ signalling 197-200. 
Proteins of the TGF-β superfamily are pleiotropic mediators, playing key roles in diverse 
developmental and physiological pathways, owing to ubiquitous expression of their signalling 
components. It is not surprising that disruptions in this tightly regulated pathway are associated with 
a wide range of human diseases, including respiratory disorders 201-203. Most research has focussed 
on the TGF-β1 ligand, showing its involvement in chronic sinus disease, pulmonary fibrosis, asthma 
and COPD 204-206.  
In this thesis, I will start with a short overview on what is currently known on TGF-β1 and then focus 
on other members of the TGF-β superfamily, more specifically activin-A and BMP-6. 
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Figure 10. Signalling components of the TGF-β superfamily. The canonical signalling pathway through the 
SMADs is shown for the transforming growth factor-βs (TGF-βs), activins, bone morphogenetic proteins (BMPs) 
and growth differentation factors (GDFs). ALK (activin receptor-like kinase), R-Smad (receptor-regulated Smad), 
I-Smad (inhibitory Smad). 
Figure reprinted with permission of Verhamme et al. Am J Respir Cell Mol Biol 2014 November 14 (Epub ahead 
of print) 
195
. 
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3.2. TGF-β1 
 
The TGF-β subfamily has 3 different isoforms, TGF-β1, TGF-β2 and TGF-β3, encoded by different 
genes. They signal through a similar cascade, exhibit overlapping properties, but can have distinct 
functions as demonstrated by different phenotypes of the respective knock-out mice 207-209. Each 
isoform is synthesized as an inactive precursor, targeted to the extracellular matrix (ECM), in complex 
with the latency associated peptide (LAP) and latent TGF-β binding protein (LTBP). Activation of TGF-
β involves release of the complex from the ECM, proteolysis and release from LAP, by which TGF-β is 
now able to interact with its receptors 210. 
TGF-β1 is the most studied and most prevalent isoform with a widespread expression and broad 
functionality. As TGF-β1 deficient mice display excessive inflammatory lesions in multiple organs and 
die prematurely, it became clear that TGF-β1 is essential for immune regulation 207. TGF-β1 serves as 
a regulatory cytokine by inducing tolerance as well as containing and resolving inflammation. It does 
so by controlling the chemotaxis, activation, proliferation and survival of a broad range of 
inflammatory cells, including mast cells, DCs, macrophages and lymphocytes 211. Most importantly, 
TGF-β1 is essential for the development and maintenance of FoxP3 expressing CD4+CD25+ Treg cells 
212. In the presence of IL-6, TGF-β1 is also able to induce the differentiation of pathogenic Th17 cells 
213. Moreover, TGF-β1 is a potent chemokine, which allows the rapid accumulation of macrophages, 
neutrophils, eosinophils and other cells at the site of inflammation 211. In summary, TGF-β1 has a 
pivotal role in immune regulation, imbalance between the pro- and anti-inflammatory action is 
associated with immune-mediated pathologies such as autoimmune diseases, inflammatory diseases 
and cancer. 
Furthermore, TGF-β1 is involved in the repair process of damaged tissue after inflammatory 
reactions, dysregulation of this process leads to tissue fibrosis and impaired organ functionality. 
Overexpression of TGF-β1 results in tissue fibrosis 214. TGF-β1 has multiple roles in this process, it can 
induce proliferation and differentiation of fibroblasts into myofibroblasts, is a potent stimulator of 
ECM production, such as fibronectin and collagen and can decrease the production of ECM-
degrading proteases. TGF-β1 target genes include connective tissue growth factor (CTGF), α-smooth 
muscle actin (α-SMA), collagen Ia2 and plasminogen activator inhibitor (PAI)-2 214-216. Another 
important action of TGF-β1 involves epithelial-to-mesenchymal transition (EMT), a process in which 
epithelial cells differentiate into fibroblasts and myofibroblasts. EMT has been proposed to 
contribute to the remodelling process in asthma and COPD 216.     
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Keeping these data in mind, TGF-β1 has emerged as an interesting regulator in the pathogenesis of 
COPD. First of all, several independent genetic studies identified single-nucleotide polymorphisms 
(SNPs) of TGF-β1 associated with COPD susceptibility or with dyspnea 217-220. Evidence of altered TGF-
β1 signalling in COPD has manifested, but the data are somewhat contradictory. TGF-β1 is present in 
airway and alveolar epithelial cells, airway and vascular smooth muscle cells and macrophages. 
mRNA and protein levels of TGF-β1 are significantly higher in the bronchiolar and alveolar epithelium 
of patients with COPD compared to subjects without COPD. Moreover, a significant correlation was 
found between TGF-β1 levels and smoking history and lung function 48;221. In contrast, when a 
subdivision of COPD severity was made based on the GOLD criteria, immunohistochemical staining 
demonstrated reduced TGF-β1 protein levels in epithelial and stromal cells and type 2 pneumocytes 
in COPD GOLD stage II compared to controls 222. The release of TGF-β1 and TIMP-1 by alveolar 
macrophages is impaired in COPD, suggestive for lower anti-inflammatory and anti-proteolytic 
activity in patients with COPD 223. 
Secondly, exposure to CS, the most important risk factor for COPD, also affects TGF-β1 signalling. Rat 
tracheal explants that were exposed to CS in vitro exhibited elevated TGF-β1 secretion 224. This has 
also been confirmed in vivo, in mice exposed to CS in acute and subacute exposure models 225-227. 
After long term exposure of 6 months CS, TGF-β1 levels declined both in the small airways as in the 
lung parenchyma 226;228. 
Persistent repair due to increased TGF-β1 signalling may contribute to airway remodelling and 
fibrosis. Correspondingly, the enhanced number of TGF-β1 expressing epithelial and submucosal cells 
of patients with chronic bronchitis correlated with basement membrane thickness and fibroblast 
number 229. Adding to this, CSE exposure of differentiated bronchial epithelial cells induced EMT by 
activation of ROS and through the release and autocrine action of TGF-β1 230. On the other hand, 
inadequate repair with decreased TGF-β1 signalling may predispose to the development of 
emphysema. Loss of integrin-mediated TGF-β1 activation causes age-dependent emphysema 
through increased macrophage expression of MMP-12 231. Moreover, Smad3 deficiency in mice 
resulted in progressive age-related airspace enlargement, associated with a high expression of MMP-
9 and MMP-12 232. Exposure of these Smad3 null mice to cigarette smoke aggravated air space 
enlargement and alveolar cell apoptosis 233. Thus, TGF-β1 is an important regulator of inflammation 
and remodelling and acts in a spatiotemporal manner in COPD. 
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3.3. Activin-A 
 
Activins are dimeric proteins consisting of 2 β subunits, βA and βB, that form the hetero- or 
homodimers, activin-A (βA:βA), activin-B (βB:βB), or activin-AB (βA:βB). Two other subunits (βC and 
βE) have also been identified  234. Activin-A is originally isolated from ovarian fluid as a stimulator of 
follicle-stimulating hormone, but recently, activin-A has emerged as a multi-faceted cytokine. 
 
3.3.1. Activin-A in inflammation and disease 
Activin-A can display pro- and anti-inflammatory properties depending on the cellular and temporal 
context 235-237. Activin-A inhibited the processing of IL-1β precursor into the mature cytokine in 
monocytic cell lines 238. Activin-A also stimulated expression of inducible nitric oxide synthase (iNOS) 
and production of NO in unactivated macrophages, but this effect was reversed in LPS-activated 
macrophages 239. Furthermore, activin-A is able to skew the macrophage polarization towards an M1 
phenotype 240. Similarly, neutrophils are a significant source of mature, stored activin-A and activin-A 
secretion by neutrophils is stimulated by the inflammatory cytokine TNF-α 241. Next to innate 
immune cells, activin-A also regulates adaptive immune cells. Activin-A acts on resting B cells by 
increasing cell growth and IgG production and acts indirectly on activated B cells through modulation 
of other immune cells 242.  
On the other hand, activin-A is known to stimulate the development of FoxP3+ regulatory T cells 243. 
Although there are many conflicting results, the current hypothesis is that activin-A exerts a pro-
inflammatory effect early on in the course of inflammation, but once the inflammatory response has 
been established, activin-A functions as an anti-inflammatory cytokine. In the light of these 
observations, it is not surprising that activin-A is implicated in several inflammatory and fibrotic 
diseases from which we will discuss Crohn Disease and inflammatory arthropathies 234. 
In patients with Crohn’s Disease or ulcerative colitis, expression of the activin βA subunit was 
increased and located in the mucosa and sub-mucosa of inflamed tissue, correlating with high 
expression of IL-1β, whereas no expression could be detected in the normal human digestive tract 
244;245. The activin type I and II receptors were expressed in intestinal tissues of both patients with 
Crohn Disease and ulcerative colitis, as well as of those from healthy controls 245. Activin-A enhanced 
the migration, inhibited the proliferation and induced apoptosis of intestinal epithelial cell lines, and 
this growth inhibition was largely reversed by follistatin, suggesting a role for activin-A in intestinal 
epithelial cell function 245;246. In several murine models of colitis, both local and systemic up-
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regulation of activin-A occurred. Importantly, in vivo administration of follistatin attenuated 
inflammation, reduced histologic score and increased survival rate, presumably by promoting the 
proliferation of epithelial cell proliferation/repair 246;247.  
Increased expression of activin-A, both on the RNA and protein level, has been found in synovial fluid 
from patients with inflammatory arthropathies but not in patients with non-inflammatory 
osteoarthritis 248-250. The majority of the activin-A producing cells in synovial tissues are CD68+ 
macrophage-like cells and fibroblast-like synoviocytes, which also express the activin receptors 251. 
Serum levels of activin-A were higher in patients with rheumatoid arthritis, systemic lupus 
erythrematosus and osteoarthritis compared to controls and correlated positively with disease 
activity parameters 248. It is still a question whether activin-A is beneficial, suggested by the fact that 
IL-6 mediated activities are suppressed by activin-A, or whether activin-A is harmful in the 
pathogenesis of rheumatoid arthritis, as activin-A promotes cell proliferation of synovial fibroblasts 
249;251. More functional studies in animal models are necessary to establish the pathophysiological 
role of activin-A in rheumatoid arthritis.  
 
3.3.2. Activin-A signalling in the lung  
Activin-A is expressed in alveolar and bronchiolar epithelium, alveolar macrophages and vascular 
smooth muscle cells 252;253. The less studied βB, βC and βE subunits have a lower expression, but can 
be detected in lung tissue 254. 
Activins interact with activin type II receptor A and B (ActR2A and ActR2B), which recruits the type I 
receptor or activin receptor-like kinase (ALK)4, but also ALK7 255. The type II receptors are broadly 
expressed in every structural cell type of the lung 253;254;256. Lung fibroblasts and bronchial epithelial 
cells are known to express the type I receptor ALK4 254.  
The activated type I receptor propagates the signal by phosphorylation of R-Smad2 and R-Smad3. 
Smad2/3 expression has been seen in several cell types in the lung, such as bronchial epithelial cells, 
fibroblasts, pulmonary artery smooth muscle cells and alveolar type 2 cells; the phosphorylated form 
of Smad2 is especially detected in bronchial epithelial cells. Also Smad4, a signalling mediator which 
is shared by different members of the TGF-β superfamily, is abundantly expressed in the lung 
222;254;257.  
Activin signalling is negatively regulated both extracellularly and intracellularly by diverse 
mechanisms (Figure 10). Inhibitory Smad6 and 7 function as a negative feedback mechanism in TGF-
β signalling 258.  Smad7 has been detected in airway epithelial cells, stromal cells and alveolar type 2 
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cells 222. Follistatin is an extracellular glycoprotein that binds and neutralizes activin with high affinity 
by blocking the receptor binding sites. Follistatin also binds with lower affinity to some other 
members of the TGF-β superfamily, including GDF-8/9 and BMP-2/5/7/8 234;258. Follistatin expression 
has been found in alveolar macrophages, bronchial and alveolar epithelial cells and vascular smooth 
muscle cells 253. Follistatin-related protein (or follistatin-like 3), which has a high degree of structural 
homology with follistatin, also binds and inhibits activins and BMPs and is expressed in lung tissue 259. 
 
3.3.3. Activin-A in respiratory disorders 
Bleomycin treatment is commonly used to study pulmonary fibrosis in animal models. Almost 20 
years ago, Matsuse and colleagues found enhanced levels of activin-A, particularly in alveolar 
macrophages and fibroblasts in the fibrotic area upon bleomycin treatment 252;253. Follistatin was only 
slightly upregulated, suggesting that the effect of activin-A may dominate the antagonistic effects of 
follistatin, whereas the levels of ActR2B were not altered 253. These data were subsequently 
confirmed in lung samples from patients with pulmonary fibrosis, where activin-A is detected in 
alveolar macrophages, metaplastic epithelium, hyperplastic smooth muscle cells and in desquamated 
cells 260. 
Functional studies showed that activin-A stimulates the proliferation and differentiation of lung 
fibroblasts into myofibroblasts (Figure 11)261;262. Furthermore, activin-A facilitates the capability of 
lung fibroblasts to contract collagen gels 263. Follistatin administration to bleomycin-treated rats was 
effective in reducing infiltration of macrophages and neutrophils and reducing lung permeability at 
an early phase and resulted in attenuated lung fibrosis at a late phase 253. Consistent with these 
findings, deficiency of Smad3, the common mediator of TGF-β/activin-A signalling, attenuated 
bleomycin-mediated lung fibrosis, as measured by deposition of collagen and fibronectin 264. 
Similarly, transient gene transfer of Smad7 partially prevented bleomycin-induced pulmonary fibrosis 
in mice 265. 
A first hint for a possible role of activin-A in asthma was offered by the discovery that activin-A was 
strongly upregulated in a mouse model of ovalbumin (OVA)-induced allergic airway inflammation, 
together with an increase of ALK4 and Smad mediators 254. Similarly, other studies in this allergic 
asthma model have shown elevated levels of activin-A in bronchoalveolar lavage fluid, released from 
airway epithelial cells or inflammatory cells, such as  activated mast cells and macrophages (Figure 
11) 
266-268. Importantly, follistatin concentrations also increased, but not as dramatically as activin-A, 
suggesting that there is a relative excess of activin-A 266. In human disease, activin-A was elevated in 
the lungs, serum and peripheral blood CD4+ T cells of patients with asthma 261;269. Furthermore, 
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patients with asthma exhibited less inhibitory Smad7 immunoreactivity in bronchial epithelial cells 
than normal subjects. After allergen challenge of asthma patients, P-Smad2, ALK4 and ActR2A 
positive cells were upregulated, whereas activin-A and follistatin levels showed no change 270. In 
contrast, Semitekolou and coworkers demonstrated, despite increased activin-A levels, declined 
ALK4 and ActR2A positive cells 269. Overall, these data suggest an activation of the activin-A pathway 
in asthma.  
Figure 11. Mechanisms of action of activin-A in lung diseases. Dysregulation of activin-A can have deleterious 
effects on normal lung homeostasis, leading to pathogenetic mechanisms in chronic lung diseases (pulmonary 
fibrosis/asthma/COPD), including inflammation, airway remodelling, emphysema and mucus hypersecretion. 
Figure adapted with permission of Verhamme et al. Am J Respir Cell Mol Biol 2014 November 14 (Epub ahead of 
print) 
195
. 
Mechanistically, activin-A appears to provide a link between early Th2-driven allergic responses and 
long-term structural changes in the airways that are characteristic for asthma. Intranasal delivery of 
follistatin in an acute OVA mouse model inhibited the allergen-specific Th2 immune response and 
mucus production 266. IL-13, the key cytokine for mucus production, controlled the activin-A secretion 
by bronchial epithelial cells 271. Systemic administration of a neutralizing antibody against activin-A 
exacerbated OVA-induced allergic airway disease, whereas recombinant activin- A reduced the 
symptoms, through the modulation of antigen-specific regulatory T cells 269. Remarkably, it thus 
seems that activin-A may exert distinct functions depending on the route of administration and type 
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of inhibitor. Finally, a role for activin-A together with TGF-β1 was suggested in Th9-mediated allergic 
inflammation upon house dust mite instillation 272. 
In vitro studies demonstrating that activin-A promotes the proliferation of airway smooth muscle 
cells and bronchial epithelial cells, pointed towards a possible role of activin-A in the process of 
airway remodelling 267;270. Activin-A neutralization by intranasal instillation of follistatin in a murine 
model of chronic allergic asthma confirmed that activin-A is crucial for mucus hypersecretion, 
subepithelial collagen deposition and thickening of the subepithelial smooth muscle (Figure 11) 273. 
Mice deficient in Smad3 have significantly decreased airway remodelling, which is associated with 
decreased numbers of peribronchial myofibroblasts 268. Smad2 overexpression in the airway 
epithelium resulted in enhanced airway hyperreactivity after allergen challenge concomitant with 
changes in smooth muscle and matrix remodelling. Remodelling was markedly inhibited by injection 
of an activin-A neutralizing antibody, providing direct evidence for a role of activin-A in remodelling 
274. 
Several studies reported dysregulated Smad signalling in the lungs of cigarette smoke-exposed mice 
and of patients with COPD. 222;226-228;275. As mentioned above, Smad3 deficient mice develop 
progressive age-related airspace enlargement, which is aggravated upon CS exposure 232;233. These 
effects are thought to be primarily mediated by TGF-β1, but activin-A can also be involved.  
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3.4. BMP-6 
 
Originally identified as proteins that stimulate bone morphogenesis, it is now clear that BMPs 
regulate the development and homeostasis of nearly all organs and tissues 276. With over 20 
mammalian members identified, BMPs constitute the largest subfamily of the TGF-β superfamily 
(Figure 10). Based on their amino acid sequence similarity, BMPs can be classified into at least 4 
subgroups: BMP-2/4, BMP-5/6/7/8, BMP-9/10, BMP-12/13/14 277. BMP-6 can signal through three 
type II receptors (ActR2A, ActR2B and BMPR2) and three type I receptors (ALK2, ALK3 and ALK6) 278. 
BMP-6 was discovered to be an essential stimulator of hepcidin expression and is thereby important 
for iron homeostasis  279;280. The hormone hepcidin was originally identified as an antimicrobial 
peptide. It functions as the “hypoferremia hormone” by degrading the iron exporter ferroportin and 
inhibiting the release of iron into the circulation. Through this mechanism, hepcidin negatively 
impacts bacterial growth by decreasing the iron availability 281. BMP-6 deficient mice develop iron 
overload in the liver, pancreas, heart and kidney by reduced hepcidin synthesis. Interestingly, BMP-6 
deficient mice have still the ability to induce hepcidin in the presence of inflammation as 
demonstrated by treatment with LPS 279;280. In a T cell transfer colitis model, treatment with an anti-
BMP-6 antibody inhibited liver hepcidin expression and colon IL-17 expression 282.  
BMP-6 can also have a direct impact on cells of the immune system. Macrophages express all three 
known type II BMP receptors and two of the three known type I receptors (ALK2 and ALK3). In vitro 
treatment of the macrophage cell line RAW264.7 with recombinant BMP-6  inhibited cell 
proliferation and induced expression of inducible nitric oxide synthase (iNOS),TNF-α and IL-
1β 283;284. Similarly, CD4+ T cells express ALK2, ALK3 and BMPR2. When Jurkat TAg cells are incubated 
with recombinant BMP-6, the BMP-6 signalling pathway was activated and proliferation was 
reduced. This anti-proliferative effect was thought to be mediated via increased inhibitor of 
differentiation (Id)1 protein levels 285. Furthermore, BMP-6 has an inhibitory effect on the 
proliferation of both naïve and memory B cells and on the differentiation of plasmablasts. In 
activated memory B cells, BMP-6 induced cell death. BMP-6 was also the most potent BMP protein in 
the inhibition of Ig production 286;287. Backwards, BMP-6 itself is regulated by inflammatory signals.  In 
cultures of fibroblast-like synoviocytes, the presence of IL-1β and TNF-α induced BMP-6 expression 
288. 
Finally, the BMP family is implicated in tissue remodelling. The first link was found in a kidney model, 
where it was discovered that BMP-7, which shares 87 %  amino acid identity with BMP-6, reversed 
TGF-β1 induced EMT in vitro and reduced renal injury in vivo 289. Similar findings were reported in 
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fibrosis models of liver and lungs, although contradictory results were found 290-293. The therapeutic 
potential of BMP-7 in pulmonary fibrosis has been confirmed in asbestos- and silica-induced animal 
models 292;293. Conversely, Murray and colleagues failed to establish a protective effect of BMP-7 in 
lung fibrosis either in vivo or in vitro 291. In vitro studies with BMP-7 demonstrated the pro-fibrotic 
function of BMP-7 in airway epithelial cells, but in cultured lung fibroblasts BMP-7 opposed TGF-β1 
dependent fibrogenic activity 294-296. In an OVA-induced mouse model of asthma, intranasal 
treatment with BMP-7 reduced lung inflammation and type 1 collagen deposition 297. 
Although initial studies could not demonstrate the same function for BMP-6, recent studies do point 
towards a role for BMP-6 in fibrosis 289;298-300. Increased numbers of myofibroblast progenitor cells in 
patients with type 1 diabetes were found to be negatively correlated with reduced BMP-6 expression 
300. The antifibrotic action of BMP-6 was confirmed in BMP-6 deficient mice which underwent 
unilateral ureteral obstruction 299. Correspondingly, BMP-6 deficiency alleviated non-alcoholic fatty 
liver disease in mice , although in this model, BMP-6 was upregulated 298 (Figure 12). 
 
 
Figure 12. Functions of BMP-6. A) Iron homeostasis: BMP-6 stimulates the expression of hepcidin (HAMP) 
which degrades the iron exporter ferroportin, and inhibits the release of iron from the cell. B) Immune system: 
BMP-6 inhibits the proliferation of macrophages, B and T cells. Moreover, BMP-6 stimulates the release of TNF-
α, iNOS and IL-1β from macrophages and inhibits immunoglobulin production. C) BMP-6 inhibits the TGF-β1 
induced pro-fibrotic actions.   
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3.4.1. BMP-6 signalling in the lung  
Few studies have addressed the specific localization of BMP-6 in lung tissue. Expression of BMP-6 has 
been detected in murine lung tissue and more specifically in bronchiolar epithelium and pulmonary 
artery smooth muscle cells (Figure 13) 257;301;302. Its receptors are abundantly expressed in the 
pulmonary vasculature, airway epithelium and lung fibroblasts 256;303-305. 
BMP-6 passes the signal on through R-Smad1, R-Smad5 and R-Smad8 (canonical pathway). 
Phosphorylation of these Smad proteins, hence an active BMP signalling, exists in airway epithelial 
cells, alveolar macrophages and lung fibroblasts, next to the pulmonary endothelium and vascular 
smooth muscle 304;306. In addition, non-canonical signalling through p38, ERK1/2 and JNK has been 
observed in pulmonary artery smooth muscle cells, lung fibroblasts and airway epithelial cells 
304;307;308.  
One of the most important targets of BMP signalling are the basic helix-loop-helix Id proteins. There 
are 4 known members in mammals (Id1 through 4), exhibiting similar, but not identical biological 
functions 309. Id4 is barely detectable in the lung, but Id1 and Id3 are expressed in pulmonary vacular 
endothelial cells and alveolar epithelium, while Id2 is detected in bronchial epithelium and smooth 
muscle cell compartments of the lung 310.  
 
 
 
 
Figure 13. Expression of BMP-6 in human lung tissue and human primary cells. mRNA expression profiling of 
BMP-6 in human lung tissue, human bronchial epithelial cells (HBECs), human airway smooth muscle cells 
(HASM) and peripheral blood mononuclear cells (PBMCs). 
Figure adapted with permission of Loth et al. Nat Genet 2014;46(7):669-677 
3
. 
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3.4.2. BMP-6 in respiratory disorders 
Very little information exists regarding BMP-6 and respiratory disorders. Already more than 10 years 
ago, an induction of pulmonary BMP-6 was observed upon OVA-induced airway inflammation in mice 
301. In addition, genetic studies revealed a possible contribution of BMP-6. Gene expression analysis 
of lung tissue from smokers without COPD and smokers with COPD demonstrated reduced BMP-6  
expression 311. Recently, the BMP-6 locus was found to be associated with FVC in a large genome 
wide association study 3. Therefore, it is interesting to study the in vivo functional role of BMP-6 in 
COPD. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
[CHAPTER 4: TRANSLATIONAL RESEARCH IN COPD – MATERIALS AND 
METHODS]  
52 CHAPTER 4: TRANSLATIONAL RESEARCH IN COPD 
 
4.1. Rationale  
 
Translation originates from Latin and means to ‘carry across’. Translational research refers to the 
bench-to-bedside (and vice versa) principle where new knowledge, mechanisms and techniques 
generated by basic research are used to provide new drugs and treatment options for human disease  
(Figure 14). 
 
Figure 14. Translational Research (in hatched area). An integrated approach where laboratory discoveries (via 
in vitro cell systems and in vivo animal models) are translated in clinical and population based research. 
 
Animal models act as a bridge between in vitro studies and studies in humans and enable to answer 
fundamental research questions. Mice are highly preferred as an animal model,  because – besides 
that they are easy to breed, house and handle – the mouse genome has been entirely sequenced and 
is highly homologue to the human genome. Another advantage is the opportunity to manipulate 
gene expression in mice by the generation of gene overexpressing, knockin and knockout mice. 
Several limitations need to be taken into account, when using murine models of COPD. No model 
mimics all the hallmarks of COPD. Moreover, there are certain differences in respiratory 
physiology/anatomy and immune system between mice and human. Our research group developed a 
murine model, in which CS inhalation – the primary cause of COPD in humans – triggers most 
pathological manifestations of COPD 312. For the detailed description, see Chapter 4.2. 
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To overcome the limitations of  murine studies, our research group has collected and studied human-
derived biological samples (lung tissue and induced sputum) from patients with COPD, smokers 
without airflow limitation and never smokers. These samples were processed to study gene and 
protein expression. This approach allows us to confirm the data generated in the mice model. For the 
detailed description, see Chapter 4.3.1. 
Airway epithelium is an important regulator of inflammatory processes in the lung through the 
production of a broad range of inflammatory mediators. In order to study the effect of CS on human 
epithelium, a third, in vitro approach was used with primary human bronchial epithelial cell cultures. 
Bronchial epithelial cells were grown on air-liquid interface to obtain mucociliary differentiation. 
Most studies examining airway epithelial cells in vitro were performed on either immortalized 
epithelial cell lines or submerged cultures of primary bronchial epithelial cells. Submerged cultures 
are however limited in their ability to develop into fully differentiated epithelial layers 313. Ease of 
operation, small test sample needed and the fact that specific mechanisms of action can be tested, 
make this model an ideal system to perform mechanistic studies. However, as with any in vitro cell 
culture model, cells grow in a milieu different from that encountered in vivo, which may result in 
outcomes irrelevant for the in vivo situation. For the detailed description, see Chapter 4.3.3. 
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4.2. Murine model of COPD 
 
4.2.1. Protocol 
Using a smoking apparatus and a plexiglass smoke chamber (7500 cm3) (Figure 15), groups of 8-10 
mice are subjected whole body to mainstream CS of 5 simultaneously lit cigarettes (Kentucky 
Reference Cigarette 3R4F without filter; University of Kentucky, Lexington, KY, USA). This exposure is 
repeated  4 times a day, with 30 minutes smoke-free intervals and 5 days a week. Because mice do 
not tolerate undiluted CS, the smoke chamber has an air supply, establishing an optimal smoke/air 
ratio of 1/6. The control groups were exposed to room air. Using this protocol, carboxyhemoglobin 
levels in serum of CS-exposed mice reached 8.35 ± 0.46 % (versus 0.65 ± 0.25 % in air-exposed mice), 
corresponding to serum levels in human smokers 314.  
 
 
Figure 15. Schematic overview of the cigarette smoke exposure model. Mice receiving whole body exposure 
of cigarette smoke in a plexiglass chamber connected to the smoke apparatus. 
 
The mice were exposed for 3 days (acute exposure), 4 weeks (subacute exposure) or 24 weeks 
(chronic exposure). The acute and subacute timepoint are sufficient to mimic the CS-induced 
pulmonary inflammation, ideally to elucidate key mechanisms of CS-induced inflammation. 
Chronically-exposed mice exhibit additional hallmarks of COPD, including emphysema, lymphoid 
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follicles and airway wall remodeling 47;312. This chronic model is highly relevant because the exposure 
period corresponds with one quarter of the murine life span, similar to the development of COPD in 
humans after at least 15 to 20 years of smoking (≈ one quarter of the human life span). This murine 
model is standardized in the C57BL/6 mouse strain, which is moderately sensitive to CS and is widely 
used in numerous genetically modified mice 315. 
24 hours after the last exposure, mice are sacrificed by an overdose pentobarbital by intraperitoneal 
injection and blood, tissue (lung tissue and lung draining mediastinal lymph nodes) and 
bronchoalveolar lavage (BAL) samples are collected to study the CS-induced effects. All in vivo 
manipulations were approved by the local Ethics Committee for animal experimentation of the 
Faculty of Medicine and Health Sciences, Ghent University. 
 
4.2.2. Inflammation in BAL, lung tissue and mediastinal lymph nodes 
BAL is performed to harvest and analyze the cell population within the alveolar spaces and airway 
lumina. Processing of the BAL cells into cytospins allows discrimination between morphologically 
different cell types such as monocytes/macrophages, neutrophils and lymphocytes, using a May-
Grünwald-Giemsa staining (Figure 16). For more detailed information of cell type markers, flow 
cytometry is used (see below). 
 
 
Figure 16. Cytospins of bronchoalveolar lavage  cells stained with May-Grünwald-Giemsa. Photomicrographs 
of BAL cells of C57BL/6 mice exposed to air A) or cigarette smoke for 24 weeks B). A) In air-exposed mice, 
resident alveolar macrophages (1) are the main cell type in the airway lumen. B) Upon CS exposure, different 
inflammatory cells populate the airway lumen, including activated macrophages (1), neutrophils (2) with 
segmented nuclei and small lymphocytes (3).  
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To obtain insights into the inflammatory cell population in the lungs and lymph nodes (LN), the lung 
(major lobe of the right lung) and lung draining lymph nodes are harvested for the preparation of 
single cell suspensions. 
Flow cytometric analysis is performed on BAL cells and cell digests of LN and lung. Flow cytometry is 
a technique for the characterization of different cell populations based on cell-specific markers, by 
using a combination of antibodies conjugated to fluorescent dyes that bind these markers (surface or 
intracellular). The number and characterization of dendritic cells (DCs), macrophages, inflammatory 
monocytes and neutrophils, T lymphocytes (CD4+, CD8+ and Tregs) and B lymphocytes are defined 
(Figure 17).  
Inflammatory mediators are measured on the RNA level by qRT-PCR using RNA extracted from total 
lung tissue (small lobe of the right lung). Analysis of protein levels is performed on BAL supernatant 
using ELISA or the multiplex Cytometric Bead Array (CBA). For the detailed description, see Chapter 
4.4. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Gating strategy for the characterization of inflammatory cells in bronchoalveolar lavage, lung and 
lymph node. A) Macrophages are identified as CD11c
+
 and high-autofluorescent cells, whereas the CD11c
+
, 
low-autofluorescent, MHC-II
+
 cell population is identified as DCs. B lymphocytes are identified as CD11c
low
 and 
CD19
bright
 population. Inflammatory monocytes are defined as CD11c
-
CD11b
+
Ly6G
-
Ly6C
+
 and inflammatory 
neutrophils as CD11c
-
CD11b
+
Ly6G
+
Ly6C
+
. B) T lymphocytes are characterized as CD3
+
 producing low side 
scatter. We identify CD4
+
 and CD8
+
 T lymphocytes B) and use CD69 as activation marker in lung tissue C). C) 
Regulatory T cells (Tregs) are CD25
+
 and FoxP3
+
 (intracellular staining). D) In the LN, we distinguished the 
CD11c
int/high
MHC-II
high
 airway derived DCs from the CD11c
high
MHC-II
int
 non-airway derived DCs.                        → 
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4.2.3. Lymphoid neogenesis 
Mice develop lymphoid tissue in the lungs, upon 24 weeks of CS exposure (chronic exposure) 
159;180;316. To localize and quantify the number of lymphoid follicles in lung tissue, lymphocytes are 
visualized on paraffin sections obtained from the left lung with an immunohistochemical CD3/B220 
double-staining (Figure 18) 159. All lymphoid infiltrates in the proximity of airways and in the lung 
parenchyma are counted. Lymphoid follicles are defined as dense organized accumulations of at least 
50 cells. We also quantified the lymphoid aggregates which are loose not-organized accumulations of 
less than 50 cells. The number of lymphoid structures was normalized for the number of airways (for 
structures around the airways) or for the area of lung parenchyma (for structures in the 
parenchyma). All measurements are performed in a blinded fashion. 
 
Figure 18. Lymphoid follicles in cigarette smoke-exposed mice. Photomicrographs of murine lung sections 
stained for CD3 (T lymphocytes shown in brown) and B220 (B lymphocytes shown in blue). A) In air-exposed 
mice, sparse lymphocytes are spread throughout the lung. B) In CS-exposed mice (chronic exposure) 
lymphocytes organize into lymphoid structures both around the airways and in the lung parenchyma.  
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4.2.4. Emphysema 
Emphysema is characterized by destruction of lung parenchyma and permanent enlargement of the 
alveolar spaces. These emphysematous lesions, interspersed by apparently normal parenchyma, are 
mimicked in C57BL/6 mice. The morphometric assessment of emphysema is based on the 
measurement of airspace enlargement (mean linear intercept or Lm) and destruction of alveolar 
walls (destructive index or DI) 317;318. All measurements are performed in a blinded fashion. 
Lung sections obtained from the left lung are stained with haematoxylin and eosin. 
Photomicrographs of the lung parenchyma are captured using a Zeiss AxioVision image analysis 
system. Only sections without cutting artefacts, compression or hilar structures are used in this 
analysis. For quantifications, a grid (100 x 100 µm) is placed over photomicrographs using image 
analysis software (Image J 1.47v). Each intercept of the horizontal and vertical grid lines with the 
alveolar walls is marked and counted. The total length of each line is divided by the number of 
intercepts and then averaged to calculate the Lm  (Figure 19). 
DI is measured by superimposing a grid with 42 points on the photomicrographs using image analysis 
software (Image J 1.47v). Structures lying under these points are classified as normal (N) or destroyed 
(D) alveolar and/or duct spaces. Points falling over other structures (duct walls, alveolar wals, etc.) 
are not included. The DI is calculated with the formula: DI = D / (D + N) x 100.  
 
 
 
Figure 19. Quantification of pulmonary emphysema in mice. The mean linear intercept (Lm) is measured by 
placing a 100 x 100 μm grid over each field (red lines). The total length of each line of the grid divided by the 
number of alveolar intercepts (red dots) per line gives the average distance between alveolated surfaces or the 
Lm.  
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4.2.5. Airway wall remodelling 
To determine the degree of airway remodelling, the deposition of collagen and fibronectin in the 
airway wall is measured on lung sections (left lung) using staining with Sirius Red and anti-fibronectin 
antibody 319. The following morphometrical parameters are marked manually on the digital 
representation of the airway (Figure 20): the length of the basement membrane (Pbm), the area 
defined by the basement membrane (Abm) and the area defined by the total adventitial perimeter 
(Ao). The total bronchial wall area (WAt) is calculated as WAt = Ao – Abm and normalized to the 
squared Pbm.  The area in the total airway wall covered by the stain is determined by the software 
(Axiovision, Zeiss). The area of collagen or fibronectin is normalized to Pbm. All airways with a Pbm 
smaller than 2000 µm and cut in reasonable cross sections are included. Quantitative measurements 
are performed in a blinded fashion. 
 
 
 
 
Figure 20. Quantification of airway wall remodelling in mice. Assessment of collagen deposition in the airway 
wall on Sirius Red stained lung sections. The area between the 2 black lines that stains positively for collagen is 
quantified by the Axiovision software (Zeiss) using an image analysis system. A) Air-exposed mice, B) CS-
exposed mice. 
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4.3. Human studies  
 
4.3.1. Lung tissue 
Lung tissue is obtained from patients who undergo lobectomy or pneumectomy for various reasons 
(mostly solitary pulmonary tumours) at the Ghent University Hospital. None of the patients were 
treated with neo-adjuvant chemotherapy or had recently encountered a COPD exacerbation. COPD 
diagnosis and severity is defined using pre-operative spirometry according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) classification 1. Written informed consent is obtained from 
all subjects prior to surgery according to protocols approved by the medical ethical committee of the 
Ghent University Hospital. All patients are interviewed about their smoking habits and medication 
use and are carefully characterized. Patients are classified as ex-smokers when they have quit 
smoking at least 1 year prior to surgery. 
Lung tissue at maximum distance from the pulmonary lesions and without signs of retro-obstructive 
pneumonia or tumour invasion is collected by a pathologist. Part of the resection specimens is 
sampled for immunohistochemical analysis from the peripheral lung, ensuring the sampling of small 
airways. These samples are fixed in paraformaldehyde and embedded in paraffin (More details on 
immunohistochemistry, see Chapter 4.4.2.).  Another part of the lung tissue is stored in RNA 
stabilizing agent (RNAlater, Qiagen, Hilden, Germany) at minus 80 °C for later RNA extraction and 
qRT-PCR (More details on qRT-PCR , see Chapter 4.4.1.). This procedure is schematically presented in 
Figure 21. 
 
 
Figure 21. Protocol for the 
collection of human lung tissue. 
Lung tissue is collected by a 
pathologist from lung lobes of 
patients who underwent lobectomy. 
In the lab, we sample a part of the 
resection specimens for 
immunohistochemical analysis and a 
part for RNA extraction and qRT-PCR 
analysis.   
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4.3.2. Induced sputum  
Patients are recruited from the outpatient pulmonary clinic of the Ghent University Hospital, while 
controls are recruited by advertising as well as from the outpatient clinic. Patients with a recent 
exacerbation (preceding 2 months), with (very) severe COPD, asthma, bronchiectasis or a respiratory 
infection (preceding 4 weeks) are excluded. Written informed consent is obtained from all subjects 
and the patients are interviewed as described above. This study is approved by the Medical Ethical 
Committee of the Ghent University Hospital. 
Sputum induction and processing are performed as previously described 61. Sterile, pyrogen-free, 
hypertonic saline at increasing concentrations of NaCl (3 %, 4 % and 5 %) is inhaled during a 5 minute 
period after premedication with salbutamol (2 x 200 µg). The saline is nebulized via an ultrasonic 
nebulizer (Ultra-Neb, Devilbiss Health Care Inc, Somerset, PA, USA). Each time after the inhalation, 
subjects are encouraged to cough and expectorate an adequate sample. Monitoring of pulmonary 
function has been performed before and after induction. Sputum plugs are selected, transferred in a 
polystyrene tube and mixed with dithiotreitol (DTT; 10 % Sputalysin, Boehringer-Calbiochem Corp, 
San Diego, CA, USA) for 30 seconds by vortex and for 15 minutes on a tube rocker. After the addition 
of PBS, samples are filtered through a 70 µm cell strainer and centrifuged for separation between the 
cell fraction and cell-free supernatant fraction. The supernatant is stored at minus 80 °C until further 
analysis.  
The cell fraction is further processed for counting in a haemocytometer and the cell concentration is 
adjusted to 0.7 x 106 cells/ml. Cytospins are prepared on Shandon II cytocentrifuge cups (Shandon 
Southern Instruments, Sewickley, PA, USA) and spun for 5 minutes at 300 rpm. The cytospins are 
stained with May-Grünwald-Giemsa for differential cell counts by 2 blinded investigators.  400 
nucleated cells per slide are counted and expressed as the percentage of intact round nucleated 
cells, excluding squamous epithelial cells.  
 
4.3.3. Bronchial epithelial cell cultures 
Primary human bronchial epithelial cells (HBECs) are obtained by enzymatic digestion from lung 
resection specimens obtained from anonymous donors during surgery for lung cancer 320. Bronchial 
rings are incubated overnight with proteinase type XIV in HBSS. Afterwards, epithelial cells are gently 
scraped off the luminal surface and cultured in supplemented keratinocyte serum-free medium 
(KSFM) on pre-coated 6-well plates until 80-90 % confluency (1-2 weeks). After near confluency is 
reached, the cells are trypsinized. The cultures are stored in liquid nitrogen until further culture. 
CHAPTER 4: TRANSLATIONAL RESEARCH IN COPD   63 
 
 
 
Cells (passage 2) are transferred to pre-coated 9 cm petri dishes and cultured for 4-6 days in 
supplemented KSFM medium until near confluency. After trypsinization, cells are seeded on pre-
coated semi-permeable Transwell membranes and grown submerged for 4-7 days until they reach 
confluence in medium containing a high concentration of retinoic acid (15 ng/ml; Lonza, Breda, The 
Netherlands). Thereafter, cells are cultured at an air-liquid interface for another 2 weeks. The apical 
side of the epithelial layers is washed with warm PBS three times a week, while the medium is 
refreshed at the same time. Mucociliary differentiation is usually observed between day 7 and 10 
after exposure to air-liquid interface. All cells are cultured at 37 °C in a humidified atmosphere of 5% 
CO2. The cell culture protocol is shown in Figure 22. 
Figure 22. Culture of primary human bronchial epithelial cells (HBECs). Primary HBECs are isolated by 
enzymatic digestion of bronchial rings. After reaching confluence, the cells are transferred to 9 cm petri dishes 
for 7 days until the cells are confluent. Then the cells are transferred to Transwell inserts. For the first 4-7 days, 
the cells are grown submerged in medium both on the apical and basal side. Thereafter, the medium on the 
apical side is removed and the cells are grown in air-liquid interface for 14  days during which mucociliary 
differentiation occurs. 
  
 
After the 14-day air-liquid interface culture period, HBECs are exposed to whole volatile smoke or air 
as a negative control, using a modification of the system reported by Beisswenger and coworkers 
(Amatngalim et al., manuscript in preparation) 321. In short, a pump generates a continuous flow of 
CS by burning Reference Cigarettes 3R4F (University of Kentucky, Lexington, KY, USA) and the smoke 
stream is guided into the exposure chamber placed inside a CO2 incubator. The pump is set on a 
constant voltage and a flow meter is used to assure a constant flow of 1 litre/minute. A ventilator 
inside the exposure chamber distributes the CS equally over the cells. A filter is used at the outlet of 
the exposure chamber to reduce smoke particles reaching the pump. It takes 5 minutes for a 
cigarette to burn, after which smoke is removed from the exposure chamber for 10 minutes. 
Immediately after the CS exposure, the medium is refreshed and the cells, together with the basal 
medium, are harvested 3, 6 and 24 hours after the CS exposure. The CS protocol is schematically 
presented in Figure 23.  
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Figure 23. Schematic overview of the cigarette smoke exposure model for in vitro use. A pump generates a 
continuous flow of CS and the smoke stream is guided into the exposure chamber in the CO2 incubator through 
a plastic tube. The pump is set on a constant voltage and together with a flow meter, this assures a constant 
flow.  A  ventilator inside the exposure chamber distributes the CS equally over the cells. Also a filter is used to 
reduce smoke particles reaching the pump. It took 5 minutes for a cigarette to burn. Immediately after the 
exposures, the medium was refreshed and the cells were harvested 3, 6 and 24 hours after the exposure. 
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4.4. Experimental techniques 
 
Several techniques have been applied, both on human and mouse lung tissue to quantify gene 
expression and to measure protein levels and localize proteins in lung tissue. In this section, these 
methods will be described. Quantitative real-time reverse transcriptase (qRT-PCR) has proven to be a 
powerful tool to quantify gene expression profiles. In order to obtain more insights into the protein 
profile, ELISA and CBA are performed on supernatant fractions (BAL or sputum). To visualize proteins, 
lung sections are subjected to immunohistochemical staining.  
 
4.4.1. Measurement of mRNA expression 
Lung mRNA is extracted using the miRNeasy Mini kit from Qiagen (Hilden, Germany) and cDNA is 
prepared with the Transcriptor Universal cDNA Master Kit (Roche, Basel, Switzerland) following 
manufacturer’s instructions. The expression of the gene of interest relative to 3 reference genes is 
analysed using TaqMan Gene Expression assays including specific primers/fluorogenic probe mix 
(Applied Biosystems, Halle, Belgium). All reactions are set up in duplicate using identical amplification 
conditions. The amplification conditions consist of 10 minutes at 95 °C and 50 cycles of 95 °C for 10 
seconds and 60 °C for 15 seconds. A standard curve derived from serial dilutions of a mixture of all 
samples is included in each run. Amplifications are performed using a LightCycler 480 detection 
system (Roche). Expression of target genes is corrected by a normalization factor that is calculated 
based on the expression of three reference genes, using the geNorm applet according to the 
guidelines and theoretical framework previously described  ( http:// medgen.ugent.be / ~jvdesomp / 
genorm/) 322. 
 
4.4.2. Measurement of protein levels 
Using ELISA, we can quantify the protein levels in lung tissue or in the airways by analyzing BAL 
supernatant. The ELISAs used in this thesis are commercially available and are performed following 
the manufacturer’s instructions. The disadvantage of this technique is that large amounts of sample 
are needed and for that reason CBA is sometimes preferred. 
Protein levels of cytokines and chemokines in BAL fluid are determined by CBA. Multiple proteins can 
be analyzed in one assay using beads of known size and fluorescence, which can be detected by flow 
cytometry. A mixture of capture bead populations, each with distinct fluorescence intensities and 
coated with a capture antibody specific for a soluble protein are prepared. The beads are incubated 
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together with PE-conjugated detection antibodies, test samples or standards to form sandwich 
complexes. Following acquisition of sample data using the flow cytometer (FACSCaliburTM flow 
cytometer, BD Biosciences), the data are analyzed using the CBA Analysis Software (BD Biosciences). 
The intensity of the fluorescent signal of each sandwich complex reveals the concentration of that 
particular protein. 
For information about the specific localization of a specific protein, immunohistochemical staining is 
performed. The quantification of activin-a in the airway epithelium by colour recognition, is shown in 
Figure 24. The epithelium is manually marked between the airway lumen and the basement 
membrane, using KS400 software (Zeiss). The epithelial area with positive activin-A staining is 
normalized to the length of the basement membrane. 
 
 
 
Figure 24. Quantification of immunohistochemical staining. Positive staining is quantified in the airway 
epithelium by Axiovision software (Zeiss) using an image analysis system. The airway epithelium is manually 
marked by 2 lines, the airway lumen in blue and the epithelial basement membrane in red.  
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COPD is a highly prevalent disorder and represents a significant burden worldwide. COPD 
susceptibility is dependent of both environmental exposures (most importantly tobacco smoke) and 
genetic susceptibility (including genes involved in the transforming growth factor-β superfamily). The 
abnormal inflammatory response in the lungs of patients with COPD results in airway wall 
remodelling and emphysema. The pathogenesis consists of a complex and not fully understood 
interplay between inflammatory cells, proteolytic activity, oxidative stress and apoptosis. Current 
treatment is pure symptomatic, indicating that novel treatments are urgently needed. 
In a first study, we focused on the functional role of lymphoid follicles in the pathogenesis of COPD, 
since it is unclear whether lymphoid follicles are harmful or beneficial in COPD. COPD is hallmarked 
by a persisting inflammation, that continues despite smoking cessation and triggers the development 
of lymphoid follicles in severe disease. Importantly, the number of follicles correlates positively with 
disease severity, suggesting a role of lymphoid follicles in the persistent nature of COPD. CXCL13 is 
crucial in B cell recruitment and formation of lymphoid tissue. We hypothesized that neutralizing 
CXCL13 abrogates the development of lymphoid follicles, enabling us to study the function of 
lymphoid follicles in COPD. This approach allows us to assess the contribution of these local 
(auto)immune responses in the development of pulmonary inflammation, emphysema and airway 
wall remodeling. Furthermore, we aimed to analyze the expression of CXCL13 in the airways and 
lungs of patients with COPD compared to control groups (never smokers and smokers without 
airflow obstruction). 
Members of the transforming growth factor (TGF)-β superfamily, which include TGF-βs, activins and 
bone morphogenetic proteins (BMPs) are implicated in fundamental physiological processes. 
Dysregulation of these pathways is associated with numerous diseases. The prototypical ligand TGF-
β1 has been extensively studied in the pathogenesis of COPD, especially considering its role in 
immune regulation and airway remodeling. However, little is known about the other ligands of this 
superfamily in the pathogenesis of COPD. Activin-A signaling is activated in chronic inflammatory 
airway diseases, such as pulmonary fibrosis and asthma. We hypothesized that activin-A plays a 
crucial role in the induction of pulmonary inflammation after CS exposure. We first analyzed the 
expression of activin-A and its natural antagonist, follistatin in the lungs of CS-exposed mice, in lungs 
of patients with COPD and in primary human bronchial epithelial cell cultures exposed to CS. The 
functional role of activin-A was investigated in CS-exposed mice, using follistatin to antagonize 
activin-A. 
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Bone morphogenetic proteins represent another subfamily of the TGF-β superfamily and were 
originally identified as proteins that stimulate bone morphogenesis. It is now becoming clear that 
these proteins regulate the development of nearly all organs and tissues. More specifically, we were 
interested in the role of BMP-6, since a recent genome wide association study (GWAS) has found an 
association between genetic variants in the gene encoding BMP-6 and the forced vital capacity (FVC). 
We hypothesized that reduced BMP-6 expression in lungs of COPD patients facilitates the 
development of CS-induced inflammation, emphysema and airway wall remodelling, mainly 
through iron-dependent mechanisms. We measured the pulmonary expression of BMP-6 in patients 
with COPD and mice exposed to CS. Next, we exposed BMP-6 deficient mice to subacute and chronic 
CS and investigated the role of BMP-6 in CS-induced hallmarks of COPD, including pulmonary 
inflammation, emphysema and airway wall remodelling. Moreover, since BMP-6 is essential to iron 
homeostasis, we studied the effect of BMP-6 deficiency on CS-induced changes in content, storage 
and transport of iron. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
[CHAPTER 6: ROLE OF CXCL13 IN CIGARETTE SMOKE-INDUCED LYMPHOID 
FOLLICLE FORMATION AND COPD] 
 
Lymphoid follicles are present in lungs of patients with severe COPD. However, the role of these 
tertiary lymphoid organs in the pathogenesis of COPD is still unknown. CXCL13 is a chemokine 
attracting B lymphocytes and is crucial for lymphoid neogenesis. In this study, we aimed to abrogate 
the formation of CS-induced lymphoid follicles by antibody mediated neutralization of CXCL13 in a 
CS-induced murine model of COPD. 
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ABSTRACT 
 
Rationale: The B-cell attracting chemokine CXCL13 is an important mediator in the formation of 
tertiary lymphoid organs (TLOs). Increased numbers of ectopic lymphoid follicles have been observed 
in lungs of patients with severe COPD. However, the role of these TLOs in the pathogenesis of COPD 
remains unknown. 
Objectives: By neutralizing CXCL13 in a mouse model of chronic cigarette smoke (CS)-exposure, we 
aimed at interrogating the link between lymphoid follicles and development of pulmonary 
inflammation, emphysema and airway wall remodelling. 
Methods: We first quantified and localized CXCL13 in lungs of air- or CS-exposed mice and in lungs of 
never smokers, smokers without airflow obstruction and patients with COPD by RT-PCR, ELISA and 
immunohistochemistry. Next, CXCL13 signaling was blocked by prophylactic or therapeutic 
administration of anti-CXCL13 antibodies in mice exposed to air or CS for 24 weeks and several 
hallmarks of COPD were evaluated. 
Measurements and main results: Both mRNA and protein levels of CXCL13 were increased in lungs of 
CS-exposed mice and patients with COPD. Importantly, expression of CXCL13 was observed within B-
cell areas of lymphoid follicles. Prophylactic and therapeutic administration of anti-CXCL13 
antibodies completely prevented the CS-induced formation of pulmonary lymphoid follicles in mice. 
Interestingly, absence of TLOs attenuated destruction of alveolar walls and inflammation in 
bronchoalveolar lavage (BAL), but did not affect airway wall remodelling. 
Conclusions: CXCL13 is produced within lymphoid follicles of patients with COPD and is crucial for the 
formation of TLOs. Neutralization of CXCL13 partially protects mice against CS-induced inflammation 
in BAL and alveolar wall destruction. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) affects the airways and lungs and is characterized by 
a progressive and not fully reversible airflow limitation 1;54. Cigarette smoking is by far the most 
important risk factor for COPD. Importantly, although smoking cessation is currently the only 
effective treatment for COPD, it only partially attenuates the accelerated decline in lung function. 
Pathology of COPD includes obstruction of the small airways and destruction of lung parenchyma 
(emphysema) 12. Until now, the mechanisms that are responsible for the development and 
progression of COPD are not well understood. Although the most common hypotheses focus on the 
role of the innate immune system, there are clear signs of adaptive immune responses in patients 
with COPD 54. CD8+ T-lymphocytes are associated with smoking and subsequent risk for COPD 88 and 
moreover, organisation of T- and B-lymphocytes in lymphoid follicles has been observed in advanced 
stages of COPD 33. 
Ectopic lymphoid follicles, also called tertiary lymphoid organs (TLOs), have a composition and 
organization reminiscent of the secondary lymphoid organs, such as lymph nodes, Peyer’s patches or 
spleen; however, their function remains largely unknown. They occur in several chronic inflammatory 
diseases, and are formed by lymphoid neogenesis, a mutual interaction between hematopoietic 
‘inducer’ cells and stromal ‘organizer’ cells 153;172. Briefly, chronic inflammation activates lymphocytes 
to express the cytokine lymphotoxin α1β2 (LTα1β2) on their membrane. Signaling through the 
lymphotoxin β receptor on stromal cells triggers the release of chemokines that orchestrate 
lymphocyte homing and compartmentalization of TLOs. CCL19 and CC21 regulate homing of CCR7+ 
naïve T-cells and mature dendritic cells, while CXCL13 attracts CXCR5+ B-cells into the lymphoid 
follicles. Additionally, CXCL13 induces LTα1β2 expression on B-cells, creating a positive feedback 
loop176.  
Increased numbers of small airways containing lymphoid follicles have been found in patients with 
severe COPD, compared to healthy subjects and patients with mild-to-moderate COPD 33;324. In 
addition, lymphoid follicles have also been detected in the lung parenchyma of patients with COPD 
and in lungs of mice upon chronic cigarette smoke (CS) exposure 158;159. Although the demonstration 
of oligoclonality in follicular B-cells suggests a local antigen-specific immune response, the role of 
lymphoid follicles in COPD is still controversial, especially since it is not known which antigens are 
involved 152. The immune response may be directed against CS-derived antigens or lung tissue 
components and thus be of a harmful (autoimmune) nature. In contrast, they may be beneficial for 
the host by providing protection against microbial colonization and infection of the lower respiratory 
tract. 
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In this study we determined the presence of the B-cell attracting chemokine CXCL13 in the lungs – 
and more specific in the lymphoid follicles – of both mice exposed to CS and patients with COPD. 
Next, using the chronic CS model of COPD, we aimed at disrupting lymphoid neogenesis by 
neutralizing CXCL13, both in a prophylactic and a therapeutic setting. This allowed us to study the 
contribution of lymphoid follicles in the CS-induced development of pulmonary inflammation, 
emphysema and airway wall remodeling and to elucidate the role of these TLOs in the pathogenesis 
of COPD. 
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MATERIALS AND METHODS 
 
Human study populations 
Written informed consent was obtained from all subjects according to protocols approved by the 
medical ethical committee of the Ghent University Hospital. Lung resection specimens were obtained 
from 53 patients diagnosed with solitary pulmonary tumours at Ghent University Hospital (Ghent, 
Belgium). Lung tissue at maximum distance from the pulmonary lesions and without signs of retro-
obstructive pneumonia or tumour invasion was collected by a pathologist. Sputum induction was 
performed on 44 subjects who were recruited from the outpatient pulmonary clinic of the Ghent 
University Hospital or by advertising. There was no overlap between the subjects of lung tissue and 
sputum analysis. Sputum induction and processing was performed as described previously 61. 
Animals 
Male C57BL/6J mice, 6-8 weeks old, were purchased from The Jackson Laboratory (Bar Harbor, ME, 
USA), maintained in standard conditions under a 12 h light-dark cycle and provided a standard diet 
(Pavan, Brussels, Belgium) and chlorinated tap water ad libitum. All in vivo manipulations were 
approved by the local Ethics Committee for animal experimentation of the Faculty of Medicine and 
Health Sciences (Ghent University). 
Cigarette smoke (CS) exposure 
C57BL/6 mice were exposed whole body to CS, as described previously 159;312. Briefly, groups of 10 
mice were exposed to the mainstream CS of 5 cigarettes (Reference Cigarette 3R4F without filter, 
University of Kentucky, Lexington, KY, USA), four times a day with 30 minutes smoke-free intervals, 5 
days a week for 4 or 24 weeks. An optimal smoke/air ratio of 1/6 was obtained. The control groups 
were exposed to room air.  
Anti-CXCL13 treatment 
8 groups of 10 C57BL/6J mice were exposed for 24 weeks (chronic exposure) to air or CS. 6 groups 
were injected intraperitoneally (i.p.) every 2 weeks from the start of the experiment (prophylactic 
treatment) with 200 µl PBS, rat IgG2a isotype control antibody (500 µg/mouse, R&D Systems, 
Abingdon, UK) or anti-CXCL13 monoclonal antibody (500 µg/mouse, R&D Systems). A further 2 
groups were injected i.p. every 2 weeks from week 13 onwards (therapeutic treatment) with 200 µl 
rat IgG2a isotype control antibody (500 µg/mouse) or anti-CXCL13 monoclonal antibody (500 
µg/mouse). All injections were performed 1 h before air- or CS-exposure. 
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Quantification and detection of CXCL13 
CXCL13 mRNA expression in total lung tissue of mice and human subjects was analyzed using 
TaqMan Gene Expression Assays (Applied Biosystems, Forster City, CA, USA), as described previously 
84. CXCL13 protein levels were determined in BAL fluid supernatant of mice and induced sputum 
supernatant of human subjects using commercially available ELISA kits (R&D Systems). 
Immunofluorescence staining with anti-CXCL13 (R&D Systems), anti-CXCR5 (R&D Systems) and anti-
CD20 (eBioscience) was performed on frozen sections of human lung tissue, as described previously 
325. Immunohistochemical staining with anti-CXCL13 (R&D Systems) was performed on paraffin 
sections of the left lung of mice, as described previously 180.  
Quantification of lymphoid follicles 
To evaluate the presence of lymphoid follicles in lung tissue, paraffin sections of the left lung were 
subjected to an immunohistolchemical CD3/B220 double-staining 159. All lymphoid infiltrates in the 
proximity of airways and in the parenchyma were counted. Dense accumulations of at least 50 cells 
were defined as lymphoid follicles, whereas accumulations of less than 50 cells were defined as 
lymphoid aggregates. Counts of infiltrates in the proximity of airways were normalized for the 
number of airways per lung section. Counts of infiltrates in the parenchyma were normalized for the 
area of lung parenchyma. 
Quantification of pulmonary inflammation 
Numbers of inflammatory cells in bronchoalveolar lavage (BAL), lung tissue and mediastinal lymph 
nodes of mice were determined as described previously 180;326-328. Protein levels of cytokines and 
chemokines were determined in BAL of mice using the Cytometric Bead Array (BD Biosciences, San 
Diego, CA, USA) 47. mRNA expression levels of 83 target genes were determined in total lung tissue by 
RT-PCR with the Biomark System (Fluidigm, San Francisco, CA, USA) using TaqMan Gene Expression 
Assays (Applied Biosystems). 
Quantification of emphysema and airway wall remodelling 
To evaluate pulmonary emphysema, we determined enlargement of alveolar spaces by quantifying 
the mean linear intercept (Lm)
318 and destruction of alveolar walls by measuring the destructive index 
(DI)317, as described previously 159;312. Immunohistochemistry for matrix metalloproteinase 12 
(MMP12) was performed as described previously 159. Airway wall remodelling was defined by 
measuring the amount of fibronectin and collagen in the airway wall 319. 
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Statistical analysis 
Statistical analysis was performed with Sigma Stat software (SPSS 19.0, Chicago, IL, USA) using non-
parametric tests (Kruskall-Wallis; Mann-Whitney U). Reported values are expressed as mean ± SEM. 
P-values < 0.05 were considered to be significant. 
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RESULTS 
Expression of CXCL13 in cigarette smoke-exposed mice and patients with COPD 
CXCL13 expression was analysed in a mouse model of cigarette smoke (CS)-exposure, as well as in 2 
independent human COPD study populations.  
RNA expression of CXCL13 was significantly increased in total lung tissue of mice exposed to CS for 24 
weeks, compared to air-exposed mice (Fig. 1A). Accordingly, CXCL13 protein levels were significantly 
elevated in BAL supernatant of mice exposed for 24 weeks to CS (Fig. 1B). No differences in CXCL13 
expression were found upon 4 weeks of CS-exposure (Fig. 1A-B). Importantly, immunohistochemistry 
on lung tissue revealed CXCL13 expression inside lymphoid follicles, which appear upon chronic CS-
exposure (Fig. 1C-D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Expression of CXCL13 in CS-exposed mice and patients with COPD. (A) RT-PCR analysis showing 
CXCL13 mRNA expression in total lung tissue of mice exposed to air- or CS for 4 or 24 weeks (n=10/group). (B) 
Protein levels of CXCL13 in BAL supernatant of mice exposed to air- or CS for 4 or 24 weeks, as analyzed by 
ELISA (n=10/group). Representative images of immunohistochemical staining for isotype control (C) or CXCL13 
(D) in pulmonary lymphoid follicles of mice exposed to CS for 24 weeks. (E) RT-PCR analysis showing CXCL13 
mRNA expression in total lung tissue of never-smokers (n=9), smokers without airflow obstruction (n=20) and 
patients with COPD (n=24). (F) Protein levels of CXCL13 in induced sputum supernatant of never-smokers 
(n=10), smokers without airflow obstruction (n=12) and patients with COPD (n=22). Values are expressed as 
mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001. 
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In a translational approach, mRNA and protein expression of CXCL13 was analysed in total lung tissue 
of 53 subjects and induced sputum supernatant of 44 subjects, respectively. The characteristics of 
these 2 independent study populations are given in Tables 1 and 2. Both populations consisted of 
never-smokers, smokers without airflow obstruction and patients with COPD (GOLD stage II). 
Compared to never-smokers, RT-PCR analysis revealed increased expression of CXCL13 mRNA in lung 
tissue of smokers without airflow obstruction and patients with COPD, although only the latter 
reached statistical significance (Fig. 1E). Accordingly, CXCL13 protein levels were significantly 
elevated in induced sputum supernatant of patients with COPD, compared to never-smokers (Fig. 
1F).  
 
Table 1: Characteristics of study subjects for lung mRNA analysis 
 
  never smokers smokers COPD 
  Number  9 20 24 
 Gender (male/female)  2/7 # 16/4 # 20/0 # 
 Age (years)  61 (51-70) 64 (55-71) 65 (59-69) 
 Current-smoker / Ex-smoker NA 11/9 14/10 
 Smoking history (pack years)  0 (0-0) 33 (15-50)* 45 (40-60)*§ 
 FEV1 post-bronchodilator (L)  2,4 (2,1-3,4) 3,1 (2,6-3,5) 2,1 (1,8-2,4)§ 
 FEV1 post-bronchodilator % predicted  103 (92-119) 96 (93-113) 68 (61-73)*§ 
  FEV1 / FVC post-bronchodilator (%)  77 (75-81) 76 (73-79) 56 (54-60)*§ 
 ICS (yes/no) 0/11 # 0/20 # 10/14 # 
 
Footnote 
NA (not applicable); FEV1 (forced expiratory volume in 1 second); FVC (forced vital capacity); ICS 
(inhaled corticosteroids). 
Data are presented as median (IQR) 
Mann-Whitney U test: * P < 0,05 versus never smokers; § P < 0,05 versus smokers 
Fisher's exact test: # P < 0,001  
 
 
Importantly, immunofluorescence staining and confocal microscopy revealed expression of CXCL13 
and its receptor CXCR5 inside lymphoid follicles of patients with severe and very severe COPD (GOLD 
stages III and IV) (Fig. 2A-B). Moreover, merged images of CXCL13, CXCR5 and CD20 
immunofluorescence staining provided clear evidence of CXCL13 expression within B-cell areas of 
lymphoid follicles (Fig. 2D). 
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Table 2: Characteristics of study subjects for sputum analysis (by ELISA) 
Footnote 
NA (not applicable); FEV1 (forced expiratory volume in 1 second); FVC (forced vital capacity); ICS 
(inhaled corticosteroids) 
Data are presented as median (IQR) 
Mann-Whitney U test: * P < 0,05 versus never smokers; § P < 0,05 versus smokers 
Fisher’s exact test # P < 0,001 
 
Figure 2. Immunofluorescence 
microscopy for CXCL13, CXCR5 
and CD20 in lymphoid follicles of 
patients with COPD. 
Representative images of 
immunofluorescence staining with 
antibodies against CXCL13 (A), 
CXCR5 (B), CD20 (C) and 
CXCL13/CXCR5/CD20 (D) in 
pulmonary lymphoid follicles of 
patients with severe to very severe 
COPD (GOLD stages III and IV). The 
yellow color in (D) represents co-
localisation of CD20 and CXCL13. 
All sections were counterstained 
with 4’,6-diamidino-2-phenylindole 
(DAPI). 
 
  
  never smokers smokers COPD 
 Number  10 12 22 
 Gender (male/female)  4/6 # 5/7 # 21/1 # 
 Age (years)  47 (24-57) 59 (51-64)* 70 (61-74)*§ 
 Current-smoker / Ex-smoker NA 2/10 4/18 
 Smoking history (pack years)  0,0 (0,0-0,0) 34 (23-46)* 29 (21-44)* 
 FEV1 post-bronchodilator (L)  3,1 (2,7-3,6) 3,2 (2,4-3,9) 2,1 (1,7-2,2)*§ 
 FEV1 post-bronchodilator % predicted  98 (95-106) 110 (101-120) 66 (63-70)*§ 
 FEV1 / FVC post-bronchodilator (%)  78 (76-92) 79 (75-82) 51 (46-59)*§ 
 ICS (yes/no) 0/10 # 0/12 # 12/10 # 
    
 Sputum differential cell count:     
 % Macrophages  43 (37-63) 40 (26-55) 21 (10-32)*§ 
 % Neutrophils  55 (32-60) 56 (43-71) 76 (62-85)*§ 
 % Eosinophils  0,2 (0,0-1,2) 0,5 (0,2-1,7) 1,1 (0,6-3,1) 
 % Lymphocytes  1,0 (0,5-1,8) 0,5 (0,0-0,7)* 0,2 (0,0-0,6)* 
 % Bronchial epithelial cells  0,4 (0,0-1,6) 0,2 (0,0-0,7) 0,2 (0,0-0,3) 
 % Squamous epithelial cells  1,3 (0,4-3,7) 1,0 (0,5-4,3) 0,4 (0,0-2,9) 
 Viability (%)  91 (83-96) 90 (85-93) 91 (81-92) 
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Neutralization of CXCL13 in cigarette smoke-exposed mice 
Briefly, 8 groups of 10 mice were exposed for 24 weeks to air or CS. 6 groups were injected i.p. every 
2 weeks from the start of the experiment (prophylactic treatment) with PBS, rat IgG2a isotype control 
antibody or anti-CXCL13 monoclonal antibody. For clarity reasons and since for none of the analyses 
differences were observed between PBS or rat IgG2a isotype treated groups, the results of the PBS 
treated groups are not shown. In addition, 2 groups were injected i.p. every 2 weeks from week 13 
onwards (therapeutic treatment) with rat IgG2a isotype control antibody or anti-CXCL13 monoclonal 
antibody. Again, for clarity reasons and since no differences were observed between prophylactic or 
therapeutic IgG2a isotype treated groups, the results of the latter group are not shown. 
Since CXCL13 creates a positive feedback loop by up-regulating lymphotoxin on B-cells, which in turn 
further induces CXCL13 176;329, we examined the CXCL13 mRNA expression levels as a control of 
effective CXCL13 neutralization. Importantly, the CS-induced increase in CXCL13 mRNA expression in 
total lung tissue was significantly attenuated upon both prophylactic and therapeutic treatment with 
anti-CXCL13 antibodies (Fig. 3). 
 
Figure 3. Effect of CXCL13 neutralization on CXCL13 mRNA expression in total lung tissue. mRNA expression of 
CXCL13 in total lung tissue of mice exposed to air or CS and treated with rat IgG2a isotype control or anti-
CXCL13 antibodies (n=8/group). Values are expressed as mean ± SEM. * p<0.05, ** p<0.01. 
 
 
Effect of CXCL13 neutralization on cigarette smoke-induced lymphoid follicle formation 
Immunohistochemistry using anti-CD3 and anti-B220 monoclonal antibodies to stain T- and B-
lymphocytes respectively, was used to identify the presence of lymphoid follicles and aggregates in 
lung tissue of mice. Representative images of a lung lobe from each of the 5 experimental groups are 
shown in Fig. 4A-E. 
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Lymphoid follicles were absent in air-exposed mice. In isotype treated, CS-exposed mice there was a 
significant increase in the number of both peribronchial and parenchymal lymphoid follicles (Fig. 4F-
G). However, both prophylactic and therapeutic administration of anti-CXCL13 antibodies resulted in 
a very strong and significant inhibition of lymphoid follicle formation around the airways and in the 
lung parenchyma (Fig. 4F-G). In contrast, there was no obvious effect of CXCL13 neutralization on the 
presence of lymphoid aggregates, defined as loose infiltrations of less than 50 lymphocytes (Fig. 4H-
I). 
 
 
Figure 4. Effect of CXCL13 
neutralization on lymphoid 
follicle formation.  
Representative images of 
CD3/B220 stained lung lobes 
of (A) air-exposed, isotype 
treated, (B) CS-exposed, 
isotype treated, (C) air-
exposed, anti-CXCL13 treated, 
(D) CS-exposed, prophylactic 
anti-CXCL13 treated and (E) 
CS-exposed, therapeutic anti-
CXCL13 treated mice. 
Quantification of (F) 
peribronchial lymphoid 
follicles, (G) parenchymal 
lymphoid follicles, (H) 
peribronchial lymphoid 
aggregates and (I) 
parenchymal lymphoid 
aggregates in lung tissue of 
mice exposed to air or CS and 
treated with rat IgG2a isotype 
control or anti-CXCL13 
antibodies (n=10/group).  
Values are expressed as mean 
± SEM. * p<0.05, ** p<0.01, 
*** p<0.001. 
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Consistent with the occurrence of lymphoid follicles, the levels of immunoglobulins IgM, IgG and IgA 
were significantly elevated in BAL supernatant of isotype treated, CS-exposed mice (Fig. 5A-C). Both 
prophylactic and therapeutic neutralization of CXCL13 significantly attenuated the CS-induced 
increase in BAL immunoglobulins (Fig. 5A-C). Importantly, upon both prophylactic and therapeutic 
treatment with anti-CXCL13 antibodies, we found a significant attenuation of the CS-induced 
increase in B-cell maturation antigen (BCMA), a marker for plasma cells 330 (Fig. 5D). No obvious 
differences were observed in serum levels of IgM, IgG or IgA (Fig. 5E-G). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of CXCL13 neutralization on immunoglobulin levels in BAL supernatant and serum. Levels of 
(A) IgM, (B) IgG and (C) IgA in BAL supernatant of mice exposed to air or CS and treated with rat IgG2a isotype 
control or anti-CXCL13 antibodies, as measured by ELISA (n=10/group). (D) mRNA expression of B-cell 
maturation antigen (BCMA) in total lung tissue of mice exposed to air or CS and treated with rat IgG2a isotype 
control or anti-CXCL13 antibodies (n=8/group). Levels of (E) IgM, (F) IgG and (G) IgA in serum of mice exposed 
to air or CS and treated with rat IgG2a isotype control or anti-CXCL13 antibodies, as measured by ELISA 
(n=10/group).Values are expressed as mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001. 
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Effect of CXCL13 neutralization on cigarette smoke-induced inflammation in broncho-
alveolar lavage, lung tissue and mediastinal lymph nodes 
In bronchoalveolar lavage (BAL) of isotype treated mice, CS-exposure resulted in a significant 
increase in the number of total BALF cells, macrophages, neutrophils, dendritic cells, B-lymphocytes 
and CD4+ and CD8+ T-lymphocytes (Fig. 6A-H). Prophylactic neutralization of CXCL13 significantly 
attenuated the CS-induced increase in total BAL cells, macrophages, neutrophils, dendritic cells and 
especially B-lymphocytes (Fig. 6A-E). The latter were also significantly reduced upon therapeutic 
administration of CXCL13 (Fig. 6E). No effect of prophylactic or therapeutic treatment with anti-
CXCL13 was observed on the CS-induced increase in CXCL1/KC, CCL2/MCP-1, CCL5/RANTES, TNFα 
and IL-6 in BAL supernatant (data not shown).  
 
 
Figure 6. Effect of CXCL13 
neutralization on 
inflammatory cell numbers 
in bronchoalveolar lavage 
(BAL). Numbers of (A) total 
cells, (B) macrophages, (C) 
neutrophils, (D) dendritic 
cells, (E) B-lymphocytes, (F) 
T-lymphocytes, (G) CD4
+
 T-
lymphocytes and (H) CD8
+
 T-
lymphocytes in BAL of mice 
exposed to air or CS and 
treated with rat IgG2a isotype 
control or anti-CXCL13 
antibodies (n=10/group). 
Values are expressed as 
mean ± SEM. * p<0.05, ** 
p<0.01, *** p<0.001. 
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In lung tissue, neutralization of CXCL13 had no significant effect on the CS-induced increase of 
macrophages, dendritic cells, B-lymphocytes, Tregs and activated (CD69+) CD4+ and CD8+ T-
lymphocytes (Fig. 7A-H). Consistently, the CS-induced increase in mRNA expression of several 
inflammatory cytokines and chemokines, including IL-1α, TNF-α, CCL19, CCL20, CXCL1 and CXCL9 was 
not influenced by anti-CXCL13 treatment (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effect of CXCL13 neutralization on inflammatory cell numbers in lung tissue. Numbers of (A) total 
cells, (B) macrophages, (C) dendritic cells, (D) B-lymphocytes, (E) T-lymphocytes, (F) Tregs, (G) CD4
+
CD69
+
 T-
lymphocytes and (H) CD8
+
CD69
+
 T-lymphocytes in lung tissue of mice exposed to air or CS and treated with rat 
IgG2a isotype control or anti-CXCL13 antibodies (n=10/group). Values are expressed as mean ± SEM. * p<0.05, 
** p<0.01, *** p<0.001. 
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In mediastinal lymph nodes (MLN), neutralization of CXCL13 significantly attenuated the CS-induced 
increase in the number of B-lymphocytes, but not of total MLN cells, airway-derived dendritic cells, T-
lymphocytes and Tregs (Fig. 8A-F). 
 
Figure 8. Effect of CXCL13 neutralization on inflammatory cell numbers in mediastinal lymph nodes (MLN). 
Numbers of (A) total cells, (B) airway-derived dendritic cells (AW-DC), (C) non airway-derived dendritic cells 
(NAW-DC), (D) B-lymphocytes, (E) T-lymphocytes and (F) Tregs in MLN of mice exposed to air or CS and treated 
with rat IgG2a isotype control or anti-CXCL13 antibodies (n=10/group). Values are expressed as mean ± SEM. * 
p<0.05, ** p<0.01, *** p<0.001. 
 
Effect of CXCL13 neutralization on cigarette smoke-induced pulmonary emphysema and 
airway wall remodelling 
To evaluate pulmonary emphysema, we determined enlargement of alveolar spaces by quantifying 
the mean linear intercept (Lm) and destruction of alveolar walls by measuring the destructive index 
(DI). Both isotype and (prophylactic or therapeutic) anti-CXCL13 treated, CS-exposed groups showed 
a significant increase in the Lm and DI, compared to air-exposed control groups (Fig. 9A-G). 
Importantly, upon chronic CS-exposure no significant differences in Lm were observed between 
isotype and anti-CXCL13 treated mice (Fig. 9A). In contrast, mice treated prophylactic with anti-
CXCL13 antibodies showed a significantly lower DI, indicating a partial protection against destruction 
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of alveolar walls (Fig. 9B). Interestingly, mRNA expression levels of matrix metalloproteinase 12 
(MMP12) were lower in lung tissue of prophylactic anti-CXCL13 treated mice (Fig. 9H) compared to 
isotype treated mice, although this trend did not reach statistical significance. However, semi-
quantitative analysis of MMP12 immunohistochemistry revealed significantly less intense MMP12 
staining in macrophages of anti-CXCL13 treated mice (Fig. 9I-N).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Effect of CXCL13 neutralization on development of pulmonary emphysema. Measurement of (A) 
mean linear intercept (Lm) and (B) destructive index (DI) in lungs of mice exposed to air or CS and treated with 
rat IgG2a isotype control or anti-CXCL13 antibodies (n=10/group). Representative images of H&E stained lung 
sections of (C) air-exposed, isotype treated, (D) CS-exposed, isotype treated, (E) air-exposed, anti-CXCL13 
treated, (F) CS-exposed, prophylactic anti-CXCL13 treated and (G) CS-exposed, therapeutic anti-CXCL13 treated 
mice. (H) mRNA expression of matrix metalloproteinase 12 (MMP12) in total lung tissue and (I) semi-
quantitative analysis of MMP12 immunostaining in tissue macrophages of mice exposed to air or CS and 
treated with rat IgG2a isotype control or anti-CXCL13 antibodies (n=8/group). Representative images of MMP12 
stained lung sections of (J) air-exposed, isotype treated, (K) CS-exposed, isotype treated, (L) air-exposed, anti-
CXCL13 treated, (M) CS-exposed, prophylactic anti-CXCL13 treated and (N) CS-exposed, therapeutic anti-
CXCL13 treated mice. Values are expressed as mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001. 
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Airway wall remodelling was investigated by measuring the deposition of fibronectin and collagen in 
the airway wall. Both isotype and (prophylactic or therapeutic) anti-CXCL13 treated, CS-exposed 
groups showed a significant increase in the deposition of fibronectin, compared to air-exposed 
control groups (Fig. 10A-F). Importantly, upon chronic CS-exposure no significant differences in 
fibronectin deposition were observed between isotype and anti-CXCL13 treated mice (Fig. 10A). 
Although deposition of collagen in the airway wall showed similar results as fibronectin deposition, 
no significant differences were observed between the study groups (data not shown). 
 
Figure 10. Effect of CXCL13 neutralization on airway 
wall remodelling. (A) Quantification of fibronectin 
deposition in the airway wall of mice exposed to air 
or CS and treated with rat IgG2a isotype control or 
anti-CXCL13 antibodies (n=10/group). Representative 
images of fibronectin-stained lung sections of (B) air-
exposed, isotype treated, (C) CS-exposed, isotype 
treated, (D) air-exposed, anti-CXCL13 treated, (E) CS-
exposed, prophylactic anti-CXCL13 treated and (F) 
CS-exposed, therapeutic anti-CXCL13 treated mice. 
Values are expressed as mean ± SEM. * p<0.05, ** 
p<0.01. 
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DISCUSSION 
 
In this study we show increased levels of CXCL13 in lung tissue and induced sputum of patients with 
COPD. Moreover, we clearly demonstrate expression of CXCL13 inside lymphoid follicles of patients 
with severe and very severe COPD. Neutralizing CXCL13 in a mouse model of chronic cigarette smoke 
(CS)-exposure, completely disrupted the formation of peribronchial and parenchymal lymphoid 
follicles. Importantly, the absence of these lymphoid follicles attenuated inflammatory cell 
recruitment in bronchoalveolar lavage (BAL)  and partially protected the mice against destruction of 
alveolar walls upon chronic CS-exposure, but it had no effect on the development of airway wall 
remodelling. 
We found increased levels of CXCL13, a potent B-cell attracting chemokine, in bronchoalveolar lavage 
(BAL) fluid and lung tissue of mice chronically exposed to CS, which is accompanied by an elevated 
accumulation of B-lymphocytes in the respective pulmonary compartments of these mice 180. In this 
manuscript we also show increased levels of CXCL13 in induced sputum and lung tissue of patients 
with COPD, compared to non-smoking controls. Similar observations have been made in other 
inflammatory diseases of the lower and upper airways such as asthma and chronic rhinosinusitis 
194;331. Importantly, CXCL13 is critically involved in organisation of secondary lymphoid organs such as 
spleen and lymph nodes, but also in the formation of ectopic lymphoid tissue 176. Indeed, CXCL13 
overexpression from the rat insulin promoter induces TLOs in pancreatic islands 184, while 
neutralization of CXCL13 or its receptor CXCR5 disrupts lymphoid neogenesis in several infectious 
and autoimmune models, as well as in OVA-induced airway inflammation 179;189-191;194. Interestingly, 
we demonstrate clear expression of CXCL13 in B-cell areas within lymphoid follicles of patients with 
severe to very severe COPD. This is in line with recent observations by Litsiou and colleagues, who 
identified pulmonary B-cells of patients with COPD as major cellular sources of CXCL13 329. 
Administration of anti-CXCL13 antibodies, either prophylactic – during the entire course of the 
chronic (6 months) exposure to CS – or  therapeutic – starting from established inflammation at 3 
months of CS-exposure – almost completely prevented the formation of peribronchial and 
parenchymal lymphoid follicles. As neutralizing CXCL13 did not affect the numbers of lymphocytes in 
the lungs, nor the presence of lymphoid aggregates (defined as loose accumulations of less than 50 
lymphocytes), it is clear that CXCL13 plays a crucial role in the organization of CS-induced lymphoid 
follicles, but is not required for the recruitment of B-cells to the lung. 
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The increase in immunoglobulins IgM, IgG and IgA in the BAL fluid, that coincides with the occurrence 
of lymphoid follicles upon chronic CS-exposure, was significantly attenuated upon both prophylactic 
and therapeutic neutralization of CXCL13. Interestingly, CXCL13 neutralization significantly 
attenuated the CS-induced increase in B-cell maturation antigen (BCMA), a receptor which is highly 
expressed in plasma cells 330. In addition, expression of myeloid cell leukemia sequence 1 (MCL1) by 
plasma cells, which promotes plasma cell survival, is sustained through the BCMA receptor 332. This 
suggests that the inhibition of follicle formation by anti-CXCL13 treatment leads to reduced numbers 
of plasma cells (due to reduced plasma cell survival and/or reduced plasma cell differentiation). 
Moreover, these data support the presence of germinal centers and plasma cell differentiation in CS-
induced lymphoid follicles. 
The role of lymphoid follicles in COPD is still unknown and controversial. The finding of oligoclonal B-
cells in the pulmonary lymphoid follicles points to a local antigen specific immune reaction 158. 
However, until now it is not known which antigens are involved. They may originate from CS 
components or derivatives, or they can be auto-antigens originating from epithelial damage or 
degradation of extracellular matrix. Either way, these antigens may elicit harmful (auto)immune 
responses that may contribute to the – even after smoking cessation – ongoing pulmonary 
inflammation. In contrast, the immune responses induced by lymphoid follicles in COPD may be 
protective when directed against antigens from microbial origin. Infection and colonization of the 
lower respiratory tract by bacteria is a common feature of COPD, especially in the more severe stages 
where it often parallels the occurrence of lymphoid follicles 163. Moreover, lymphoid neogenesis can 
be induced in mice by infection with Haemophilus influenzae or by chronic exposure to bacterial 
products 333;334. 
Preventing the formation of lymphoid follicles by neutralizing CXCL13 in CS-exposed mice offers a 
platform to assess the contribution of harmful local (auto)immune responses in the development of 
pulmonary inflammation, emphysema and airway wall remodelling. Both prophylactic and 
therapeutic administration of anti-CXCL13 completely abrogated the recruitment of B-cells to the 
bronchoalveolar compartment and mediastinal lymph nodes (MLN). Importantly, prophylactic 
treatment with anti-CXCL13 antibodies significantly attenuated the increase in macrophages, 
dendritic cells and neutrophils in the BAL upon chronic CS-exposure. This is consistent with reported 
results in other models of airway and non-airway diseases, such as OVA-induced allergic airway 
inflammation or intestinal nematode infection, where targeting CXCL13 or CXCR5 also results in 
reduced immune responses 194;335.  
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We assessed the development of pulmonary emphysema by quantifying the mean linear intercept 
(Lm) – as a measure of airspace enlargement – and the destructive index (DI) – as a measure of 
alveolar wall destruction. Although the CS-induced increase in Lm was not influenced by CXCL13 
neutralization, we did observe a partial but significant protection against destruction of alveolar 
walls, reflected in an attenuated increase in the DI. The discrepancy between these two methods 
may be due to the relative small increase in Lm upon CS-exposure, making it difficult to study the 
effects of an intervention such as CXCL13 neutralization. In contrast, the DI offers a more distinct 
increase upon CS-exposure. Nevertheless, confirmation of the observed effect of anti-CXCL13 
treatment on the development of emphysema requires more robust methods, such as micro-CT or 
pulmonary function tests, which is a limitation of the current study. However, in line with the 
observed effect of CXCL13 neutralization on alveolar wall destruction, we found reduced expression 
of matrix metalloproteinase 12 (MMP12) in macrophages of CS-exposed, anti-CXCL13 treated mice, 
compared to isotype-treated controls. MMP12, also known as macrophage metalloelastase, has been 
implicated as one of the key proteinases in the  development of emphysema upon CS-exposure 64;336. 
On the other hand, we have previously shown that the innate immune system suffices to develop 
specific hallmarks of COPD, as severe combined immunodeficiency (scid) mice – which lack B- and T-
lymphocytes – still develop pulmonary emphysema 47. Still, this does not rule out the presence of an 
autoimmune component in COPD, which could aggravate inflammation and alveolar destruction in 
chronic disease. 
In conclusion, we have shown that the B-cell attracting chemokine CXCL13 is increased in lungs of CS-
exposed mice and patients with COPD, and that this chemokine is crucial for the CS-induced 
development of ectopic TLOs. Importantly, disrupting lymphoid follicles by neutralizing CXCL13 had a 
sustained effect on inflammation in BAL and on destruction of alveolar walls, but did not affect the 
development of airway wall remodelling. These findings have important consequences for future 
therapeutic strategies that target adaptive immune responses and lymphoid neogenesis in COPD. 
 
  
  
  
 
 
 
 
 
 
 
[CHAPTER 7: ROLE OF ACTIVIN-A IN CIGARETTE SMOKE-INDUCED 
INFLAMMATION AND COPD] 
 
Activin-A is a pleiotropic cytokine, belonging to the TGF-β superfamily and has been implicated in 
respiratory disorders such as acute lung injury, asthma and pulmonary fibrosis. However, the role of 
activin-A and its endogenous inhibitor, follistatin, in the pathogenesis of Chronic Obstructive 
Pulmonary Disease (COPD) is unknown. 
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ABSTRACT 
 
Objective: Activin-A is a pleiotropic cytokine belonging to the TGF-β superfamily and has been 
implicated in asthma and pulmonary fibrosis. However, the role of activin-A and its endogenous 
inhibitor, follistatin, in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD) is 
unkown.  
Methods: We first quantified activin-A and follistatin in lungs of air- or CS-exposed mice and in lungs 
of patients with COPD by immunohistochemistry, ELISA and qRT-PCR. We subsequently studied the 
effect of CS on primary human bronchial epithelial cells (HBECs) in vitro. Next, activin-A signalling was 
antagonized in vivo by administration of follistatin in mice exposed to air or CS for 4 weeks. 
Results: Protein levels of activin-A were increased in the airway epithelium of patients with COPD 
compared with never-smokers and smokers. CS-exposed HBECs expressed higher levels of activin-A 
and lower levels of follistatin. Both mRNA and protein levels of activin-A were increased in lungs of 
CS-exposed mice, whereas follistatin levels were reduced upon CS exposure. Importantly, 
administration of follistatin attenuated the CS-induced increase of inflammatory cells and mediators 
in the bronchoalveolar lavage fluid in mice. 
Conclusions: These results suggest that an imbalance between activin-A and follistatin contributes to 
the pathogenesis of CS-induced inflammation and COPD. 
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INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease with obstruction of 
the small airways (obstructive bronchiolitis) and destruction of lung parenchyma (emphysema). The 
major risk factor for COPD is tobacco smoking, but air pollution and occupational exposure to dusts 
and chemicals are also important contributors together with genetic susceptibility 1. COPD is a 
leading cause of morbidity and mortality worldwide 14. Besides smoking cessation, current treatment 
of COPD is mainly symptomatic. It is believed that a complex interaction between a dysregulated 
immune response, oxidative stress, imbalanced proteolytic activity and increased apoptosis leads to 
the pathology seen in patients with COPD 37;54;338. To date, the precise molecular mechanisms 
underlying the pathogenesis of COPD are not fully understood. 
Members of the transforming growth factor (TGF)-β superfamily, which include TGF-βs, activins and 
bone morphogenetic proteins (BMPs) are pleiotropic cytokines regulating fundamental physiological 
processes and have been linked to numerous diseases 201. Since TGF-β has a key role in immune 
regulation and tissue remodelling in COPD, other members of the TGF-β superfamily may also be 
involved in the pathogenesis of COPD 48;211;221. Activin-A is a homodimeric protein comprising 2 
inhibin βA subunits (INHBA) and signals via a constitutively active activin type II receptor (Act-RIIA 
and Act-RIIB) that recruits and phosphorylates an activin type I receptor (activin-receptor-like kinases 
(ALK) -4 and/or -7). The receptor complex propagates the signal by phosphorylating the same 
intracellular Smads (Smad2 and Smad3) as TGF-β. Phosporylated Smad2/3 subsequently translocate 
to the nucleus in association with Smad4 to initiate gene transcription 339;340. Regulation of activin-A 
signalling is achieved by the endogenous inhibitor, follistatin that binds activin-A with high affinity 
and blocks the interaction between activin-A and the type II receptor 341. Follistatin can also bind and 
inhibit several BMPs (BMP-2, -4, -5, -6, -7, -8) and TGF-β3, although the binding affinity of follistatin is 
much higher for activin-A than for BMPs 342;343. 
Several groups have demonstrated activation of the activin-A signalling pathway in an experimental 
model of allergic asthma and in patients with asthma 254;261;266;270. Similarly, patients with acute 
respiratory distress syndrome or pulmonary fibrosis have higher levels of activin-A in 
bronchoalveolar lavage (BAL) fluid and lung tissue, respectively, compared to control patients 260;344. 
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Since activin-A is an important inflammatory mediator in several respiratory diseases, we 
hypothesized that activin-A plays a significant role in the pathogenesis of COPD. To elucidate this, we 
investigated the expression of activin-A and follistatin in lungs of never-smokers and smokers with 
and without COPD and in primary human bronchial epithelial cell (HBEC) cultures exposed to 
cigarette smoke (CS). Finally, we used a CS-induced mouse model of COPD to examine the in vivo 
functional role of activin-A by administering its endogenous inhibitor follistatin.  
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MATERIALS AND METHODS 
 
Human study populations 
Lung resection specimens were obtained from 100 patients, of which 89 from surgery for solitary 
pulmonary tumours (Ghent University Hospital, Ghent, Belgium) and 11 from explant lungs of end-
stage COPD patients undergoing lung transplantation (University Hospital Gasthuisberg, Leuven, 
Belgium). Lung tissue of 64 (out of 100) patients, including 11 never-smokers, 24 smokers without 
airflow limitation and 29 patients with COPD GOLD II was used for mRNA expression analysis (Table 
1). Lung tissue of 71 (out of 100) patients, including 10 never-smokers, 26 smokers without airflow 
limitation and 35 patients with COPD (21 GOLD II, 4 GOLD III and 10 GOLD IV) was used for 
immunohistochemical analysis (Table 2). Lung tissue of 35 (out of 100) patients was used for both 
mRNA and immunohistochemical analysis. 
Written informed consent was obtained from all subjects. This study was approved by the medical 
ethical committees of the Ghent University Hospital and the University Hospital Gasthuisberg 
Leuven.  
Activin-A immunohistochemistry and quantification  
Paraffin-embedded sections of human lung tissue were subjected to activin-A staining using anti-
activin-A antibody as previously described 84. Immunohistochemical staining with anti-activin-A (R&D 
Systems, Abingdon, UK) was performed on paraffin sections of the left lung of mice. The area with 
positive activin-A staining was quantified using KS400 software (Zeiss) and was normalized to the 
length of the basement membrane. 
Phospho-Smad2 immunohistochemistry 
Paraffin sections were incubated overnight with primary phospho-Smad2 (Ser465/467) Ab (Cell 
Signaling Technology, Danvers, USA) or isotype rabbit IgG (Abcam, Cambridge, UK). Next, the slides 
were incubated with PowerVision poly-horseradish peroxidase-anti-rabbit (Immunovision 
Technologies, Burlingame, USA) and stained with 3,3’-diaminobenzidine substrate (Dako, Glostrup, 
Denmark). Finally, sections were rinsed in demineralised water, counterstained with Mayer’s 
hematoxylin (Sigma-Aldrich, St. Louis, USA) and mounted in DPX (Klinipath, Duiven, The 
Netherlands). 
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Culture of human bronchial  epithelial cells 
Primary human bronchial epithelial cells (HBECs) were obtained by enzymatic digestion from lung 
resection specimens obtained from anonymous donors during surgery for lung cancer, as described 
previously 320. Cells from passage 2 were cultured at an air-liquid interface in medium containing a 
high concentration of retinoic acid to induce mucociliary differentiation, as described previously 345.   
After the 14-day air-liquid interface culture period, HBECs were exposed to whole volatile smoke or 
air as a negative control, using a modification of the system reported by Beisswenger and coworkers 
321. In other experiments, HBECs were stimulated both on the apical and basal side with recombinant 
human activin-A (R&D Systems) or with recombinant human TGF-β1 (R&D Systems) as positive 
control. 
Cigarette smoke exposure 
C57BL/6 mice (Charles River Laboratories) were exposed to CS, as described previously 312.  
Administration of follistatin 
C57BL/6 mice were injected i.p. with 1 μg of recombinant mouse follistatin-288 (R&D Systems) or 
PBS (controls) 246. Mice were injected 3 times a week in a subacute (4 weeks) CS experiment, 30 
minutes before air or CS exposure. 
Statistical analysis 
Statistical analysis was performed with Sigma Stat software (SPSS 19.0, Chicago, IL,  USA), using 
Kruskal-Wallis, Mann-Whitney U, Wilcoxon Signed Rank, Fisher’s exact test and Spearman correlation 
analysis. Characteristics of the study population are expressed as median and interquartile range. 
Pearson correlation and linear regression analysis were performed on log-transformed data. Values 
from the in vitro study with HBECs are reported relatively to the control group. Reported values are 
expressed as mean ± SEM. Differences at p-values < 0.05 were considered to be significant (*P<0.05, 
**P<0.01 and *** P<0.001). 
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RESULTS 
Activin-A and follistatin mRNA expression in lungs of patients with COPD 
To characterize the expression of activin-A and follistatin in human lung tissue, we extracted mRNA 
from total lung tissue of a study population containing 11 never-smokers, 24 smokers without airflow 
limitation and 29 patients with COPD, GOLD II. The characteristics of the different study groups are 
summarized in Table 1. Activin-A is a homodimer of inhibin βA subunits. By measuring the mRNA 
expression of the inhibin βA subunit (INHBA), we observed higher mRNA levels of activin-A in lung 
tissue of current smokers both with and without COPD, compared to never-smokers. Moreover, 
current smokers had significantly higher activin-A mRNA expression, compared to ex-smokers (Figure 
1A). The mRNA expression of follistatin (Figure 1B) was similar between the different study groups. 
Taken together, the ratio of activin-A to follistatin is increased in current smokers both with and 
without COPD in comparison with never-smokers. (Figure 1C).  
 
Table 1: Characteristics of study subjects for lung mRNA analysis (by qRT-PCR) 
 never smokers smokers COPD II 
Number 11 24 29 
Age (years) 60 (47-70) 64 (55-71) 65 (59-69) 
Gender (m/f) 3/8 # 18/6 # 29/0 # 
Current-smoker/Ex-smoker NA 12/12 ° 17/12 ° 
Pack-years NA 28 (14-49) † 45 (40-60) †* 
FEV1 (% predicted) 104 (92-119) 96 (92-113)  69 (63-74) 
†§ 
FEV1/FVC (%) 77 (75-80) 76 (73-78) 56 (54-60) 
†§ 
ICS (yes/no) 0/11 ° 1/23 ° 12/17 ° 
 
Footnote 
m (male); f (female); FEV1 (forced expiratory volume in 1 second); FVC (forced vital capacity); ICS 
(inhaled corticosteroids); NA (not applicable) 
Data are presented as median (IQR) 
Mann-Whitney U test: † P<0.001 vs never-smokers, * P<0.01 vs smokers, § P<0.001 vs smokers 
Fisher’s exact test: ° P<0.01 and  # P<0.001 
 
 
102 CHAPTER 7: ROLE OF ACTIVIN-A IN COPD 
 
 
Figure 1. Pulmonary mRNA expression of INHBA (activin-A) and follistatin in human subjects. mRNA levels of 
activin-A (INHBA: inhibin βA subunit) (A) and follistatin (B) in total lung of never-smokers (N = 11) , current-
smokers (N = 12), ex-smokers (N = 12), current-smokers with COPD (N = 17) and ex-smokers with COPD (N = 
12), as measured by qRT-PCR. In (C) the ratio of activin-A to follistatin mRNA expression is shown. mRNA levels 
were corrected using a calculated normalization factor based on mRNA expression of three reference genes 
(GAPDH, PPIA, HPRT-1). Data are expressed as box-and whisker plots (*P<0.05 and **P<0.01).  
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Increased activin-A signalling in airway epithelium of patients with COPD 
In order to localize pulmonary activin-A signalling, we performed immunohistochemical staining for 
activin-A and phospho-Smad2 on lung tissue sections of never-smokers, smokers and patients with 
COPD GOLD II-IV. The demographic, clinical and lung functional characteristics of the study subjects 
are presented in Table 2. Figure 2 shows representative lung sections stained for activin-A in never-
smokers (Figure 2A), smokers (Figure 2B), patients with COPD GOLD II (Figure 2C) and patients with 
COPD GOLD IV (Figure 2D and 2F). We observed positive staining for activin-A in bronchiolar 
epithelial cells with a minor staining of smooth muscle cells and alveolar macrophages in the lungs of 
never-smokers (Figure 2A). Using imaging analysis software, we quantified the activin-A positive 
staining in the airway epithelium. Protein levels of activin-A in the airway epithelium were 
significantly increased in patients with COPD GOLD II and GOLD III-IV, compared to never-smokers 
and smokers without airflow limitation (Figure 2G). The expression of activin-A in the airway 
epithelium is significantly associated with disease severity, expressed as post-bronchodilator FEV1 (% 
predicted) and FEV1/FVC (%) (data not shown). After adjustment for various confounders, the 
association with FEV1 remained significant (data not shown). After semi-quantitative scoring, we also 
demonstrated higher scores for activin-A in the airway smooth muscle cell layer and alveolar 
macrophages of patients with COPD compared to never smokers (data not shown). 
 
Table 2: Characteristics of study subjects for immunohistochemical study  
 never smokers smokers COPD II COPD III-IV 
Number 10 26 21 14 
Age (years) 59 (51-70) 57 (51-65) 66 (60-70) 52 (50-59) ¤ 
Gender (m/f) 2/8 # 20/6 # 20/1 # 10/4 # 
Current-smoker/Ex-smoker NA 13/13 ° 12/9 ° 3/11 ° 
Pack-years NA 24 (15-36) † 50 (40-61) †* 30 (25-39) †~ 
FEV1 (% predicted) 103 (93-118) 102 (90-113) 68 (59-74) 
†§ 25 (24-42) †§¶ 
FEV1/FVC (%) 76 (75-82) 76 (72-80) 56 (53-60) 
†§ 36 (32-42) †§¶ 
ICS (yes/no) 0/10 # 0/26 # 7/14 # 13/1 # 
 
Footnote 
m (male); f (female); FEV1 (forced expiratory volume in 1 second); FVC (forced vital capacity); ICS 
(inhaled corticosteroids); NA (not applicable) 
Data are presented as median (IQR) 
Mann-Whitney U test: † P<0.001 vs never-smokers, * P<0.01 vs smokers, § P<0.001 vs smokers, ~ 
P<0.05 vs GOLD II, ¤ P<0.01 vs GOLD II and ¶ P<0.001 vs GOLD II 
Fisher’s exact test: ° P<0.01 and  # P<0.001 
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We evaluated the phosphorylation status and nuclear accumulation of Smad2 as a hallmark for 
activated activin-A signalling. Almost no positive nuclear staining was present in the airway epithelial 
cells of never smokers and smokers without COPD (Figure 2H-I), whereas, nuclei of airway epithelial 
cells of patients with COPD stained strongly (Figure 2J-M). Importantly, there was a significant, 
positive correlation between the semi-quantitative levels of p-Smad2 and activin-A in the airway 
epithelium (data not shown). 
 
Figure 2. Pulmonary activin-A 
and phospho-Smad2 expression 
in human lungs by 
immunohistochemistry. 
Representative 
photomicrographs for activin-A of 
human lung sections of a never-
smoker (A), smoker without 
airflow limitation (B), patient with 
COPD GOLD II (C) and patient 
with COPD GOLD IV (D). Isotype 
control  is presented in (E). (F) is a 
detailed picture from (D). 
Quantification of activin-A protein 
expression in airway epithelium 
of never-smokers (N = 10), 
smokers (N = 26) and patients 
with COPD GOLD II (N = 21) and 
COPD GOLD III-IV (N = 14) is 
shown in (G). Results are 
expressed as the epithelial area 
positive for activin-A normalized 
to the length of the basement 
membrane (Pbm). Data are 
expressed as box-and whisker 
plots (*P<0.05, **P<0.01). 
Representative 
photomicrographs for p-Smad2 of 
human lung sections of a never-
smoker (H), smoker without 
airflow limitation (I), patient with 
COPD GOLD II (J) and patient with 
COPD GOLD IV (K). Isotype 
control  is presented in (L). (M) is 
a detailed picture from (K). 
Original magnification 200x. Scale 
bar = 100 µm.  
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Cigarette smoke exposure increases expression of activin-A in human bronchial epithelial 
cells  
To confirm the results seen in patients with COPD, primary human bronchial epithelial cells (HBECs), 
grown in vitro at air-liquid interface, were exposed to mainstream CS. HBECs and basal media were 
harvested 3, 6 and 24 hours after CS exposure. RT-PCR analysis on mRNA extracted from HBECs 
revealed a significant increase in expression of activin-A 3, 6 and 24 hours after CS exposure, 
compared to air-exposed cells (Figure 3A). The follistatin mRNA expression was slighty lower in CS-
exposed HBECs (Figure 3B). This resulted in a significantly increased ratio of activin-A to follistatin in 
CS-exposed HBECs compared to air-exposed HBECs (Figure 3C). Accordingly, the release of activin-A 
in the basal medium from CS-exposed HBEC cultures was augmented, especially 24 hours after CS 
exposure (Figure 3D), whereas the release of follistatin was decreased after CS exposure (Figure 3E). 
In conclusion, the ratio of activin-A to follistatin was significantly increased in basal medium of CS-
exposed HBECs 24 hours after CS exposure (Figure 3F). These data show that expression and release 
of activin-A in response to CS is enhanced in human HBECs. 
  
 
Figure 3. Expression of activin-A and 
follistatin in air-liquid interface 
human bronchial epithelial cell 
(HBEC) cultures upon exposure to air 
or cigarette smoke. Basal media and 
cells were harvested 3, 6 and 24 
hours after exposure. mRNA from 
HBECs was isolated and analyzed for 
the expression of INHBA (inhibin βA 
subunit of activin-A) (A), FST 
(follistatin) (B) by RT-PCR. In (C) the 
ratio of activin-A to follistatin mRNA 
expression is shown. mRNA levels 
were corrected using a calculated 
normalization factor based on mRNA 
expression of two reference genes 
(RPL13A, ATP5B). Protein levels of 
activin-A (D) and follistatin (E) in the 
basal medium were analyzed by 
ELISA. In (F) the ratio of activin-A to 
follistatin protein is shown. Data are 
reported relatively to the air-exposed 
group. Results are depicted as mean 
± SEM of 5 different experiments 
each performed in duplicate and 
using cells from different donors 
(*P<0.05). 
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Increased pulmonary expression of activin-A upon CS exposure in mice 
As previously shown by our group 312, exposure of C57BL/6 mice to CS for 4 weeks or 24 weeks lead 
to inflammation in the bronchoalveolar lavage compartment and lung tissue, characterized by 
increased numbers of macrophages, neutrophils, dendritic cells and B and T lymphocytes. The effect 
of CS on the pulmonary expression of activin-A and follistatin was determined in total lung tissue by 
quantitative RT-PCR and immunohistochemistry and in BAL fluid supernatant by ELISA. Activin-A 
mRNA expression in lung tissue was significantly increased upon chronic CS exposure, compared to 
air-exposed littermates (Figure 4A), while CS significantly downregulated follistatin mRNA expression 
(Figure 4B). Importantly, immunohistochemistry on lung tissue revealed activin-A staining in airway 
epithelium (Figure 4H), which was increased upon chronic (24 weeks) CS exposure (Figure 4D), 
similar to our observations in patients with COPD. Activin-A protein levels were increased 
significantly in BAL fluid at all timepoints, with an especially marked increase after 24 weeks CS 
exposure (Figure 4E). In contrast, the protein levels of follistatin in BAL fluid were similar between 
air- and CS-exposed mice (Figure 4F). Taken together, the ratio of activin-A to follistatin was 
increased after CS exposure at all timepoints, both on mRNA and protein level (Figure 4C and 4G). 
To determine if activin-A levels persist after smoke cessation, we analyzed protein levels of activin-A 
and numbers of inflammatory cells in BAL fluid of C57BL/6 mice on day 1, 14 and 56 following 
subacute exposure to air or CS (Figure 5). CS-induced inflammation (monocytes, dendritic cells, CD4+ 
T lymphocytes) was mostly resolved on day 14 post-exposure, except for neutrophils and CD8+ T 
lymphocytes (Figure 5B-D). Inflammation in the BAL fluid was completely cleared 56 days after 
exposure (Figure 5). Consistent with the inflammation data, there was a notable persistence of 
activin-A in the BAL fluid on day 14, whereas by day 56, activin-A levels were restored to normal 
(Figure 5A). 
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Figure 4. Expression of activin-A and follistatin in C57BL/6 mice upon acute (3 days), subacute (4 weeks) and 
chronic (24 weeks) exposure to air or cigarette smoke. mRNA levels of Inhba (inhibin βA subunit of activin-A) 
(A) and follistatin (B) in total lung, as measured by qRT-PCR. In (C) the ratio of activin-A to follistatin mRNA 
expression is shown. mRNA levels were corrected using a calculated normalization factor based on mRNA 
expression of three reference genes (GAPDH, TFRC, HPRT-1). Quantification of activin-A protein expression in 
airway epithelium of mice upon exposure to air or CS is shown in (D). Results are expressed as the epithelial 
area positive for activin-A normalized to the length of the basement membrane (Pbm). (H) Representative 
images of activin-A-stained lung sections of air- and CS-exposed mice. Original magnification 200x. Scale bar = 
100 µm. Protein levels of activin-A (E) and follistatin (F) in bronchoalveolar lavage (BAL) fluid measured by 
ELISA. In (G) the ratio of activin-A to follistatin protein is shown. Data are expressed as mean ± SEM (N = 8-10 
animals/group; *P<0.05, **P<0.01 and *** P<0.001). 
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Figure 5. Pulmonary expression of activin-A and pulmonary inflammation in C57BL/6 mice on day 1, 14 and 
56 after subacute exposure to air or cigarette smoke. Protein levels of activin-A (A) in bronchoalveolar lavage 
(BAL) fluid measured by ELISA. (B-D) Cell differentiation in bronchoalveolar lavage (BAL) fluid. Neutrophils (B), 
lymphocytes (C) were counted on cytospins and CD8
+
 T lymphocytes (D) were enumerated by flow cytometry. 
Data are expressed as mean ± SEM (N = 8 animals/group; *P<0.05, **P<0.01). 
 
 
CS-induced inflammation in BAL is attenuated upon neutralization of activin-A by follistatin 
To elucidate whether activin-A is involved in the pulmonary inflammation upon CS exposure, we 
exposed C57BL/6 mice to CS for 4 weeks (subacute exposure) and injected the mice i.p. 3 times a 
week with 1 µg follistatin or PBS. In PBS treated mice, exposure to CS significantly increased the total 
number of BAL cells and absolute numbers of monocytes, neutrophils and CD4+ and CD8+ T 
lymphocytes in BAL fluid (Figure 6A-F). In contrast, follistatin treatment significantly attenuated the 
accumulation of monocytes and CD8+ T lymphocytes in CS-exposed mice (Figure 6B, 6D and 6F).  
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Figure 6. Effect of CS exposure and neutralization of activin-A with follistatin on the total number of 
bronchoalveolar lavage (BAL) cells and cell subsets in BAL fluid (A-F). Total BAL cells (A), monocytes (B), 
neutrophils (C), lymphocytes (D), CD4
+
 T lymphocytes (E) and CD8
+
 T lymphocytes (F) in C57BL/6 mice upon 4 
weeks exposure to air or CS, injected intraperitoneally 3 times a week with follistatin or PBS. All cell types were 
enumerated by cytospin counts, except for the CD4
+
 and CD8
+
 T lymphocytes which were determined by flow 
cytometry. Data are expressed as mean ± SEM (N = 8 animals/group; *P<0.05, **P<0.01). 
Follistatin affects cytokine and chemokine expression upon CS exposure  
Because we observed a decreased inflammatory cell recruitment in BAL of follistatin treated mice 
upon 4 weeks CS exposure, we measured cytokines IL-6, TNFα and IL-10 and chemokines MCP-1 and 
KC in BAL fluid by cytometric bead array. In PBS treated mice, CS exposure significantly increased the 
protein levels of IL-6, TNFα, MCP-1 and KC. In follistatin treated mice, the increase of IL-6, MCP-1 and 
KC was significantly attenuated, compared to PBS treated mice (Figure 7A and 7D-E). Follistatin 
treated mice showed a trend towards an attenuation of the CS-induced increase of TNFα in BAL fluid 
(P=0.061; Figure 7B). In contrast, IL-10 protein levels did not increase upon CS exposure in PBS-
treated mice, while follistatin treatment significantly increased IL-10 protein expression upon CS 
(Figure 7C). 
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Figure 7. Inflammatory cytokines and chemokines in the bronchoalveolar lavage (BAL) fluid of C57BL/6 mice 
upon 4 weeks exposure to air or CS, injected i.p. 3 times a week with follistatin or PBS. IL-6 (A), TNFα (B), IL-
10 (C) MCP-1 (D) and KC (E) protein levels, measured by cytometric bead array. Data are expressed as mean ± 
SEM (N = 8 animals/group; *P<0.05, **P<0.01 and *** P<0.001).  
 
Follistatin reduces CS-induced pulmonary activin-A/TGF-β signalling in mice 
We determined activin-A and TGF-β1 protein levels in BAL fluid of PBS and follistatin treated mice by 
ELISA. In follistatin treated mice, the CS-induced increase of activin-A and TGF-β1 was significantly 
attenuated, compared to PBS treated mice (Figure 8A-B). In contrast, the mRNA expression of 
activin-A was not influenced by the follistatin treatment (Figure 8D). Using ELISA, we also quantified 
the phosphorylation state of Smad2 as a marker of active signalling. CS exposure induced a 
significant increase of p-Smad2 in the lung homogenates of PBS-treated mice, which was strongly 
suppressed in follistatin-treated mice (Figure 8C). These results indicate that follistatin was effective 
as an antagonist for activin-A. 
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Figure 8. Activin-A/TGF-β signalling in the bronchoalveolar lavage (BAL) fluid (A-B) and lungs (C) of C57BL/6 
mice upon 4 weeks exposure to air or CS, injected with follistatin or PBS. Activin-A (A), TGF-β1 (B) and 
phosphorylated-Smad2 (C-expressed as raw optical density values at 450 nm) levels were quantified by ELISA. 
Activin-A (Inhba: inhibin βA subunit) mRNA levels (D) were measured using qRT-PCR. Data are expressed as 
mean ± SEM (N = 8 animals/group; *P<0.05 and **P<0.01). In (E) a schematic overview of the effect of 
cigarette smoke (CS) exposure on pulmonary activin-A signalling is shown. CS induces activin-A expression in 
airway epithelial cells, but attenuates its endogenous antagonist follistatin. Activin-A binds to type II receptors 
on the surface of target cells, which oligomerize with type I receptors. The activated type I receptor 
phosphorylates intracellular protein Smad2, which forms a complex with Smad4 and translocates to the 
nucleus to initiate gene expression of target genes such as TGF-β1, which signals through the same Smad 
proteins. TGF-β1 in turn can induce the expression of activin-A, creating a positive feedback loop mechanism. 
TGF-β1: transforming growth factor-β1, I: activin type I receptors, II: activin type II receptors, P: phosphorylated 
form. 
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DISCUSSION 
 
In this study, we demonstrate a marked role for activin-A in CS-induced inflammation and COPD 
using a combination of ex vivo studies on human subjects, in vitro studies on CS-exposed primary 
human bronchial epithelial cell (HBEC) cultures and in vivo studies using CS-exposed mice. We show 
for the first time increased levels of activin-A in the lungs of CS-exposed mice and patients with 
COPD. Moreover, we can mimic this in vitro by exposing HBEC cultures to CS. Neutralizing activin-A 
with follistatin, its natural inhibitor, in a mouse model of subacute CS exposure, attenuates 
inflammation in the bronchoalveolar lavage fluid.  
We demonstrated a higher activin-A mRNA expression in the lungs of current smokers irrespective of 
airflow limitation, suggesting a CS-driven effect, rather than an effect of the disease itself. In 
addition, at the protein level, epithelial activin-A was solely augmented in patients with COPD and 
not in smokers without airflow limitation, implicating a disease effect. The discrepancy between 
mRNA and protein levels may be explained by epigenetic mechanisms and/or differences in 
translational control that contribute to the translation of mRNA into protein. Also in the CS-driven 
murine model of COPD, we revealed increased levels of activin-A in BAL fluid and lung tissue. 
Importantly, activin-A levels, together with neutrophil and CD8+ T lymphocyte counts, were still 
elevated 14 days after final CS exposure, suggesting that activin-A release is not merely due to an 
acute CS effect. After CS cessation, neutrophil counts and activin-A levels dropped more rapidly than 
CD8+ T lymphocytes. The persistence of CD8+ T lymphocytes in the airways can be explained by the 
recruitment of effector T cells which are generated in the draining lymph nodes after stimulation 
with airway-derived DCs. 
Since the increase in activin-A in patients with COPD and CS-exposed mice is not accompanied by an 
up-regulation of follistatin, there is a relative excess of activin-A, unopposed by follistatin. Similarly, 
there is evidence from several studies that activin-A is increased in pulmonary diseases such as 
pulmonary fibrosis and asthma, but also in other non-pulmonary inflammatory disorders such as 
inflammatory bowel disease and rheumatoid arthritis 244;251;260;261. Accordingly, in airway epithelium 
of patients with COPD phosphorylation of Smad2, a downstream mediator of activin-A, was elevated. 
However, we should keep in mind that Smad2 can also be activated by other ligands of the TGF-β 
superfamily and that other non-canonical pathways (e.g. NF-κB,  …) can propagate the activin-A 
signal 346. 
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To support the finding that epithelial cells produce activin-A upon CS exposure, we exposed primary 
human bronchial epithelial cells (HBECs) in vitro to CS. In vitro, it has been shown that CS can down-
regulate the TGF-β pathway in bronchial epithelial cells 347. However, we demonstrated that mRNA 
levels of activin-A increase upon CS exposure while follistatin expression is hardly influenced. 
Furthermore, CS exposure stimulates the secretion of activin-A and inhibits the secretion of 
follistatin, resulting in a relative excess of activin-A.  Interestingly, activin-A is also increased in 
cultured airway epithelial cells challenged with human rhinovirus, which is frequently associated with 
COPD exacerbations 348.  
In accordance with the data in patients with COPD, activin-A was increased in the lungs and BAL fluid 
of mice exposed to CS. To elucidate whether activin-A is an innocent bystander or plays an active role 
in pulmonary inflammation upon CS, we blocked activin-A by administering follistatin in CS-exposed 
mice. We demonstrated a significant attenuation of the CS-induced increase of CD8+ T lymphocytes 
in the BAL fluid, which is the predominant T cell population in patients with COPD 88. Strikingly, the 
secretion of several chemokines (MCP-1 and KC) and cytokines (IL-6 and TNFα) was reduced in 
follistatin treated CS-exposed mice compared to the PBS treated group. Interestingly, the secretion 
of IL-10, an anti-inflammatory cytokine is increased upon follistatin treatment in CS-exposed mice. CS 
exposure induced increased regulatory T cell numbers in the lung and in the draining lymph nodes, 
however this was not affected by follistatin treatment (data not shown) 326. 
This is the first study exploring the potential of blocking activin signalling to inhibit inflammation in a 
CS-driven murine model. Our in vivo data are in line with experimental data in animal models of 
other respiratory diseases, showing that the pro-inflammatory effects of activin-A can be blocked in 
an in vivo settting. Exogenous follistatin reduced the number of macrophages and neutrophils in BAL 
fluid of a bleomycin-induced rat model of pulmonary fibrosis 253. Furthermore, neutralization of 
endogenous activin-A with ActRIIB-Fc protein reduced the acute lung injury-like pathology in LPS-
instilled mice, diminishing neutrophilic inflammation and IL-6 protein levels in BAL 344. Several reports 
studied blockade of the activin-A pathway as a treatment for allergic asthma, which resulted in 
conflicting outcomes. In one study, intranasal administration of follistatin reduced ovalbumin-
induced Th2 immune responses in mediastinal lymph nodes of mice, while another study showed 
that systemic depletion of activin-A by a neutralizing antibody exacerbated ovalbumin-induced 
asthmatic disease 266;269. These last papers suggest that the route of administration of follistatin may 
influence the outcome. In our study set-up – systemic administration of follistatin by intraperitoneal 
injection – it is not possible to differentiate between a local or extrapulmonary effect.  
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An intriguing aspect of activin-A is that - like TGF-β – it has both pro- and anti-inflammatory activities 
depending on the type of tissue and injury 235.  A pro-inflammatory activity is suggested by the 
capability of activin-A to skew the macrophage polarization towards an M1 phenotype 240. In 
contrast, activin-A is known to stimulate the development of FoxP3+ regulatory T cells 243. The current 
hypothesis is that activin-A exerts a pro-inflammatory effect early on in the course of inflammation, 
but once the inflammatory response has been established, activin-A may stimulate anti-inflammatory 
effects 234. Overall, our data suggest that activin-A promotes the pulmonary inflammation after CS. 
Accordingly, when we stimulated HBECs with increasing doses of activin-A for 24 or 48 hours, a dose-
dependent, but not significant increase of IL-1β, TGF-β1 and IL-8 mRNA expression was observed, 
together with an enhanced secretion of IL-8 (data not shown). 
One of the strengths of our study is its translational character. Observations made ex vivo in patients 
with COPD were confirmed in vitro in HBEC cultures and in vivo in CS-exposed mice. A limitation is 
that only pulmonary inflammation was investigated which is only one aspect of the complex 
pathogenesis of COPD. Accumulating data suggest that activin-A is also involved in airway 
remodelling. In vitro results indicate that activin-A can stimulate proliferation of human lung 
fibroblasts and smooth muscle cells  262;267. Moreover blocking activin-A inhibited collagen deposition 
and thickening of the subepithelial smooth muscle layer in two different murine models of allergic 
asthma 273;274. Similarly, it would be helpful to study the relation between activin-A and peribronchial 
fibrosis in patients with COPD. In the murine model of COPD it is practically not feasable to study the 
effect of activin-A silencing on airway remodelling using a pharmacological approach (follistatin or a 
neutralizing antibody), since it is only after 24 weeks of CS exposure that airway wall remodelling 
appears 312. Interestingly, we demonstrated that follistatin treatment suppresses protein levels of the 
pro-fibrotic cytokine TGF-β1 in BAL supernatant of CS-exposed mice. Since follistatin does not 
antagonize TGF-β1, the attenuated TGF-β1 levels are likely the result of reduced activin-A based 
stimulation of TGF-β1 secretion 261. Importantly, TGF-β1 can also stimulate activin-A expression, 
inducing a positive feedback loop 261. In Figure 8E we schematically show the effect of CS exposure 
on activin-A signalling in the lungs.  
In conclusion, these data demonstrate that activin-A is increased in the airway epithelium of patients 
with COPD and in the lungs of CS-exposed mice. Also, in vitro we confirmed that exposing HBEC 
cultures to CS modulates the delicate balance between activin-A and follistatin. Moreover, our in vivo 
studies in a CS-driven murine model indicate that activin-A contributes to the pathogenesis of CS-
induced pulmonary inflammation.  
  
 
 
 
 
 
 
 
[CHAPTER 8: MODULATION OF PULMONARY INFLAMMATION AND IRON 
HOMEOSTASIS BY BONE MORPHOGENETIC PROTEIN 6 IN COPD] 
 
Bone morphogenetic protein (BMP)-6 is a member of the TGF-β superfamily. An association between 
the BMP-6 locus and forced vital capacity has been found in a genome-wide association study. 
However, the role of BMP-6 in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD) is 
unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Verhamme FM, Bracke KR, Delanghe J, Verleden GM, Joos GF, Brusselle GG. Modulation of pulmonary 
inflammation and iron homeostasis by bone morphogenetic protein 6 in COPD.  
Manuscript in preparation. 
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ABSTRACT 
 
Rationale: Chronic Obstructive Pulmonary Disease (COPD) is associated with abnormal inflammatory 
responses and airway wall remodelling, leading to reduced lung function. An association between the 
bone morphogenetic protein (BMP-6) locus and forced vital capacity has been found in a genome-
wide association study. However, the role of BMP-6 in the pathogenesis of COPD remains unknown. 
Methods: The expression and localization of BMP-6 was analyzed in lungs of never smokers, smokers 
without COPD and patients with COPD and in lungs of air- or cigarette smoke (CS)-exposed mice, by 
qRT-PCR and immunohistochemistry. Next, we exposed BMP-6 KO mice and control littermates to air 
or CS for 4 (subacute) or 24 weeks (chronic) and evaluated pulmonary inflammation, airway wall 
remodelling and iron homeostasis. 
Results: mRNA levels of BMP-6 were decreased in lungs of smokers with and without COPD 
compared with never smokers and in lungs of CS-exposed mice. Importantly, BMP-6 mRNA 
expression declined with disease severity. Expression of BMP-6 protein was observed in airway 
smooth muscle cells, endothelial cells and pulmonary macrophages by immunohistochemistry. After 
subacute CS exposure, the CS-induced increase in macrophage and neutrophil numbers in BAL fluid 
was aggravated in BMP-6 KO mice, compared to control littermates. Accordingly, the CS-induced 
increase in MCP-1 and KC mRNA levels, chemokines attracting monocytes and neutrophils, and 
protein levels of TGF-β1, were higher in BMP-6 deficient mice. After chronic CS exposure, however, 
there was no difference in pulmonary inflammation and airway wall remodelling between WT and 
BMP-6 KO mice. Finally, BMP-6 KO mice develop massive iron overload in the lungs.   
Conclusions: These results suggest that down-regulation of BMP-6 - as observed in lungs of smokers 
and patients with COPD - contributes to pulmonary inflammation after subacute CS exposure, but 
appears less important in chronic CS-induced inflammation and remodelling. 
 
 
 
  
CHAPTER 8: ROLE OF BMP-6 IN COPD   117 
 
 
 
INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by a progressive and not fully 
reversible airflow limitation that is associated with an enhanced chronic inflammatory response in 
the airways and the lung. The major risk factor for COPD is tobacco smoking. Pathology of COPD 
includes obstruction of the small airways (obstructive bronchiolitis) and destruction of lung 
parenchyma (emphysema). The diagnosis of  COPD is made using spirometry. A ratio of the Forced 
Expiratory Volume in one second (FEV1) to the Forced Vital Capacity (FVC) below 0.70 determines the 
presence of airflow limitation 1.  
COPD results from a complex interplay between genetic susceptibility and environmental exposures. 
The genetics underlying COPD are currently unknown, although recent studies have identified 
interesting genetic loci associated with impaired lung function 3;4. In a recent meta-analysis of 
genome-wide association studies by the CHARGE and SpiroMeta consortia six new loci were 
identified that were associated with FVC, including the gene encoding bone morphogenetic protein 
(BMP)-6 3. 
BMP-6 is a member of the transforming growth factor (TGF)-β superfamily, which includes TGF-βs, 
activins, BMPs and growth differentiation factors (GDFs) 349. The BMP subfamily was initially 
identified as a family of proteins that induce ectopic cartilage and bone formation, but during the last 
years, data has accumulated demonstrating the involvement of BMPs in development and 
homeostasis in various organs 350;351. BMP-6 is essential for iron homeostasis, as it is an important 
regulator of hepcidin, a hormone that controls iron export 279;280. An increased iron sequestration has 
been observed in macrophages of patients with COPD, which correlated positively with emphysema 
severity, suggesting that iron dysregulation might contribute to oxidative stress 352. Whether BMP-6 
is simply a non-specific bystander or whether BMP-6 actively contributes to disease pathology, 
remains to be elucidated. 
We hypothesized that BMP-6 contributes to the pathogenesis of COPD by modulating pulmonary 
inflammation, airway wall remodelling and iron homeostasis. First, we determined the expression of 
BMP-6 in the lungs of smokers and patients with COPD and in the lungs of mice exposed to CS 312. 
Next, we exposed BMP-6 KO mice and control littermates to CS for 4 weeks (subacute exposure) and 
24 weeks (chronic exposure). We analyzed the inflammatory responses in both bronchoalveolar 
lavage (BAL) and lung tissue and quantified the extent of airway wall remodelling. Finally, we studied 
the effect of BMP-6 deficiency on CS-induced changes in content, storage and transport of iron. 
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MATERIALS AND METHODS 
 
Human study populations 
Lung resection specimens were obtained from 84 patients, of which 70 had surgery for solitary 
pulmonary tumours (Ghent University Hospital, Ghent, Belgium) and 14 underwent lung 
transplantation for end-stage COPD (University Hospital Gasthuisberg, Leuven, Belgium). Lung tissue 
at maximum distance from the pulmonary lesions and without signs of retro-obstructive pneumonia 
or tumour invasion was collected by a pathologist. None of the patients operated for malignancy 
were treated with neo-adjuvant chemotherapy.  
COPD diagnosis and severity were defined according the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) classification, using pre-operative spirometry 1. Written informed consent was 
obtained from all subjects. This study was approved by the medical ethical committees of the Ghent 
University Hospital and the University Hospital Gasthuisberg Leuven.  
Animals 
Male C57Bl/6Jx129Sv BMP-6 knockout (KO) (Bmp6m1rob)  mice were mated with female C57Bl/6J mice 
in the animal facility at the Faculty of Medicine and Health Sciences, Ghent University (Ghent, 
Belgium). Genotyping of the offspring was performed on toe DNA following a standard procedure, as 
already described 353. From the offspring, male BMP-6 KO mice and their WT littermates were used 
for the present study. C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA). All mice were housed in sterilized cages with filter tops under 12h light/dark cycle and ad 
libitum access to food (Pavan, Brussels, Belgium) and chlorinated tap water. All in vivo manipulations 
were approved by the local Ethics Committee for animal experimentation of the Faculty of Medicine 
and Health Sciences, Ghent University. 
Cigarette smoke exposure 
Mice were exposed to CS, as described previously 312. Briefly, animals were exposed whole body to 
mainstream CS of 5 cigarettes (Reference Cigarette 3R4F without filter; University of Kentucky) 4 
times a day with 30-min smoke free intervals, for 4 weeks (subacute), 12 weeks or 24 weeks 
(chronic). The control groups were exposed to room air. An optimal smoke/air ratio of 1/6 was 
obtained. 24 hours after the last exposure, mice were sacrificed by an intraperitoneal (i.p.) injection 
of pentobarbital (CEVA-Sanofi, Paris, France). 
Collection of serum 
Blood was sampled  from the orbital sinus and processed for the collection of serum. 
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Bronchoalveolar lavage 
Bronchoalveolar lavage (BAL) was performed as previously described 225. Briefly, lungs were first 
lavaged using 3 times 300 μl HBSS, without Ca2+ and Mg2+ and supplemented with 1% BSA (for 
protein measurement), followed by 3 times 1 ml HBSS without Ca2+ and Mg2+ supplemented with 0.6 
mM EDTA, via a tracheal cannula. The lavage fractions were pooled. Total BAL counts were obtained 
using a Bürker chamber.  
Lung harvest and preparation of single-cell suspensions 
Following BAL, the pulmonary and systemic circulation was rinsed with saline, supplemented with 5 
mM EDTA. The left lung was used for histology, as previously described 312. The right lung was 
clamped and removed for RNA extraction (small lobe), preparation of lung homogenates (middle 
lobe) and preparation of single-cell suspensions (major lobe).  For the latter, the lung tissue was 
thoroughly minced, digested and subjected to red blood cell lyses. After passage through a 50 µm 
cell strainer, cells were counted with a Z2 particle counter (Beckman-Coulter, Inc., Fullerton, CA, USA) 
312. 
Flow cytometry 
Cells (both BAL and lung single-cell suspensions) were first incubated with FcR blocking antibody 
(anti-CD16/CD32, clone 2.4G2) to reduce non-specific binding. Secondly, labelling reactions were 
performed to identify the macrophages, inflammatory monocytes, inflammatory neutrophils and 
lymphocytes, using the following Abs: APC conjugated CD11c (clone HL3), PE conjugated MHC class II 
(clone AF6-120.1), biotin conjugated CD11b (clone M1/70), FITC conjugated Ly6C (clone AL -21), PE 
conjugated Ly6G (clone 1A8), FITC conjugated CD4 (clone GK1.5), FITC or PE conjugated CD8 (clone 
53-6.7), APC conjugated CD3 (clone 145-2C11) and PE conjugated CD69 (H1.2F3). All reactions were 
performed on ice in FACS-EDTA buffer. All monoclonal Abs were purchased from BD Biosciences (San 
Diego, CA, USA). The macrophages were identified as the CD11cbright, high autofluorescent cell 
population, as described by Vermaelen and Pauwels 328. Inflammatory monocytes were defined as 
CD11c-CD11b+Ly6G-Ly6C+  and inflammatory neutrophils as CD11c-CD11b+Ly6G+Ly6C+. T lymphocytes 
were characterized as small, CD3+, which are further separated in CD4+ and CD8+ T lymphocytes in 
BAL and lung and add CD69 as activation marker for the lung T lymphocytes. Finally, samples were 
incubated with 7-Amino-actinomycin D for exclusion of dead cells (BD Biosciences). 
Flow cytometry data acquisition was performed on a dual-laser FACS CaliburTM flow cytometer 
running CellQuestTM software (BD Biosciences). FlowJo Software (Tree Star Inc., Ashland, OR, USA) 
was used for data analysis.  
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Additionally, macrophages populations were sorted from lung CD11c+ cells (after enrichment with 
anti-CD11c microbeads and passage through a VarioMACS magnetic cell separator) and total BAL 
cells on a FACS Vantage with a Sort Enhancement Module, according to the gating strategy detailed 
above 336.   
Preparation of lung tissue homogenate 
The middle lobe of the right lung was snap-frozen (in liquid nitrogen) and stored at -80°C until further 
analysis. The lobes were transferred to tubes containing 1 ml RIPA buffer (Cell Signaling Technology, 
Danvers, USA) containing HaltTM Protease Inhibitor Cocktail Kit  (Thermo Scientific, Waltham, MA, 
USA) and homogenized on ice using TissueRuptor (Qiagen, Hilden, Germany). The homogenates were 
sonicated (4 times for 5 seconds) and centrifuged (14000 rpm for 10 minutes at 4°C) and the middle 
layer was transferred to microcentrifuge tubes. Total protein concentration was measured using the 
PierceTM BCA Protein Assay Kit (Thermo Scientific). Lung tissue homogenates were diluted with RIPA 
buffer to a final protein concentration of 500 µg/ml.  
ELISA  
We determined BMP-6 levels in lung homogenate using a commercially available kit (USCNK Life 
Science Inc, Hubei, China). TGF-β1 and ferritin protein levels in the BAL fluid were determined by an 
ELISA kit purchased from R&D Systems (Abingdon, UK) for TGF-β1 and from Abcam (Cambridge, UK) 
for ferritin. All ELISAs were performed following the manufacturer’s instructions.  
BMP-6 immunohistochemistry and quantification  
To evaluate BMP-6 expression in lung tissue (both human and mice), paraffin-embedded sections 
were subjected to BMP-6 staining using an anti-BMP-6 antibody (Abcam). 3µm thick paraffin 
embedded sections were cut on poly-L-lysin coated slides. After dewaxing with Ultra Clear (Klinipath, 
Duiven, The Netherlands) and rehydrations, antigen retrieval was performed using citrate-buffer. 
After blocking for endogenous peroxidase activity and application of Fc-block, slides were incubated 
with rabbit monoclonal anti-BMP-6 or isotype rabbit IgG (Abcam) during 24h, followed by incubation 
with PowerVision poly-horseradish peroxidase-anti-rabbit (Immunovision Technologies, Burlingame, 
USA). After rinsing with PBS containing 0.3% Triton X-100, diaminobenzidine substrate (Dako, 
Glostrup, Denmark) was added for 30 minutes, sections were rinsed in demineralised water, 
counterstained with Mayer’s hematoxylin (Sigma-Aldrich, St. Louis, USA), dehydrated and mounted 
in DPX (Klinipath, Duiven, The Netherlands). 
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Photomicrographs were taken of all airways and the area of the airway smooth muscle layer was 
marked manually on the digital presentation of the airways using Axiovision software (Zeiss, 
Oberkochen, Germany) and was normalized to the total bronchial wall area (WAt). All airways with a 
Pbm larger than 500 µm and smaller than 2000 µm and cut in reasonable cross sections are included. 
Quantitative measurements are performed in a blinded fashion. 
Quantification of airway wall remodelling  
To determine the degree of airway remodelling, the deposition of collagen and fibronectin in the 
airway wall is measured on lung sections (left lung) using staining with Sirius Red or anti-fibronectin 
antibody 319. The following morphometrical parameters are marked manually on the digital 
representation of the airway: the length of the basement membrane (Pbm), the area defined by the 
basement membrane (Abm) and the area defined by the total adventitial perimeter (Ao). The total 
bronchial wall area (WAt) is calculated as WAt = Ao – Abm and normalized to the squared Pbm.  The 
area in the total airway wall covered by the stain is determined by the software (Axiovision). The area 
of collagen or fibronectin is normalized to Pbm. All airways with a Pbm smaller than 2000 µm and cut 
in reasonable cross sections are included. Quantitative measurements are performed in a blinded 
fashion. 
RNA extraction and real-time PCR-analysis 
Total RNA was extracted from isolated macrophages and from total lung tissue (human and mice) 
with the miRNeasy Mini kit (Qiagen). cDNA was obtained by the Transcriptor First Strand cDNA 
synthesis kit (Roche, Basel, Switzerland), following manufacturer’s instructions. Expression of target 
genes BMP-6, CCL2, CXCL1, Id1, hepcidin and reference genes Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), Hypoxanthine   phosphoribosyltransferase-1 (HPRT-1) and Peptidylpropyl 
isomerase 1 (PPIA) were analyzed using Taqman Gene Expression Assays (Applied Biosystems, 
Forster City, CA, USA). Real-time PCR reactions were set up in duplicate using diluted cDNA using 
identical amplification conditions for each of the target and reference genes. A standard curve 
derived from serial dilutions of a mixture of all samples were included in each run. The amplification 
conditions consisted of: 10 minutes at 95°C and 50 cycles of 95°C for 10 seconds and 60°C for 15 
seconds. Amplifications were performed using a LightCycler 480 detection system (Roche). Data were 
processed using the standard curve method. Expression of target genes was corrected by a 
normalization factor that was calculated based on the expression of two or three reference genes, 
using the geNorm applet according to the guidelines and theoretical framework previously described 
(http://medgen.ugent.be/~jvdesomp/genorm/) 322. 
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Quantification of iron concentration  
The iron concentration in lung homogenates and serum was assayed using a ferrozine-based 
colorimetric method on a Cobas 8000 analyzer (Roche).  
Statistical analysis 
Statistical analysis was performed with Sigma Stat software (SPSS 19.0, Chicago, IL,  USA), using 
Kruskal-Wallis, Mann-Whitney U and Fisher’s exact test. Characteristics of the study population are 
expressed as median and interquartile range. Reported values are expressed as mean ± SEM. 
Differences at p-values < 0.05 were considered to be significant (*P<0.05, **P<0.01 and *** 
P<0.001). 
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RESULTS 
BMP-6 expression and localization in lungs of patients with COPD 
To characterize the expression of BMP-6 in human lung tissue, we extracted mRNA from lung tissue 
of 84 subjects (16 never-smokers, 24 smokers without airflow limitation, 30 patients with COPD 
GOLD II and 14 patients with COPD GOLD III-IV). The demographic and clinical characteristics of the 
different study groups are summarized in Table 1. The mRNA levels of BMP-6 are significantly lower 
in smokers without COPD and patients with COPD compared to never-smokers. Moreover, the BMP-
6 mRNA expression was significantly lower in severe COPD compared to smokers without COPD 
(Figure 1A). Interestingly, immunohistochemical staining on human lung tissue sections revealed 
strong positive staining for BMP-6 in airway smooth muscle cells, endothelial cells and pulmonary 
macrophages, as well as a weak staining in airway epithelial cells (Figure 1B-E). 
 
Table 1: Characteristics of study subjects for lung mRNA analysis (by qRT-PCR) 
 never smokers smokers COPD II COPD III-IV 
Number 16 24 30 14 
Age (years) 64 (51-71) 65 (55-71) 65 (59-69) 56 (54-60) • ç ¶ 
Gender (m/f) 3/13# 19/5# 29/1# 8/6# 
Current-smoker/Ex-smoker 0/0# 12/12# 17/13# 0/14# 
Pack-years NA 33 (15-50) † 45 (40-60) † ç 30 (25-30) †¶ 
FEV1 (% predicted) 110 (92-118) 96 (92-113) 69 (64-74)
 †§ 23 (20-33) †§¶ 
FEV1/FVC (%) 78 (75-83) 76 (73-78) 56 (53-60)
 †§ 32 (27-35) †§¶ 
ICS (yes/no) 0/16# 1/23# 13/17# 13/1# 
 
Footnote 
m (male); f (female); FEV1 (forced expiratory volume in 1 second); FVC (forced vital capacity); ICS 
(inhaled corticosteroids); NA (not applicable) 
Data are presented as median (IQR) 
Mann-Whitney U test: • P<0.05 vs never-smokers, † P<0.001 vs never-smokers, ç P<0.05 vs smokers,  § 
P<0.001 vs smokers and ¶ P<0.001 vs GOLD II 
Fisher’s exact test: # P<0.001 
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Figure 1. Pulmonary mRNA expression and localization of BMP-6 in human subjects. mRNA levels of BMP-6 
(A) in lung of never-smokers (N = 16) , smokers without airflow limitation (N = 24), patients with COPD GOLD II 
(N = 30) and patients with COPD GOLD III-IV (N = 14), as measured by qRT-PCR. mRNA levels were corrected 
using a calculated normalization factor based on mRNA expression of three reference genes (GAPDH, PPIA, 
HPRT-1). Data are expressed as box-and whisker plots (*P<0.05 and ***P<0.001). In (B-E) representative 
photomicrographs of immunohistochemical staining for BMP-6 of lung sections of a patient with COPD (GOLD 
II) is shown.  Detail on C) airway smooth muscle cells and bronchial epithelial cells, D) endothelial cells and E) 
alveolar macrophages. Original magnification 200x. 
 
 
BMP-6 expression and localization in lungs of CS-exposed mice 
The effect of CS on the pulmonary expression of BMP-6 was determined in lung tissue by 
quantitative RT-PCR, ELISA and immunohistochemistry. mRNA expression of BMP-6 was significantly 
decreased in lung tissue of mice exposed to CS for 24 weeks, compared with air-exposed controls. 
Accordingly, the expression of Id1, a target gene of BMP-6 signalling, was also reduced in mice 
exposed to CS (Figure 2A-B). Immunohistochemistry on murine lung tissue demonstrated BMP-6 
staining in airway smooth muscle cells, endothelial cells and pulmonary macrophages, similar to our 
observations in human lung tissue. Figure 2E-F shows representative lung sections stained for BMP-6 
in air-exposed mice (Figure 2E) and CS-exposed mice (Figure 2F). Using imaging analysis software, we 
quantified the BMP-6 positive staining in the airway smooth muscle cell layer. No differences in 
protein levels of BMP-6 in the airway smooth muscle cells were found after 24 weeks of CS exposure 
(Figure 2D). In fluorescence-activated cell sorted lung macrophages from CS-exposed mice, BMP-6 
expression was significantly lower compared to lung macrophages from the air-exposed control 
group  (Figure 2C). 
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Figure 2. Pulmonary mRNA expression and localization of BMP-6 in cigarette smoke- exposed C57BL/6 mice. 
mRNA levels of Bmp-6 (A) and Id1 (B) in lung of C57BL/6 mice exposed to CS for 4 and 24 weeks, as measured 
by qRT-PCR. mRNA levels of Bmp-6 (C) in macrophages isolated from lung tissue of C57BL/6 mice exposed to CS 
for 4 and 24 weeks. mRNA levels were corrected using a calculated normalization factor based on mRNA 
expression of three reference genes (GAPDH, TFRC, HPRT-1). Representative images of BMP-6-stained lung 
sections of (E) air- and (F) CS-exposed mice. Quantification of BMP-6 protein expression in airway smooth 
muscle cell layer of mice upon exposure to air or CS for 24 weeks is shown in (D). Results are expressed as the 
airway smooth muscle cell area positive for BMP-6 normalized to the total airway wall (total area). Data are 
expressed as mean ± SEM (N = 8-10 animals/group; **P<0.01). 
 
 
Pulmonary inflammation is increased in BMP-6 KO mice after 4 weeks CS exposure, but not 
after 24 weeks CS 
The role of BMP-6 in CS-induced pulmonary inflammation was evaluated by exposing BMP-6 KO and 
control WT mice to CS for 4 (subacute) and 24 weeks (chronic exposure). Exposure to CS significantly 
increased the absolute numbers of total BAL fluid cells, macrophages, neutrophils, monocytes and 
CD4+ and CD8+ T lymphocytes (Figure 3A-F). After subacute CS exposure, the CS-induced increase in 
total cells, macrophages, neutrophils, monocytes and CD4+  T cells in the BAL fluid was significantly 
aggravated in BMP-6 KO mice, compared to control littermates. In contrast, BMP-6 deficiency had no 
effect on the CS-induced inflammation in BAL after chronic exposure (Figure 3). 
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Figure 3. Effect of CS exposure and BMP-6 deficiency on the total number of bronchoalveolar lavage (BAL) 
cells and cell subsets in BAL fluid. Total BAL cells (A), macrophages (B), neutrophils (C), monocytes (D), CD4
+
 T 
lymphocytes (E) and CD8
+
 T lymphocytes (F) in bronchoalveolar lavage fluid of WT and BMP-6 deficient mice 
upon 4 and 24 weeks exposure to air or CS. All cell types were enumerated by flow cytometry. Data are 
expressed as mean ± SEM (N = 8-12 animals/group; *P<0.05, **P<0.01, ***P<0.001 ). 
 
In lung homogenates, only macrophages numbers are significantly increased after CS exposure at 
both timepoints in WT mice (Figure 4A). After 4 weeks of CS, BMP-6 KO mice displayed higher 
numbers of activated CD4+ T lymphocytes, compared to the control group (Figure 4B), whereas the 
other cell types were not different between the 2 mouse strains (Figure 4A and 4C). Similar to the 
BAL fluid, the CS-induced inflammation in lung tissue was not altered by the genotype after 24 weeks 
exposure (Figure 4). 
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Figure 4. Effect of CS exposure and BMP-6 deficiency on inflammatory cell numbers in lung tissue. 
Macrophages (A), CD4
+
 CD69
+
 T lymphocytes (B) and CD8
+
 CD69
+ 
T lymphocytes (C) in lung tissue of WT and 
BMP-6 deficient mice upon 4 and 24 weeks exposure to air or CS. All cell types were enumerated by flow 
cytometry. Data are expressed as mean ± SEM (N = 8-12 animals/group; *P<0.05, **P<0.01, ***P<0.001 ). 
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Effect of BMP-6 deficiency on cytokine/chemokine levels after 4 weeks of CS exposure 
Because we observed an increased inflammatory cell recruitment in BMP-6 KO mice upon 4 weeks CS 
exposure, we measured the pulmonary mRNA expression of the chemokines CCL2 and CXCL1, which 
attract monocytes and neutrophils, respectively. While CS exposure had no influence on the 
expression in WT mice, the mRNA levels of CCL2 and CXCL1 were significantly higher in CS-exposed 
BMP-6 KO mice, compared to both air-exposed BMP-6 KO mice and CS-exposed WT mice (Figure 5A-
B). Furthermore, the CS-induced increase in protein levels of TGF-β1 was significantly aggravated in 
BMP-6 KO mice (Figure 5C).  
 
Figure 5. Effect of CS exposure and BMP-6 deficiency on chemokines in lung tissue and TGF-β1 in BAL 
supernatants. CCL2 (A) and CXCL1 (B) mRNA expression in lung tissue of WT and BMP-6 deficient mice upon 4 
weeks exposure to air or CS. mRNA levels were corrected using a calculated normalization factor based on 
mRNA expression of three reference genes (GAPDH, TFRC, HPRT-1). Protein levels of TGF-β1 (C) in BAL 
supernatants of WT and BMP-6 deficient mice upon 4 weeks exposure to air or CS, as measured by ELISA. Data 
are expressed as mean ± SEM (N = 8-12 animals/group; *P<0.05, **P<0.01, ***P<0.001 ). 
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CS-induced airway wall remodelling is not affected by CS or BMP-6 deficiency 
Airway wall remodelling was investigated by measuring the deposition of fibronectin and collagen in 
the airway wall of WT and BMP-6 KO mice exposed to CS for 24 weeks. However, deficiency of BMP-
6, exposure to CS or the combination of both, did not alter the fibronectin and collagen deposition in 
the airway wall (Figure 6A-B). 
 
 
Figure 6. Effect of chronic CS exposure and BMP-6 deficiency on airway wall remodelling. (A) Quantification 
of fibronectin deposition in the airway wall of WT and BMP-6 deficient mice exposed to air or CS for 24 weeks. 
Representative images are shown on the right. (B) Quantification of collagen deposition in the airway wall of 
WT and BMP-6 deficient mice exposed to air or CS for 24 weeks. Representative images are shown on the right. 
Data are expressed as mean ± SEM (N = 8-12 animals/group). 
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BMP-6 deficiency results in increased pulmonary iron deposition 
BMP-6 deficiency was significantly associated with increased iron levels in serum and lung 
homogenates and increased concentration of ferritin, an iron storage protein, in the BAL supernatant 
(Figure 7A-C). In the subacute exposure model, CS increased iron concentration in serum in WT mice, 
but decreased iron levels in BMP-6 KO mice (Figure 7A). Iron levels in the BAL fluid could not be 
detected. After 4 weeks of CS, CS-exposed BMP-6 KO mice showed a significant increase in ferritin 
compared to air-exposed BMP-6 KO mice and CS-exposed WT mice (Figure 7C). 
Figure 7. Effect of CS exposure and BMP-6 deficiency on iron and ferritin levels. Quantification of the iron 
concentration in serum (A) and lung homogenates (B) of WT and BMP-6 deficient mice exposed to air or CS for 
4 and 24 weeks. Protein levels of ferritin (C) in BAL supernatants of WT and BMP-6 deficient mice upon 4 and 
24 weeks exposure to air or CS, as measured by ELISA. Data are expressed as mean ± SEM (N = 8-12 
animals/group; *P<0.05, **P<0.01, ***P<0.001 ). 
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DISCUSSION 
 
We reveal decreased mRNA expression of BMP-6 in the lungs of patients with COPD and CS-exposed 
mice. BMP-6 levels decreases with disease severity. In lung tissue, BMP-6 protein expression is 
observed in airway smooth muscle cells, endothelial cells and pulmonary macrophages. Using in vivo 
studies with BMP-6 KO and control WT mice, we demonstrate that BMP-6 deficiency aggravates the 
pulmonary inflammation after a subacute CS exposure of 4 weeks. After chronic CS exposure, both 
strains show similar inflammation and airway wall remodelling. Moreover, BMP-6 deficient mice 
develop massive iron overload in the lungs.   
We demonstrated a lower BMP-6 mRNA expression in the lungs of smokers without airflow 
limitation and patients with COPD compared to never smokers. Importantly, patients with severe 
COPD had the lowest BMP-6 levels, which were also significantly lower than the levels of smokers 
without airflow limitation. We confirm thus decreased expression of BMP-6 in patients with COPD, as 
found in a recent gene expression analysis 311.  Also in the CS-driven murine model of COPD, we 
revealed decreased levels of BMP-6 at the mRNA level in lung tissue after 24 weeks of CS. In 
experimental models of fibrosis, both increased and decreased BMP-6 levels were reported in 
respectively liver and kidney fibrosis models 298;299. BMP-6 is also induced in chronic human skin 
wounds 354. Data regarding the expression of BMP-6 in respiratory models are scarce. One study has 
demonstrated higher BMP-6 levels in an OVA-induced mouse model of allergic asthma 301. To fully 
address whether the BMP-6 pathway is up- or downregulated, activation of downstream mediators 
and/or target genes, such as phosphorylation of Smad1/5/8 should be investigated. 
Next, we determined the localization of BMP-6 protein in lung tissue of patients with COPD and CS-
exposed mice by immunohistochemical staining. Interestingly, airway smooth muscle cells, 
endothelial cells and pulmonary macrophages stained positively for BMP-6. This is in agreement with 
in vitro studies demonstrating that both smooth muscle cells and endothelial cells can express BMP-6 
257;355. The localization of BMP-6  in these specific cell types makes sense, knowing its regulatory role 
in endothelial activation and macrophage proliferation 283;356. Next, we looked more into detail to the 
expression of BMP-6 by macrophages. For this purpose, we isolated macrophages from lung tissue of 
mice exposed to CS for 4 and 12 weeks. Expression of BMP-6 is reduced in lung macrophages of CS-
exposed mice.  
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Exposure of mice to CS for 4 weeks results in pulmonary inflammation characterized by increased 
numbers of macrophages, neutrophils, DCs and lymphocytes in BAL fluid 312. Most of these 
manifestations were aggravated in BMP-6 KO mice. Elevated levels of the chemokines CCL2 and 
CXCL1 can explain the increased recruitment of monocytes and neutrophils to the airways of CS-
exposed BMP-6 KO mice. The protective effect of BMP-6 appears to involve modulation of 
chemokine production, as is also shown in kidney epithelial cells, but BMP-6 can also directly affect 
inflammatory cells 357. Macrophages and CD4+ T cells express functional type II BMP receptors and 
type I receptors and BMP-6 is able to inhibit cell proliferation of both cell types 283;285. 
In the chronic CS exposure model, loss of BMP-6 had no influence on the levels of pulmonary 
inflammation. It is possible that functional redundancy occurs and that other BMP proteins can take 
over, such as BMP-7. BMP-6 and BMP-7 are structurally very similar and BMP-7 also displays anti-
inflammatory actions 357. We assessed the development of airway wall remodelling in the chronic 
experiment by quantification of collagen and fibronectin in the airway wall. Similar to the 
inflammation findings, we did not observe a difference between WT and BMP-6 KO mice, nor 
between air- and CS- exposed mice. Exposure of C57BL/6 mice to CS for 24 weeks normally results in 
the development of chronic inflammation and airway wall remodelling, as already published by our 
research group 159. In our chronic CS experiment, the CS-induced inflammation is mild and no airway 
wall remodelling is present. We hypothesize that the hybrid C57Bl/6Jx129Sv genetic background of 
the BMP-6 KO mice is relatively resistant to the effects of CS. Indeed, the development of CS-induced 
inflammation is strain dependent and the 129SvJ strain has been shown to be resistant to CS-
mediated inflammatory and oxidative responses 358. Therefore, experiments with BMP-6 KO mice on 
a pure C57BL/6 background should be performed.  
We hypothesize that the loss of BMP-6 signalling releases the control break on the expression of pro-
growth factor signalling pathways, such as TGF-β1. We have indeed observed elevated TGF-β1 
protein levels in BAL fluid of CS-exposed BMP-6 KO mice in the subacute experiment. Similar 
observations were made in renal fibrosis in mice 299.    
Finally, BMP-6 KO mice develop iron accumulation in the lungs. With these data, we expand the list 
of organs (liver, pancreas, heart and kidney) where massive iron overload is present in BMP-6 KO 
mice 279. We speculate that iron accumulation in the lungs contributes to tissue damage and 
inflammation via oxidative stress. Indeed, increased concentrations of iron and ferritin, an iron 
storage protein, have been found in healthy smokers and patients with COPD 359. Furthermore, the 
percentage of iron containing macrophages was positively correlated with COPD and emphysema 
severity 352. This pulmonary iron overload in smokers can have functional implications, considering 
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the tight link between iron, immunity and oxidative stress 360. By limiting iron availability for 
colonizing and/or invading bacteria, the immune system can protect the host from bacterial 
overgrowth. High iron Fe (Hfe) deficiency, characterized by systemic iron overload quite similar to 
BMP-6 deficiency, impairs pulmonary neutrophil recruitment in response to intratracheal instillation 
of LPS 361. However in our experiments, iron levels are not different between air- and CS-exposed 
mice, so we cannot conclude whether iron-mediated oxidative stress also contributes to the higher 
CS-induced accumulation of inflammatory cells in BMP-6 KO mice. Although we revealed a subtle, 
but significantly higher increase in ferritin levels in CS-exposed BMP-6 KO mice compared to the 
control group, the functional consequences are not clear. 
In conclusion, we have shown that BMP-6 mRNA expression is significantly decreased in the lungs of 
CS-exposed mice and patients with COPD. Deficiency of BMP-6 renders mice more susceptible to the 
development of CS-induced pulmonary inflammation in a subacute setting, while in a chronic setting, 
deficiency of BMP-6 is dispensable for both inflammation and airway wall remodelling. Future studies 
have to further unravel the role of BMP-6 in airway remodelling and iron-induced oxidative stress 
after CS exposure. 
 
 
 
 
 
 
 
 
 
  
  
  
 
 
 
 
 
 
 
[CHAPTER 9: TGF-β SUPERFAMILY IN OBSTRUCTIVE LUNG DISEASES: 
MORE SUSPECTS THAN TGF-β ALONE] 
 
The TGF-β superfamily comprises TGF-βs, activins, bone morphogenetic proteins (BMPs) and growth 
differentiation factors (GDFs). TGF-β1 is the most studied ligand in obstructive lung diseases; 
however considerable evidence has been presented for a role of many of the other ligands of the 
TGF-β superfamily in lung pathology, including activins, BMPs and GDFs. 
 
 
 
 
 
 
 
 
 
Reprinted with permission of the American Thoracic Society. Copyright © 2014. 
Verhamme FM, Bracke KR, Joos GF, Brusselle GG. TGF-β superfamily in obstructive lung diseases: more 
suspects than TGF-β alone. American Journal of Respiratory Cell and Molecular Biology. 2014 November 14. 
Epub ahead of print 
195
. 
136 CHAPTER 9: TGF-β SUPERFAMILY IN OBSTRUCTIVE LUNG DISEASES 
 
ABSTRACT 
 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are respiratory disorders and a major 
global health problem with increasing incidence and severity. Genes originally associated with lung 
development could be relevant in the pathogenesis of COPD/asthma, either due to an early life origin 
of adult complex diseases or due to their dysregulation in adulthood upon environmental stressors 
(e.g. smoking). The TGF-β superfamily is conserved through evolution and is involved in a range of 
biological processes both during development and in adult tissue homeostasis. TGF-β1 has emerged 
as an important regulator of lung and immune system development. However, considerable 
evidence has been presented for a role of many of the other ligands of the TGF-β superfamily in lung 
pathology, including activins, bone morphogenetic proteins (BMP), and growth differentiation factors 
(GDF). In this review, we summarize the current knowledge on the mechanisms by which activin, 
BMP and GDF signalling contribute to the pathogenesis of obstructive airway diseases. 
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INTRODUCTION 
 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are both obstructive airway diseases, 
that involve chronic inflammation and remodelling of the respiratory tract. The airflow limitation 
present in asthma is variable and reversible, but progressive and largely irreversible in COPD. 
Patients with asthma/COPD experience wheezing, breathlessness, abnormal sputum production and 
cough. Although several similarities exist between COPD and asthma, the inflammatory profile and 
anatomical sites of involvement are different, resulting in different  responses to treatment 1;362. 
Most patients with asthma are atopic and present with aberrant immune responses towards inhaled 
allergens. The inflammation in asthma, primarily eosinophilic and Th2 driven, is located in the larger 
conducting airways and bronchioles. Subepithelial fibrosis, due to collagen deposition at the 
basement membrane, is present. In COPD, the most important risk factor is cigarette smoking, 
causing an abnormal inflammatory response, primarily consisting of macrophages, neutrophils and 
CD8+ T lymphocytes. Collagen is deposited throughout the airway wall (small airway remodelling) and 
there is destruction of the lung parenchyma, leading to emphysema 363;364. 
Accumulated evidence suggests that developmental processes have a substantial effect on long-term 
lung health, since interference with many key genes of lung development results in early-onset lung 
disease 365. One of these essential growth factor pathways is the transforming growth factor (TGF)-β 
pathway, which is one of the most evolutionarily conserved signal transduction pathways within the 
animal kingdom 196. There are more than 30 TGF-β superfamily ligands in mammals, including the 
TGF-βs, activins, bone morphogenetic proteins (BMPs) and growth differentiation factors (GDFs).  
Proteins of the TGF-β superfamily are pleiotropic mediators, playing key roles in diverse 
developmental and physiological pathways, owing to ubiquitous expression of their signalling 
components. It is not surprising that disruptions in this tightly regulated pathway are associated with 
a wide range of human diseases, including respiratory disorders 201-203.  Both  candidate gene and 
genome-wide association studies demonstrated association of several genes of the TGF-β 
superfamily, such as TGF-β1/2 and BMP-6 genes, with lung function 3;4;219;366. Most research has 
focussed on the TGF-β1 ligand, showing its involvement in chronic sinus disease, pulmonary fibrosis, 
asthma and COPD 204-206. In this review, we want to shed light on the other members of the TGF-β 
superfamily such as activins, BMPs and GDFs, both in the normal development of the lung and in 
obstructive pulmonary diseases (asthma/COPD). 
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TGF-β SUPERFAMILY 
 
All ligands of the TGF-β superfamily are synthesized as prepropeptide precursors and then processed 
and secreted as homodimers or heterodimers. The mature ligands are dominated by the cystine-knot 
architecture that results from 6-9 conserved cysteine residues forming intra- and intermolecular 
disulfide bonds. Next to structural features, this protein family also shares a similar signal 
transduction cascade. For signalling, each ligand requires a set of type I and type II serin/threonine 
kinase receptors. In humans, 5 type II and 7 type I receptors  have been identified. The activated 
receptor complex propagates the signal into the canonical pathway through phosphorylation of the 
receptor-regulated Smads (R-Smads), subsequently forming complexes with Co-Smad4 and 
translocating to the nucleus to regulate gene expression (Figure 1). Other pathways can also be 
activated by the TGF-β family, such as mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K), and are referred to as ‘non-canonical’ signalling 197-200. 
 
 
Figure 1. Signalling components of the TGF-β superfamily. The canonical signalling pathway through the 
SMADs is shown for the transforming growth factor-βs (TGF-βs), activins, bone morphogenetic proteins (BMPs) 
and growth differentation factors (GDFs). ALK (activin receptor-like kinase). 
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Activins 
Originally isolated from ovarian fluid as a stimulator of follicle-stimulating hormone, activin-A is a 
multi-faceted cytokine regulating many aspects of the immune system. Activin-A can display either 
anti- or pro-inflammatory properties depending on the cellular and temporal context 235-237. Activin-A 
inhibits the processing of IL-1β precursor into the mature cytokine and stimulates the development 
of regulatory T cells 238;243. On the other hand, the pro-inflammatory function of activin-A is 
underlined by its ability to promote M1 macrophage polarization 240. Activin-A has been implicated in 
inflammatory and fibrotic diseases of the lung, but also in other organs such as the gut in 
inflammatory bowel diseases 247. 
Activins are dimeric proteins consisting of 2 β subunits, βA and βB, that form the hetero- or 
homodimers, activin-A (βA:βA), activin-B (βB:βB), or activin-AB (βA:βB). Two other subunits (βC and 
βE) have also been identified  234. Activin-A is expressed in alveolar and bronchiolar epithelium, 
alveolar macrophages and vascular smooth muscle cells 252;253. The less studied βB, βC and βE 
subunits have a lower expression, but can be detected in lung tissue 254. 
Activins interact with activin type II receptor A and B (ActR2A and ActR2B), which recruits the type I 
receptor (ALK4, but also ALK7) 255. The type II receptors are broadly expressed in every structural cell 
type of the lung 253;254;256. Lung fibroblasts and bronchial epithelial cells are known to express the type 
I receptor ALK4 254.  
The activated type I receptor propagates the signal by phosphorylation of R-Smad2 and R-Smad3. 
Smad2/3 expression has been seen in several cell types in the lung, such as bronchial epithelial cells, 
fibroblasts, pulmonary artery smooth muscle cells and alveolar type 2 cells; the phosphorylated form 
of Smad2 is especially detected in bronchial epithelial cells. Also Smad4, a signalling mediator which 
is shared by different members of the TGF-β superfamily, is abundantly expressed in the lung 
222;254;257.  
Activin signalling is negatively regulated both extracellularly and intracellularly by diverse 
mechanisms (Figure 1). Inhibitory Smad6 and 7 function as a negative feedback mechanism in TGF-β 
signalling 258.  Smad7 has been detected in airway epithelial cells, stromal cells and alveolar type 2 
cells 222. Follistatin is an extracellular glycoprotein that binds and neutralizes activin with high affinity 
by blocking the receptor binding sites. Follistatin also binds with lower affinity to some other 
members of the TGF-β superfamily, including GDF-8/9 and BMP-2/5/7/8 234;258. Follistatin expression 
has been found in alveolar macrophages, bronchial and alveolar epithelial cells and vascular smooth 
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muscle cells 253. Follistatin-related protein (or follistatin-like 3), which has a high degree of structural 
homology with follistatin, also binds and inhibits activins and BMPs and is expressed in lung tissue 259. 
Bone morphogenetic proteins (BMPs) 
Originally identified as proteins that stimulate bone morphogenesis, it is now clear that bone 
morphogenetic proteins regulate the development of nearly all organs and tissues 276. Abnormalities 
in BMP genes are linked to a wide variety of clinical disorders. Genetic studies have shown that 
patients with familial and sporadic pulmonary arterial hypertension (PAH) exhibit heterozygous, 
germline mutations in the BMP receptor type 2 gene (BMPR2), which encodes a type II receptor 
member (BMPR-II) 367-369. However, the functional contribution of the BMP family in the lung is still 
not fully understood. 
With over 20 mammalian members identified, BMPs constitute the largest subfamily of the TGF-β 
superfamily (Figure 1). Based on their amino acid sequence similarity, BMPs can be classified into at 
least 4 subgroups: BMP-2/4, BMP-5/6/7/8, BMP-9/10, BMP-12/13/14 277. Most BMP ligands are 
present in the lung, more specifically in pulmonary artery smooth muscle cells, but also in  the airway 
epithelium, lung fibroblasts and pulmonary endothelium 257;301;304;305;370;371.  
Originally, 3 type II receptors (BMPR2, ActR2A and ActR2B) and 3 type I receptors (ALK2, ALK3 and 
ALK6) were described for the BMPs. However, ligand-receptor promiscuity can occur in the TGF-β 
superfamily, particularly in the BMP/GDF  subfamily, indicating that ligands can bind to several 
receptors of either subtype and vice versa 198. Similar to the BMP ligands, also its receptors are 
abundantly expressed in the pulmonary vasculature, airway epithelium and lung fibroblasts 256;303-305. 
BMPs pass the signal on through R-Smad1, R-Smad5 and R-Smad8 (canonical pathway). 
Phosphorylation of these Smad proteins, hence an active BMP signalling, exists in airway epithelial 
cells, alveolar macrophages and lung fibroblasts, next to the pulmonary endothelium and vascular 
smooth muscle 304;306. In addition, non-canonical signalling through p38, ERK1/2 and JNK has been 
observed in pulmonary artery smooth muscle cells, lung fibroblasts and airway epithelial cells 
304;307;308.  
One of the most important targets of BMP signalling are the basic helix-loop-helix inhibitor of 
differentiation (Id) proteins. There are 4 known members in mammals (Id1 through 4), exhibiting 
similar, but not identical biological functions 309. Id4 is barely detectable in the lung, but Id1 and Id3 
are expressed in pulmonary vacular endothelial cells and alveolar epithelium, while Id2 is detected in 
bronchial epithelium and smooth muscle cell compartments of the lung 310.  
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The activity of BMPs is controlled at different molecular levels. Smad6 is, similar to Smad7, an 
inhibitory Smad (I-Smad) protein preferentially repressing BMP signalling 372. Smad6 is expressed in 
pulmonary artery smooth muscle cells and airway epithelial cells 257;373. At the extracellular level, 
BMP antagonists have been classified into 3 subfamilies: the Dan, the Twisted gastrulation and the 
Chordin/Noggin family 278. Gremlin is a member of the Dan family and specifically binds to and 
inhibits BMP-2, BMP-4 and BMP-7. Gremlin expression is reported in the pulmonary endothelium, 
but also in lung fibroblasts, alveolar macrophages and epithelial cells 374. BMP-binding endothelial 
cell precusor-derived regulator (BMPER), belonging to the Chordin family, is found in alveolar and 
bronchial epithelial cells. BMPER binds directly to BMPs and prohibits BMPs from binding their 
cognate receptors 375. 
Growth differentiation factors (GDFs) 
The growth differentiation factor (GDF) proteins form the most heterogeneous subfamily of the TGF-
β superfamily. More distant members, such as GDF-9 are categorized in this group, and few studies 
have explored the expression of these ligands in the lungs 198. GDF-5 is localized in alveolar type 1 
epithelial cells, endothelium and alveolar interstitial fibroblasts of adult rat lung 376. Expression of 
GDF-15 is found in endothelial cells of small pulmonary arteries, alveolar macrophages, smooth 
muscle cells and bronchial ephithelial cells 377;378. 
Several receptors exist for the GDF superfamily. Next to the activin and BMP receptors, GDF ligands 
can also bind the TGF-β type II (TGFBR2) and type I receptors (ALK5). Both receptors are abundantly 
expressed in lung cells such as pulmonary artery smooth muscle cells, fibroblasts, endothelial cells, 
bronchial and alveolar epithelial cells254;256;304. After ligand binding, the signalling occurs through the 
canonical pathway, both via R-Smad2/3 or R-Smad1/5/8, or through non-canonical signalling 
pathways like ERK.   
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LUNG DEVELOPMENT 
 
During branching morphogenesis, the BMP canonical pathway is mainly active in the vascular 
network and the airway smooth muscle layer.  During later stages, the BMP pathway is activated in 
developing airway and alveolar epithelial cells, after which BMP signalling declines to minimal levels 
in adult mice 379. BMP-5 and BMP-7 are expressed in the mesenchyme and endoderm, respectively, 
while BMP-4 is found mostly in the distal tips of the epithelium, but also in the adjacent mesenchyme 
380;381. There is still some debate whether BMP-4 promotes or inhibits epithelial cell proliferation 
380;382;383.  
Conditional epithelium-specific ALK3 knockout mice have abnormal lungs containing large, fluid-filled 
sacs due to reduced proliferation combined with extensive apoptosis of both epithelium and 
mesoderm 384. Another approach with inducible abrogation of ALK3, also specifically in epithelium, 
resulted in prenatal lung malformation and respiratory failure by disrupting distal airway formation 
385. Further downstream of the pathway, Smad1 protein is found mainly in peripheral airway 
epithelial cells of early embryonic lung tissue, whereas more Smad1 positive mesenchymal cells are 
found in late gestation. Similar to the phenotypes described above, knockdown of Smad1 negatively 
regulates lung branching by inhibiting epithelial cell proliferation and differentiation 386;387.  
Finally, BMP antagonist follistatin-like 1 (Fstl1) is also detected in the developing mouse lung both in 
the mesenchymal and epithelial compartment 388. The observed respiratory failure of Fstl1 KO mice 
by two independent studies demonstrated that Fstl1 is essential for tracheal cartilage formation and 
alveolar maturation 389;390. Gremlin, another extracellular BMP antagonist is observed in the proximal 
airway epithelium during development and its overexpression disrupted proximal-distal patterning 
and BMP-4-induced branching morphogenesis 391;392.  
Collectively, these data provide evidence that tight control of BMP signalling activity in every step of 
the BMP pathway is required for normal lung development, especially for the proximal-distal axis 
formation in lung epithelial cells. During normal lung development, extensive modelling of the lung 
takes place. In asthma and COPD, this modelling process is partially recapitulated in response to 
(persistent) injury/inflammation leading to altered tissue structure and abnormal airway function. It 
is interesting to speculate whether BMP proteins - originally described in developmental processes - 
may participate in complex adult lung diseases, including asthma and COPD. 
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ASTHMA 
 
Activins 
In human disease, activin-A was elevated in the lungs, serum and peripheral blood CD4+ T cells of 
patients with asthma 261;269. Furthermore, patients with asthma exhibited less inhibitory Smad7 
immunoreactivity in bronchial epithelial cells than normal subjects. After allergen challenge of 
asthma patients, P-Smad2, ALK4 and ActR2A positive cells were upregulated, whereas activin-A and 
follistatin levels showed no change 270. In contrast, Semitekolou and coworkers demonstrated, 
despite increased activin-A levels, declined ALK4 and ActR2A positive cells 269.  
In a mouse model of ovalbumin (OVA)-induced allergic airway inflammation, activin-A was strongly 
upregulated, together with an increase of ALK4 and Smad mediators 254. Similarly, other studies in 
this allergic asthma model have shown elevated levels of activin-A in bronchoalveolar lavage fluid, 
released from airway epithelial cells or inflammatory cells, such as  activated mast cells and 
macrophages 266-268. Importantly, follistatin concentrations also increased, but not as dramatically as 
activin-A, suggesting that there is a relative excess of activin-A 266. Overall, these data suggest an 
activation of the activin-A pathway in experimental asthma.  
Mechanistically, activin-A appears to provide a link between early Th2-driven allergic responses and 
long-term structural changes in the airways that are characteristic for asthma (Figure 2). Intranasal 
delivery of follistatin in an acute OVA mouse model inhibited the allergen-specific Th2 immune 
response and mucus production 266. IL-13, the key cytokine for mucus production, controlled the 
activin-A secretion by bronchial epithelial cells 271. Systemic administration of a neutralizing antibody 
against activin-A exacerbated OVA-induced allergic airway disease, whereas recombinant activin- A 
reduced the symptoms, through the modulation of antigen-specific regulatory T cells 269. Remarkably, 
it thus seems that activin-A may exert distinct functions depending on the route of administration 
and type of inhibitor. Finally, a role for activin-A together with TGF-β1 was suggested in Th9-
mediated allergic inflammation upon house dust mite instillation 272. 
In vitro studies demonstrating that activin-A promotes the proliferation of airway smooth muscle 
cells and bronchial epithelial cells, pointed towards a possible role of activin-A in the process of 
airway remodelling 267;270. Furthermore, activin-A stimulates the proliferation and differentiation of 
lung fibroblasts into myofibroblasts 261;262. Activin-A neutralization by intranasal instillation of 
follistatin in a murine model of chronic allergic asthma confirmed that activin-A is crucial for mucus 
hypersecretion, subepithelial collagen deposition and thickening of the subepithelial smooth muscle 
273. Mice deficient in Smad3 have significantly decreased airway remodelling, which is associated with 
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decreased numbers of peribronchial myofibroblasts 268. Smad2 overexpression in the airway 
epithelium resulted in enhanced airway hyperreactivity after allergen challenge concomitant with 
changes in smooth muscle and matrix remodelling. Remodelling was markedly inhibited by injection 
of an activin-A neutralizing antibody, providing direct evidence for a role of activin-A in remodelling 
274. 
Bone morphogenetic proteins (BMPs) 
In patients with mild asthma, it has been demonstrated that protein levels of ALK2, ALK6 and BMPR2 
in epithelial cells are decreased at baseline. Allergen challenge was associated with up-regulation of 
BMP-7 in the airway epithelium and inflammatory cells (mostly eosinophils) and with increased levels 
of P-Smad1/5 and ALK6 305.  
In an ovalbumin-induced airway inflammation model, almost all bronchial epithelial cells in the 
inflamed airways stained positively for phosphorylated Smad1/5, in contrast to the healthy 
epithelium. This activated Smad signalling is accompanied by an upregulation of BMP type I receptors 
(ALK2, 3 and 6), mainly in bronchial epithelial and endothelial cells. Furthermore, BMP ligands BMP-
2, 4 and 6 were induced, whereas BMP-5 and 7 were decreased in ovalbumin-exposed mice 301. 
Another study in a similar mouse model of asthma (also OVA-induced) demonstrated higher BMP-7 
expression in an acute setting, whereas in the chronic setting, no difference was observed. 
Moreover, they found an elevated TGF-β1/BMP-7 ratio, which correlated with the levels of collagen 
deposition. Treatment of asthmatic mice with recombinant BMP-7 reduced lung inflammation and 
collagen deposition  297. 
Several mechanistic studies pointed towards a role for BMPs in remodelling and epithelial-to-
mesenchymal transition (EMT), 2 mechanisms implicated in the pathogenesis of asthma. In vitro 
studies with BMP-7 demonstrated the pro-fibrotic function of BMP-7 in airway epithelial cells, but in 
cultured lung fibroblasts BMP-7 opposed TGF-β1 dependent fibrogenic activity 294-297. BMP-4 induced 
a mesenchymal-like morphology in airway epithelial cells in a wound closure model by altering E-
cadherin, vimentin and α-smooth muscle actin expression, thereby facilitating cell migration 295;308;393. 
However, BMP-4 inhibited TGF-β1 induced cell proliferation of normal human lung fibroblasts and 
extracellular matrix protein release 296. Next to BMP-4, BMP-2 can also stimulate the acquisition of an 
epithelial-mesenchymal transition phenotype in epithelial cells 295. Moreover, gremlin, an 
extracellular antagonist of BMPs, stimulates the promotion of myofibroblast generation, likely 
through decreased BMP-mediated fibroblast apoptosis and higher susceptibility to TGF-β induced 
epithelial-to-mesenchymal transition 394.  
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Growth differentiation factors (GDFs) 
Although the TGF-β and activin-A subfamily have been extensively studied in asthma, very little is 
known about the expression and functionality of GDFs in asthma. One study revealed that GDF-15 
could induce MUC5AC expression in human lung NCI-H292 cells, indicating a possible role in mucus 
hypersecretion 395. GDF-15 is a divergent member of the TGF-β superfamily, operates during stress 
responses, and is a promising new biomarker for cardiovascular disease 396. Expression and functional 
studies in relevant animal models and patients with asthma should elucidate the role of GDFs in 
asthma.  
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COPD 
 
Activins 
Recently, our group has demonstrated that epithelial levels of activin-A are higher in patients with 
COPD compared to never-smokers and smokers without airflow limitation 337. Several studies 
reported dysregulated Smad signalling in the lungs of patients with COPD 222;227;275. Smad3 deficiency 
in mice resulted in progressive age-related airspace enlargement, associated with a high expression 
of MMP-9 and MMP-12 232. Exposure of these Smad3 null mice to cigarette smoke aggravated air 
space enlargement and alveolar cell apoptosis 233. These effects are thought to be primarily mediated 
by TGF-β1, based on its known immunomodulatory and fibrogenic functions and since TGF-β1 is 
increased in patients with COPD 48;221. Activin-A is induced in bronchial epithelial cells upon cigarette 
smoke exposure. Activin-A levels are increased in the lungs of cigarette smoke-exposed mice, 
whereas follistatin levels are reduced. Interestingly, systemic administration of follistatin reduced 
cigarette smoke-induced inflammation in mice 337. Taking these new observations together with the 
fact that activin-A has similar functions as TGF-β1, activin-A should be considered as an important 
mediator in the pathogenesis of COPD. However, its role in the full spectrum of COPD, including 
airway wall remodelling, emphysema and exacerbations, still needs to be elucidated.  
Bone morphogenetic proteins (BMPs) 
There is indirect evidence that the BMP signalling pathway is also dysregulated in COPD. Bronchial 
biopsies of patients with COPD showed reduced expression of Smad6 and Smad7 373. The Secreted 
Frizzled-related proteins (SFRPs) are extracellular antagonists of Wingless/Integrated (Wnt) 
signalling, but are also involved in the negative regulation of the BMP pathway 397. SFRP2 is 
upregulated in bronchial brushings from healthy smokers and smokers with COPD compared to never 
smokers. Moreover, cigarette smoke extract increased the expression of SFRP2 in airway epithelial 
cells in vitro 398. In a Pseudomonas aeruginosa-induced rat model of COPD, BMP-7 expression was 
reduced 399.  
Since BMPs are involved in remodelling and epithelial-to-mesenchymal transition (EMT), one can 
hypothesize that BMPs contribute to these processes in COPD. Additional studies are necessary to 
unravel the functional role of BMPs in the pathogenesis of COPD. 
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Growth differentiation factors (GDFs) 
Plasma levels of GDF-15 were increased in patients with COPD compared to healthy smokers 400. In 
this context, exposure to cigarette smoke, the major risk factor for COPD, induced GDF-15 
production in human airway epithelial cells, which subsequently promoted MUC5AC expression 395. 
However, mechanistic studies in animal models are needed to elucidate whether GDF-15 is merely a 
biomarker or an active contributor to the pathogenesis of COPD. 
COPD is a complex disease characterized by airflow obstruction, but in many patients also by 
systemic manifestations, such as skeletal muscle wasting, which is associated with exercise limitation 
and reduced quality of life 21. The expression of GDF-8 or myostatin, a negative regulator of skeletal 
muscle growth, was higher in quadriceps muscle biopsies of smokers versus non-smokers and in 
quadriceps and diaphragm muscle biopsies of patients with COPD compared to controls 401-404.  In 
addition, GDF-8 serum levels are elevated in patients with COPD as compared with healthy controls 
and are positively correlated with TNF-α levels 405. Both cigarette smoke and chronic hypoxia can 
induce myostatin expression. Together these studies suggest the involvement of GDF-8 in the 
pathogenesis of skeletal muscle atrophy associated with COPD 402;403.  Interestingly, GDF-8 null mice 
are partially protected against skeletal muscle loss upon intratracheal instillation of LPS 406. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Evidence in favour for a role of TGF-β superfamily members in the pathogenesis of obstructive airway 
diseases (asthma and COPD) has emerged from genetic studies. The candidate gene association 
approach has identified single-nucleotide polymorphisms of the TGF-β1 gene that were associated 
with asthma and COPD 219;366. Through genome-wide association studies, the TGFB2 and BMP-6 locus 
were found to be associated with pulmonary function which is used to define airflow 
limitation/obstruction 3;4. 
Secondly, expression data from ex vivo studies indicate differential expression of TGF-β superfamily 
ligands between patients with obstructive lung diseases and control subjects. From a mechanistic 
point of view, in vitro studies on cell lines and primary human cells emphasize divergent roles, going 
from epithelial repair/homeostasis to mucus production and immune regulation. Lastly, experimental 
in vivo studies using animal models provide promising possibilities for treatment by interfering with 
the TGF-β pathway. However, caution is needed, since the clinical relevance of acute animal models 
for chronic human diseases is doubtful. Also species differences and difference in outcomes 
(pathology in animal models vs. lung function in patients) and timing of the intervention (prevention 
vs treatment) have to be accounted for. The potential actions of the TGF-β ligands in obstructive lung 
diseases, based on the existing evidence, are summarized in Figure 2. 
For reasons of simplicity, we have discussed the different subfamilies separately; however, as with 
every signalling pathway, interaction between the different TGF-β members is possible. For example, 
BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition in the kidney 407. This 
provides evidence that the balance between TGF-β and BMP signalling is of crucial importance during 
repair processes. Furthermore, cross-talk between the TGF-β superfamily and other pathways is 
common. During lung bud morphogenesis, Bmp-4 and fibroblast growth factor 10 (Fgf-10) play 
opposing roles 408. In order to get a complete picture of the molecular pathways underlying lung 
disease, studies using systems biology approaches and bio-informatic tools investigating this 
interplay, are required. 
For TGF-β1, the prototype protein of the TGF-β family, both harmful and protective roles have been 
postulated, depending on the cell type and stimulation involved. Similarly, a pleiotropic action of 
activin-A during the course of inflammation is known, where activin-A exerts a pro-inflammatory 
effect early on in the course of inflammation, but functions as an anti-inflammatory cytokine, once 
the inflammatory response has been established 234. Given this complexity, the use of future 
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therapies targeting the TGF-β family is not straightforward. This highlights the fact that route of 
administration, timing and dose of agents that modulate the TGF-β signalling will need further 
investigation. 
 
Figure 2. Mechanisms of action of activins and bone morphogenetic proteins (BMP) in obstructive lung 
diseases. Dysregulation of activins and BMPs can have deleterious effects on normal lung homeostasis, leading 
to pathogenetic mechanisms in obstructive lung diseases (asthma/COPD), including inflammation, airway 
remodelling, emphysema and mucus hypersecretion.  
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10.1. CXCL13 and lymphoid follicles 
 
Patients with severe COPD develop pulmonary ectopic lymphoid follicles, also termed tertiary 
lymphoid organs (TLOs). Importantly, the number of lymphoid follicles increased with disease 
progression 33. How these lymphoid follicles are formed and whether they are “the good or the bad 
guys” remain unanswered questions. CXCL13 is a lymphoid chemokine that attracts CXCR5+ B cells 
and is involved in the development of secondary lymphoid organs (SLOs) 175;409. The importance of 
CXCL13 in TLO development has been strengthened by the fact that overexpression of CXCL13 
induces TLO formation, while blocking CXCL13 disrupts this process 184;189. We hypothesized that 
pulmonary CXCL13 levels are increased in COPD and that neutralization of CXCL13 will eliminate the 
development of lymphoid follicles and will impact disease progression. 
10.1.1. Expression study 
First, we have demonstrated that the levels of CXCL13 are increased in the lungs and airways of CS-
exposed mice and patients with COPD. This is in line with the observation of increased CXCL13 in 
other inflammatory airway diseases, such as asthma and chronic rhinosinusitis 194;331. CXCL13 was 
found to be elevated in patients with COPD with lymphoid follicles versus those without lymphoid 
follicles. Moreover, a significant association between total CXCL13 levels and density of pulmonary 
lymphoid follicles was apparent 329. While we observed positive staining for CXCL13 in the B cell zone 
of lymphoid follicles, we have not addressed the exact cellular sources of CXCL13. CXCL13 is mainly 
produced by non-hematopoietic stromal cells and DCs, but also B cells can produce CXCL13, 
suggesting that B cells can acquire the function of lymphoid tissue inducer cells 165;179;329. As is shown 
for the formation of SLOs, CXCL13 also induces a positive feed-back loop during the formation of 
TLOs by upregulating lymphotoxin (LT) which further promotes CXCL13 production 329. 
10.1.2. Functional study 
Administration of anti-CXCL13 antibodies to mice during 6 months of CS exposure completely 
prevented the formation of lymphoid follicles, accompanied by decreased levels of immunoglobulins 
IgM, IgG and IgA in BAL fluid. This indicates that CXCL13 is crucial for the formation of lymphoid 
follicles upon CS exposure. In contrast, our research group has demonstrated that LTα and CCR7 are 
not essential for the development of CS-induced lymphoid follicles, although it is still possible that  
LTα and CCR7 are needed for the organization of functional lymphoid follicles180;181. Importantly, the 
CS-induced influx of inflammatory cells into the airways (BAL) was significantly reduced upon CXCL13 
neutralization. Also in the ovalbumin (OVA)-induced mouse model of allergic asthma, CXCL13 
neutralization abrogated the inflammatory process 194. While the recruitment of B cells into the BAL 
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and mediastinal lymph nodes (MLN) was completely prevented, the number of B cells in the lung 
tissue was not altered. We conclude that CXCL13 is not required for the recruitment of B cells to the 
lung, but rather important for the organization into lymphoid follicles. 
In this setting, we could assess the contribution of CS-induced ectopic lymphoid follicles to other 
hallmarks of COPD, such as emphysema and airway wall remodelling. Alveolar wall destruction was 
partially reduced by CXCL13 neutralization, in parallel with lower levels of MMP-12, a metalloelastase 
implicated in the development of  emphysema.  On the other hand, antibody treatment  had no 
effect on lung inflammation, airway remodeling and airspace enlargement. These last data support 
our previous work in which SCID mice, which lack B and T lymphocytes, still develop emphysema 47. 
Altogether, we conclude from our study that disruption of lymphoid follicles is partially protective 
against CS-induced airway inflammation and alveolar wall destruction.  
10.1.3. Future directions 
Nevertheless, we have to keep in mind that it is possible that lymphoid follicles are initially formed to 
be protective against infectious agents entering the lower airways. However, the persistent nature of 
these lymphoid structures may result in tissue destruction, thereby generating (altered) self-antigens 
and self-reactive lymphocytes, ultimately leading to autoantibodies and potentially more lung 
damage in a vicious circle 152. Although presence of autoantibodies has been reported, there is still 
some debate about their importance 168;171.  
In this context, research into the involvement of lymphoid follicles in a combined CS exposure-
infection model would be an added value. This is especially interesting since patients with COPD are 
susceptible to recurrent respiratory infections, which could result in disease exacerbation and 
hospitalization. The protective role of lymphoid follicles in an influenza model has already been 
confirmed 164. But studying the impact of CS on the formation of TLOs upon infection with respiratory 
pathogens would be clinically more relevant. Several groups have developed animal models of that 
kind. CS-exposure before influenza infection in mice resulted in exacerbated inflammation, higher 
viral titers and higher mortality 410;411. Of interest, mice that were exposed to CS followed by infection 
with nontypeable Haemophilus influenzae developed increased lung inflammation but compromised 
adaptive immunity with impaired IgG1, IgG2a and IgA class switching 412. Nevertheless, none of these 
studies investigated the functional role of pulmonary lymphoid tissue.  
Secondly, more research is needed into the reversibility of the neogenesis process of ectopic 
lymphoid tissue. One can wonder whether the lymphoid aggregates, which are not influenced by the 
anti-CXCL13 antibody, would organize into lymphoid follicles once the antibody treatment is 
stopped. Or, from another perspective, whether smoking cessation induces the regression of 
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lymphoid follicles or whether these structures persist, similar to what is seen in patients with COPD 
who have stopped smoking. Our study should also be expanded by analyzing other hallmarks of 
COPD, such as mucus hypersecretion and worsened lung function. Finally, the burning issue remains 
the identification of the antigen(s) to which the B cell responses are directed.  
Although we have demonstrated that CXCL13 is essential for the formation of lymphoid follicles, 
other molecules and pathways can be targeted to modulate TLO formation, such as adhesion 
molecules, other lymphoid chemokines or molecules that promote B cell survival and proliferation 
151. B-cell activating factor of tumor necrosis factor family (BAFF) is a crucial survival factor for B cells 
and is associated with autoimmunity 413. It has been shown that BAFF is increased in alveolar 
macrophages and lymphoid follicles of patients with COPD compared with healthy smokers and 
never smokers 414. Scavenging BAFF with a soluble protein comprised of a human IgG1-Fc fused with 
the extracellular domain of the mouse TACI receptor reduced asthma symptoms in an OVA-induced 
mouse model 415. Neutralization of BAFF and/or other chemokines/cytokines in a CS-induced mouse 
model of COPD could be advantageous and provide an additional platform to study lymphoid 
follicles. 
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10.2. Activin-A 
 
Activin-A belongs to the transforming growth factor (TGF)-β superfamily, which is one of the most 
evolutionarily conserved signal transduction pathways within the animal kingdom 196. There are more 
than 30 TGF-β superfamily ligands in mammals, including the TGF-βs, activins, bone morphogenetic 
proteins (BMPs) and growth differentiation factors (GDFs). Activin-A is originally identified as a 
stimulator of follicle-stimulating hormone, but during last years, activin-A has emerged as a multi-
faceted cytokine. Activin-A has been extensively studied in the context of pulmonary fibrosis and 
asthma, however not yet in the pathogenesis of COPD. We hypothesized that activin-A levels were 
increased in patients with COPD and investigated whether neutralization impacts the development of 
pulmonary inflammation after 4 weeks of CS exposure. 
10.2.1. Expression study 
We performed immunohistochemical and expression analysis on an extensive study population 
comprised of subjects who have never smoked, smokers without airflow limitation and patients with 
COPD. Activin-A expression analysis revealed that activin-A mRNA levels are significantly higher in 
current smokers, independent of airflow limitation. Because of its multifunctional nature, activin-A 
can be synthesized by many cells in the body 416;417. In our immunohistochemical study, we observed 
strong staining for activin-A in bronchiolar epithelial cells with a minor staining of smooth muscle 
cells and macrophages. We have demonstrated that the production of activin-A is up-regulated in 
patients with COPD, especially in the airway epithelium. This suggests that the epithelium is the main 
source of activin-A in COPD, consistent with previous findings in allergic asthma 269. Indeed, we have 
confirmed in vitro that exposure of primary human bronchial epithelial cell cultures to CS induced the 
expression and secretion of activin-A. Not only epithelial cells, but also neutrophils, mast cells and 
CD4+ T cells have been described as possible sources of activin-A in the lungs267;270. We conclude that 
pulmonary levels of activin-A are increased in patients with COPD. This corresponds with similar 
observations made in pulmonary fibrosis and asthma 260;261.  
We also confirmed increased activin-A signalling by the presence of phosphorylated Smad2 in the 
airway epithelium. In patients with COPD, different results have been found. Podowski and 
colleagues found that p-Smad2 levels are elevated in both the airspace and airway compartment of 
patients with moderate COPD, compared to ex-smoking controls 227. On the other hand, it has been 
suggested that p-Smad2 signalling activity is different according to the localisation in lung tissue. p-
Smad2 is reduced in emphysematous lung tissue, while in thickened peribronchial areas increased p-
156 CHAPTER 10: DISCUSSION AND FUTURE PERSPECTIVES 
 
Smad2 has been found 275. It would be interesting to test whether activin-A levels are also 
differentially expressed in emphysematous lung tissue versus fibrotic lung tissue.  
Follistatin is the endogenous antagonist of activin-A by binding to activin-A and thus preventing 
activin-A from binding to its receptor. Interestingly, follistatin levels were either unchanged or 
decreased in response to CS both in vivo and in vitro. This indicates that there is a relative excess of 
activin-A, unopposed by follistatin. In our human study population, follistatin mRNA expression was 
not significantly different between the study groups. However, we have not investigated the protein 
levels, nor the localization of follistatin in the lung tissue of patients with COPD. Data regarding the 
localization of follistatin in lung tissue are scarce. Follistatin is present in bronchial epithelium, 
pneumocytes and macrophages in lung tissue of control mice. Allergen challenge with OVA 
decreased folllistatin immunoreactiviy in the airway epithelium, in parallel with goblet cell 
metaplasia 266;273. There is definitely a need for a better characterization of follistatin in lung tissue of 
patients with COPD. 
10.2.2. Functional  study and future directions 
To study the functional role of activin-A in the development of CS-induced inflammation, we 
performed a subacute in vivo neutralization experiment  where we exposed C57BL/6 mice to CS for 4 
weeks and administered follistatin 3 times a week. We observed that mice treated with follistatin 
were partially protected against CS-induced influx of monocytes and lymphocytes in the airways. 
Moreover, the CS-induced increase of several chemokines and cytokines was reduced upon activin-A 
neutralization. Although we can conclude that activin-A is implicated in CS-induced inflammatory 
responses, the protective effect of follistatin was, albeit statistically significant, rather small. 
Therefore, it would be advantageous to repeat the experiment with a higher dose and/or higher 
frequency of follistatin injections.  
Another possibility is to use alternative agents to antagonize activin-A, such as a neutralizing anti-
activin-A antibody, which is efficiently used in an OVA-induced experimental model of allergic asthma 
269. This would generate a more specific inhibition, since follistatin can bind to other members of the 
TGF-β superfamily, including several BMPs such as BMP-2, -4, -5, -6, -7, -8. However, it should be 
kept in mind that the binding affinity of follistatin for activin-A is comparable to the affinity of activin-
A for the activin receptor itself and is essentially non-reversible, whereas the affinity of follistatin for 
BMPs is much lower 342. Another way of activin-A neutralization is by the administration of a soluble 
form of the activin type IIB receptor (ActR2B), which is demonstrated to attenuate LPS-induced acute 
lung injury 344. Finally, different routes of administration (systemic vs local, intraperitoneal vs 
intranasal) should be tested, since this can affect outcome 269. 
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In this study, we have only investigated the development of pulmonary inflammation upon CS 
exposure, which is only one aspect of the complex pathogenesis of COPD. In future research, activin-
A should be neutralized in a chronic CS experiment in mice, where after airway wall remodelling, 
emphysema, lymphoid follicle formation, mucus production and lung function should be evaluated. It 
will be interesting to test whether activin-A still functions as a pro-inflammatory cytokine in a chronic 
setting, similar as we found in our subacute experiment, or whether activin-A shifts towards an anti-
inflammatory cytokine once inflammation is established.  Finally, activin-A might affect other organs 
than the lungs and influence systemic manifestations such as muscle weakness and cardiovascular 
disease. Activin-A is expressed in atherosclerotic lesions and is involved in atherogenesis by inducing 
differentiation of neointimal smooth muscle cells 418. Moreover, muscle injury is attenuated by 
inhibition of activin-A in mice 419. This highlights that we should also look outside the lungs for a role 
of activin-A in COPD.  
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10.3. BMP-6  
 
Bone morphogenetic protein (BMP)-6 is, similar to activin-A, a member of the TGF-β superfamily. The 
BMP proteins form the largest subfamily within the TGF-β superfamily. BMP proteins were initially 
discovered to induce bone growth in muscle. Today, it is generally accepted that BMPs regulate 
processes throughout the entire body and can be called “body morphogenetic proteins” 351. BMP-6 
was of particular interest since its locus is associated with forced vital capacity in a genome wide 
association meta-analysis of 2 large consortiums 3. Even more, BMP-6 is identified to control tissue 
remodeling and iron homeostasis, 2 mechanisms implicated in the pathogenesis of COPD 279;420. We 
hypothesized that the BMP-6 pathway is dysregulated in COPD and that this will contribute to the CS-
induced development of inflammation and airway wall remodelling. 
10.3.1. Expression study 
We started by investigating whether the pulmonary expression of BMP-6 was indeed altered in 
patients with COPD compared to smokers without COPD and never smokers. The results 
demonstrated that BMP-6 expression is decreased in both patients with COPD and smokers. 
Importantly, patients with severe COPD (GOLD stage III and IV) had lowest BMP- levels, indicating 
that BMP-6 levels decrease with disease severity. In line with these observations, exposure of mice to 
CS for 24 weeks, but not 4 weeks reduced BMP-6 levels at the mRNA level.  
Furthermore, we were interested in what kind of cells in the lungs are capable of producing BMP-6. It 
is known from in vitro studies that smooth muscle cells, bronchial epithelial cells and endothelial cells 
can express BMP-6 3;257;355. Our results confirm that airway smooth muscle cells, endothelial cells and 
macrophages are the main source of BMP-6 in both human and murine lung tissue. Quantification of 
BMP-6 in the smooth muscle cell layer around the airways in mice revealed no differences between 
air- and CS-exposed mice. On the other hand, pulmonary macrophages isolated from the lungs of CS-
exposed mice expressed less BMP-6 mRNA compared to macrophages derived from air-exposed 
murine lungs.  
10.3.2. Functional study 
We aimed to characterize the in vivo functional role of BMP-6 in the pathogenesis of COPD by using 
BMP-6 deficient mice (and the appropriate WT control littermates) in a CS model of COPD. In the 
context of inflammation, the outcome was different between the subacute 4 weeks experiment and 
chronic 24 weeks experiment. While BMP-6 deficiency resulted in an aggravated pulmonary 
inflammation upon 4 weeks of smoke, no effect of BMP-6 deficiency on the development of 
inflammation was observed in mice exposed to CS for 24 weeks. The enhanced inflammation by loss 
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of BMP-6 has been reported earlier in models of hepatic and renal fibrosis 298;299. This suggests that 
BMP-6 predominantly  plays a role in the subacute inflammatory response to CS. The fact that BMP-6 
deficiency has no influence on CS-induced inflammation after chronic CS exposure could suggest a 
redundancy mechanism where other proteins of the BMP family could take over. Especially BMP-7 is 
a good candidate, since BMP-6 and BMP-7 are structurally very similar and BMP-7 can act as an anti-
inflammatory cytokine 357. Furthermore, we assessed airway wall remodeling by measuring the 
deposition of collagen and fibronectin after 24 weeks of smoke. Consistent with the inflammation 
data, BMP-6 deficiency had no influence on airway wall remodeling. However, 24 weeks of CS was 
not sufficient to induce airway wall remodeling in these mice, so we cannot make any conclusions 
about the effect of BMP-6 deficiency on CS-induced airway wall remodelling.  
On the other hand, 4 weeks of CS exposure was sufficient to induce the pro-fibrotic TGF-β1 in the 
BAL supernatants. Importantly, the TGF-β1 protein levels were significantly higher in CS-exposed 
BMP-6 deficient mice compared to the CS-exposed control group. This effect has also been observed 
in the renal fibrosis model and has been suggested to be derived from the inhibition of the TGF-β1 
auto-inductive mechanism by BMP-6 299. Although reversing TGF-β1-induced actions was originally 
described to BMP-7, BMP-6 is equally potent in inhibiting TGF-β1 functions 289;300. The interaction of 
BMP-6 and TGF-β1 should be further researched in the context of CS-induced airway wall 
remodelling. 
As a final part of our study, we measured levels of iron and ferritin, an iron storage protein, in CS-
exposed BMP-6 deficient mice. Next to increased levels of iron in the serum of BMP-6 deficient mice, 
we report for the first time iron overload in the lungs, similar to the iron accumulation found in the 
liver, pancreas, heart and kidney 279. Iron levels were not influenced by exposure to CS both after 4 
and 24 weeks of CS. In contrast, ferritin levels were significantly elevated in BMP-6 deficient mice 
exposed to CS for 4 weeks compared to the control groups.  This could result in more oxidative stress 
and account for the higher inflammatory response in BMP-6 deficient mice. This hypothesis should 
be tested further.   
10.3.3. Future directions 
The BMP family comprises more than 30 members, some of them are structurally and functionally 
very similar to each other. None of these proteins has been studied in COPD. It would be interesting 
to  build a complete expression profile of the BMP family in patients with COPD, similar to what has 
been reported for asthma. In an OVA-induced mouse model of allergic airway inflammation, 
activation of the BMP pathway was evident as indicated by the presence of phosphorylated 
Smad1/5. This is accompanied by increased levels of the BMP type I receptors ALK2, ALK3, ALK6 and 
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the BMP ligands BMP-2, BMP-4 and BMP-6, whereas BMP-5 and BMP-7 expression is reduced 301. In 
contrary, patients with asthma exhibit reduced BMP receptor expression, while allergen provocation 
increased expression of BMP-7 and activated BMP signalling 305.  
Especially BMP-7 is an excellent candidate for future research. In cultured lung fibroblasts BMP-7 
opposed TGF-β1 dependent fibrogenic activity. Moreover, BMP-7 has a protective effect in animal 
models of asbestos- and silica-induced pulmonary fibrosis 292-294. In an OVA-induced mouse model of 
asthma, intranasal treatment with BMP-7 reduced lung inflammation and type 1 collagen deposition 
297. Also BMP-4, involved in lung morphogenesis and epithelial-to-mesenchymal transition, can be 
targeted 380;393.  
Finally, the BMP signalling pathway is tightly regulated at different levels. Extracellular antagonists 
negatively regulate signalling by binding to the BMP ligands and inhibiting receptor binding. BMP 
antagonists have been classified into 3 subfamilies: the Dan, the Twisted gastrulation and the 
Chordin/Noggin family 278. Evidence for the functional significance of these antagonists in disease 
pathology has been extensively documented. For example, overexpression of gremlin, belonging to 
the Dan family, resulted in lung fibrosis 421. These endogenous antagonists should be taken into 
account when studying BMP signalling in COPD.  
 
 
 
 
 
Figure 25. Schematic overview of our research work. A) CXCL13, a lymphoid chemokine attracting CXCR5
+
 B 
cells is increased in the lungs of patients with COPD. Moreover, CXCL13 is found in the B cell zone of lymphoid 
follicles. Lymphoid follicles may contain high endothelial venules (HEV), follicular dendritic cells (FDC) and 
germinal centers with the potential to produce plasma cells and antibody responses against infectious agents 
and/or autoantigens, such as breakdown fragments from the extracellular matrix (ECM). We have 
demonstrated that neutralization of CXCL13 prevented the formation of lymphoid follicles and attenuated 
cigarette smoke (CS)-induced inflammation and alveolar wall destruction. B) Activin-A, a pleiotropic cytokine of 
the TGF-β superfamily, and phosphorylated Smad2, a downstream mediator, are increased in the airway 
epithelium of patients with COPD. In contrast, follistatin, a natural antagonist of activin-A is decreased upon CS 
exposure. An imbalance between activin-A and follistatin contributes to CS-induced inflammation. C) Bone 
morphogenetic protein-6 (BMP-6), also a member of the  TGF-β superfamily, is decreased in the lungs of 
patients with COPD. While we have found that BMP-6 is important for pulmonary inflammation upon sub-acute 
CS exposure, BMP-6 seems less important in chronic CS-induced inflammation and remodelling. Reduced 
pulmonary BMP-6 levels result in decreased levels of hepcidin, a hormone that degrades the iron exporter 
ferroportin. Eventually, iron will accumulate in the lungs, potentially contributing to oxidative stress. (s)Ig: 
(secretory) immunoglobulin, CXCL: chemokine (c-x-c motif) ligand, CXCR: chemokine (c-x-c motif) receptor, IL: 
interleukin, TNF-α: tumor necrosis factor-α, TGF-β1: transforming growth factor-β1, MCP-1: monocyte 
chemotactic protein-1, KC: keratinocyte chemoattractant, Fe: iron.        → 
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10.4. General conclusion 
 
We conclude that CXCL13 is increased in patients with COPD and is crucial for the organization of CS-
induced lymphoid follicles in mice. Neutralization of CXCL13 partially protects mice against CS-
induced inflammation in bronchoalveolar lavage and alveolar wall destruction (Figure 25). 
We have demonstrated that activin-A and BMP-6, 2 members of the TGF-β superfamily, are 
respectively increased and decreased in COPD. While neutralization of activin-A partially attenuated 
CS-induced inflammation, deficiency of BMP-6 aggravated CS-induced inflammation in a subacute 
setting. In contrast, BMP-6 is less important in CS-induced inflammation and airway wall remodelling 
after chronic exposure to CS (Figure 25). With these data, we underline that TGF-β1 is not the only 
member of the TGF-β superfamily that is involved in COPD and more research is needed into this 
interesting protein family. 
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SUMMARY 
 
Chronic Obstructive Pulmonary Disease (COPD) represents a major cause of chronic morbidity and 
mortality throughout the world. COPD is characterized by an abnormal inflammatory reaction in the 
airways and lung parenchyma to cigarette smoke (CS), resulting in destruction of lung parenchyma (= 
emphysema) and structural changes in and around the airways. Therapies or drugs that slow down 
the accelerated decline in lung function in patients with COPD are still lacking. Therefore, it is 
essential to unravel the mechanistic processes that underlie the inflammatory reaction and 
subsequent structural changes in COPD. The main objective of this study was to explore the 
functional role of lymphoid follicles and the TGF-β superfamily in the pathogenesis of COPD. 
Patients with severe COPD develop pulmonary lymphoid follicles. It was unclear whether these 
highly specialized lymphoid structures were harmful or beneficial in COPD. CXCL13 is a chemokine 
that attracts B lymphocytes and is crucial for lymphoid neogenesis. We studied the role of lymphoid 
follicles by neutralization of CXCL13. First, we have demonstrated that CXCL13 is increased in COPD 
and is produced within the B cell zone of lymphoid follicles of patients with severe COPD. Secondly, 
preventing the formation of lymphoid follicles by pharmacological neutralization of CXCL13 partially 
inhibited airway inflammation and destruction of the lung parenchyma, but had no influence on the 
development of airway wall remodelling.  
The transforming growth factor (TGF)-β superfamily comprises TGF-βs, activins and bone 
morphogenetic proteins (BMPs). Dysregulation of TGF-β1, the most studied ligand of the 
superfamily, is associated with numerous fibrotic and immune-mediated diseases, including COPD. 
However, little is known about the other ligands of this superfamily in the pathogenesis of COPD. 
Since activin-A signaling is activated in pulmonary fibrosis and asthma, we reasoned that activin-A is 
involved in CS-induced inflammation and COPD. First, we have found that activin-A is increased in the 
airway epithelium of patients with COPD. Moreover, activin-A is induced upon CS exposure both in 
vivo in a murine model, and in vitro in epithelial cell cultures. By administration of follistatin, an 
endogenous inhibitor of activin-A, the recruitment of inflammatory cells and mediators was partially 
inhibited after subacute CS exposure.  
BMPs are the largest subfamily of the TGF-β superfamily with more than 20 members. We have 
investigated the role of BMP-6 in the pathogenesis of COPD, since its locus is associated with lung 
function. Moreover, BMP-6 is important for tissue remodelling, which indicates a clear rationale to 
study the role of BMP-6 in CS-induced inflammation and airway wall remodelling. We have 
documented that BMP-6 mRNA expression is decreased in the lung tissue of patients with COPD and 
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of CS-exposed mice. BMP-6 deficiency renders mice more susceptible to the development of 
pulmonary inflammation after 4 weeks of smoke. In a chronic setting however, BMP-6 is not 
important for pulmonary inflammation, nor for the development of airway wall remodelling. Finally, 
we observed iron accumulation in the lungs of BMP-6 deficient mice which could contribute to 
oxidative stress. With these results, we underline that future research on the role of the TGF-β 
superfamily in COPD, should be expanded beyond the classical TGF-β1 ligand. 
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SAMENVATTING 
 
Chronisch obstructief longlijden (COPD) is wereldwijd een belangrijke oorzaak van chronische 
morbiditeit en mortaliteit. COPD wordt gekarakteriseerd door een abnormale inflammatoire reactie 
in de luchtwegen en long parenchym op sigarettenrook (SR), wat resulteert in de destructie van het 
long parenchym (=emfyseem) en structurele verandering in en rond de luchtwegen. Therapieën of 
medicatie die de versnelde daling in longfunctie in patiënten met COPD vertragen, ontbreken nog 
steeds. Daarom is het essentieel om de mechanismen die aan de basis liggen van de inflammatoire 
reactie en de daaropvolgende structurele veranderingen in COPD te ontrafelen. Het belangrijkste 
doel van deze studie is het onderzoeken van de functionele rol van lymfoïde follikels en de TGF-β 
superfamilie in de pathogenese van COPD.  
Patiënten met ernstig COPD ontwikkelen lymfoïde follikels in het longweefsel. Het was niet duidelijk 
of deze zeer gespecialiseerde lymfoïde structuren schadelijk zijn of beschermend werken in COPD. 
CXCL13 is een chemokine dat B lymfocyten aantrekt en is cruciaal voor lymfoïde neogenese. We 
hebben de rol van lymfoïde follikels bestudeerd door neutralisatie van CXCL13. Ten eerste hebben 
we aangetoond dat CXCL13 is toegenomen in COPD en wordt geproduceerd binnen de B cel zone van 
lymfoïde follikels van patiënten met ernstig COPD. Ten tweede wordt de luchtweg inflammatie en 
destructie van het long parenchym partieel geïnhibeerd door het verhinderen van de vorming van 
lymfoïde follikels door farmacologische neutralisatie van CXCL13. 
De transforming growth factor (TGF)-β superfamilie bestaat uit TGF-β's, activines en bone 
morphogenetic proteins (BMP’s). Dysregulatie van TGF-β1, het meest bestudeerde ligand van de 
superfamilie, is geassocieerd met verschillende fibrotische en immuun-gemedieerde ziektes, 
waaronder COPD. Er is echter weinig gekend over de andere liganden van deze superfamilie in de 
pathogenese van COPD. Aangezien activine-A signalisatie geactiveerd is in pulmonaire fibrose en 
astma, redeneerden we dat activine-A betrokken is in SR-geïnduceerde inflammatie en COPD. 
Allereerst hebben we gevonden dat activine-A verhoogd is in het luchtweg epitheel van patiënten 
met COPD. Bovendien wordt activine-A geïnduceerd na blootstelling aan SR, zowel in vivo in een 
muismodel, als in vitro in epitheliale celculturen. Door administratie van follistatine, een endogene 
inhibitor van activine-A, is de rekrutering van inflammatoire cellen en mediatoren gedeeltelijk 
geïnhibeerd na subacute SR blootstelling. 
BMP’s zijn de grootste subfamilie van de TGF-β superfamilie met meer dan 20 leden. We hebben de 
rol van BMP-6 onderzocht in de pathogenese van COPD, aangezien zijn locus geassocieerd is met 
longfunctie. Bovendien is BMP-6 belangrijk voor weefsel remodellering, wat een duidelijk rationale 
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aantoont om de rol van BMP-6 te bestuderen in SR-geïnduceerde inflammatie en luchtweg wand 
remodellering. We hebben aangetoond dat de mRNA expressie van BMP-6 verminderd is in het 
longweefsel van patiënten met COPD en van SR-geïnduceerde muizen. BMP-6 deficiëntie zorgt 
ervoor dat muizen meer gevoelig zijn voor de ontwikkeling van pulmonaire inflammatie na 4 weken 
rook. In een chronische setting daarentegen, is BMP-6 niet belangrijk voor pulmonaire inflammatie, 
noch voor de ontwikkeling van de luchtweg wand remodellering. Tenslotte, hebben we accumulatie 
van ijzer waargenomen in de longen van BMP-6 deficiënte muizen, wat mogelijk kan bijdragen tot 
oxidatieve stress. Met deze resultaten, benadrukken we dat toekomstig onderzoek naar de rol van de 
TGF-β superfamilie in COPD, moet uitgebreid worden zich verder moet focussen op deze eiwit 
familie, verder dan het typische TGF-β1 ligand. 
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ABBREVIATIONS 
 
BAL Bronchoalveolar lavage 
BALT Bronchus-associated lymphoid tissue 
BMP Bone morphogenetic protein 
CD Cluster of differentiation 
COPD Chronic obstructive pulmonary disease 
CS Cigarette smoke 
DC Dendritic cell 
DI Destructive index 
ELISA Enzyme-linked immunosorbent assay 
FDC Follicular dendritic cell 
FEV1 Forced expiratory volume in 1 second 
FVC Forced vital capacity 
GDF Growth differentiation factor 
GOLD Global Initiative for chronic obstructive lung disease 
GWAS Genome wide association study 
HBEC Human bronchial epithelial cell 
HEV High endothelial venule 
iBALT Inducible bronchus-associated lymphoid tissue 
Ig Immunoglobulin 
IL Interleukin 
KO Knockout 
LF Lymphoid follicle 
Lm Mean linear intercept 
LPS Lipopolysaccharide 
LT lymphotoxin  
MLN Mediastinal lymph node 
MMP Matrix metalloproteinase 
Pbm Length of the basement membrane 
PRR Pattern recognition receptor 
qRT-PCR Quantitative real time polymerase chain reaction 
ROS Reactive oxygen species 
SLO Secondary lymphoid organ 
SNP Single nucleotide polymorphism 
TGF-β Transforming growth factor-beta 
TLO Tertiary lymphoid organ 
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